INDEX OF AUTHORS

Abelson, D. S., 532
Abildskov, J. A., 556
Abrams, H. L., 593
Aguilar, M. J., 520
Aikawa, J. K., 1093
Alexander, R. W., 800
Alsobrook, W. L., 373
Armen, R. N., 1079
Atherton, C. W., 373

Ball, K. P., 766
Ball, R. E., 568
Bauersfeld, S. R., 512
Bawell, M. B., 1159
Becu, L. M., 349
Behrend, A., 379
Best, M. M., 344
Blackford, L. M., 1114
Blumberg, L., 379
Bollet, A. J., 125
Bradley, S. M., 1073
Brecher, G., 125
Bridwell, T., 250
Brown, J. F., 584
Bruce, R. A., 72
Bufalari, A., 859, 1129
Bunim, J. J., 125
Burchell, H. B., 200, 349, 806
Burroughs, R. W., 72
Buzina, R., 854
Bywaters, E. G. L., 1153

Cera, L. J., 33
Chasis, H., 260
Clagett, O. T., 806
Claiborn, T. S., 1090
Cohen, W. D., 365
Corcoran, A. C., 221, 868
Cordes, J. F., 48
Cournand, A., 163
Crane, J. T., 520
Cregg, H. A., 847
Crosley, A. P., Jr., 584
Crumpton, C. W., 584

Davila, J. C., 175
DeFazio, V., 90
Dempsey, M. E., 77
Dias, E., 1035
Ditzel, J., 386
Dotter, C. T., 509
Downing, D. F., 188
Drake, E. H., 254
Dreifus, L. S., 815
Duncan, C. H., 344
Dunn, W. J., 540
DuShane, J. W., 349
Dustan, H. P., 221

Edwards, J. E., 349, 398, 540
Elkinton, J. R., 1027
Evans, J. M., 790

Farquhar, J. W., 77
Felson, B., 874
Ferrer, M. I., 163
Finby, N., 115
Fitz, R. H., 1093
Fontana, R. S., 349
France, R., 373
Frank, E., 83
Furbetta, D., 859, 1129

Gasul, B., 412
Gibson, W., 745
Gigee, W., 614
Glover, R. P., 175
Goldring, W., 260
Goodwin, J. F., 766
Grant, R. P., 233
Green, R. S., 407
Greene, D. G., 250
Griffith, G. C., 784, 800

Haimovici, H., 532
Halasz, N. A., 826
Halloran, K. H., 826
Harrison, C. V., 766
Harvey, A. M., 125
Harvey, R. M., 163
Heath, D., 323
Hecht, H. H., 265
Heidorn, G. H., 1104
Hellems, H. K., 90
Helm, R. A., 874
Hershberger, R., 380
Hetzel, P. S., 200, 212
Higano, N., 365
Hilbish, T. F., 125
Hines, E. A., Jr., 806
Hisey, B. L., 556
Hoobler, S. W., 1061
Hopkins, W. A., 1090
Hosier, D. M., 9
Hull, J. B., 1099
Hurwitt, E. S., 532
Huston, J. H., 584
Huth, E. J., 60

Iglauer, A., 407, 874
Ingerson, W. E., 556

Janton, O. H., 175
January, L. E., 227
Jenss, R. M., 250
Jepson, R. P., 1084
Johnston, F. D., 48

Keyes, J. W., 254
Keys, A., 100, 854
Kirklin, J. W., 349
Klassen, K. P., 847
Kotte, J. H., 874
Kusher, D. S., 412
Kvale, W. F., 622

Laranja, F. S., 1035
Leight, L., 90
Lepeschkin, E., 614
Levinson, D. C., 784
Lewis, B. I., 227
Lewis, L. A., 55
Liebow, A. A., 826
Linenthal, A. J., 745
Lubin, R. I., 227

Manger, W. M., 622
Marriott, H. J. L., 38, 1073
Massell, B. F., 44
McCarty, M., 1138
McCubbin, J. W., 161
McGuire, J., 874
McNamara, A. P., 1104
McNamara, D. G., 512
Meehan, J. P., Jr., 784
Miranda, A., 1035
Moragues, V., 1159
Morris, G., 380
Morrow, C. S., 1079
Mortimer, E. A., Jr., 1144
Morton, R. F., 1069
Moyer, J. H., 380
Myhre, J. R., 185

Nobrega, G., 1035
Norman, L. R., 745

Oser, B. M., 1099
Ostrow, B. H., 790

Page, I. H., 3, 55, 161, 221, 868
Paul, M. H., 745
Perera, G. A., 321
Perry, H. M., Jr., 105
Pick, A., 815
Pitts, J. L., 9
Polis, G. N., 790
Pontius, R., 380
Popper, H., 412
Priestley, J. T., 622
Pruitt, R. D., 540

Raab, W., 614
Rammelkamp, C. H., Jr., 1144
Regan, T. J., 90
Reynolds, E. W., Jr., 48
Richards, D. W., 163
Riseman, J. E. F., 422
Robinson, R. W., 365
Roth, G. M., 622
Rowe, G. G., 584
Roy, S. B., 44
Rusted, I. E., 398
Ryan, J. M., 1099

Santucci, F., 859, 1129
Scarborough, W. R., 435
Scheifley, C. H., 398
Schieve, J. F., 1099
Schreiner, G. E., 260
Schroeder, H. A., 105
Schwartz, L. H., 784
Scott, R. C., 407, 874
Seiden, G. E., 83
Seidenberg, B., 532
Sherer, J. W., Jr., 365
Shrader, E. L., 1159
Simonson, E., 100
Smith, F. J., 254
Smith, H. W., 260
Smith, J. R., 1061
Smith, P. W., 847
Smith, R. E., 77
Sniffen, R. C., 365
Sokoloff, L., 125
Sokolow, M., 568
Solinas, P., 859, 1129
Soloff, L. A., 25
Squires, R. D., 60
Starcheska, Y. K., 614
Starr, I., 1117
Steinberg, D., 790

Steinberg, I., 115
Stephens, H. B., 520
Stern, T. N., 1069
Swan, H. J. C., 200, 212
Szent-Györgyi, N., 17

Talbot, S. A., 435
Talmers, F. N., 90
Taussig, H. B., 9, 512
Thomson, G. W., 757
Ticktin, H. E., 790
Tuchman, H., 584

Van Scott, E., 125

Watt, J., 743
Whitaker, W., 323
White, B. D., 512
Wild, J. B., 227
Willis, P. W., III, 48
Wood, E. H., 200, 212, 806
Wright, I. S., 1
Wright, J. L., 806

Zatuchni, J., 25
Zoll, P. M., 745

INDEX OF SUBJECTS

(*Page numbers in italics refer to abstracts*)

Abbott's cyanosis tardive, *633*
Abdomen
abnormalities
of arteries, 520
inversus of all organs, 521
angina, 426–427
distention
and heart failure, 412
and hypertensive pulmonary disease, 329
resection, 474
urographic study and retrograde brachial aortography, 595
Abscess
brain, and anastomosis, 516–517
of lung, and coronary embolism, 1161
Accrochage and synchronization, atrioventricular, 38–43
Acetozoleamide, and renal disease, *1167*
Acetylcholine
arrhythmia due to, *646*
and cholinesterase system, *646*
and cooling, *889*
excitation of and temperature, *889*
Acetylstrophanthidin, myocardial transfer of sodium, potassium, calcium after, *952*
Acid-base
and ammonium chloride, *152*
and hypertension, 589
and hypertonic sodium bicarbonate, *1176*
and mercurial diuretics, *1164*
Acidosis
and ammonium chloride in elderly, *152*
and carbon dioxide tension, 282
circulatory responses to, *988*
and Diamox, 1168
and postural fall in pressure, 65
extracellular potassium, pH responses, 821
respiratory, and total body fluids, *304*
Aconitine nitrate, arrhythmia due to, *646*
ACTH, *See* Corticotropin
Adam's-Stokes seizure, and Chagas' disease, 1050–1052
Adenocarcinoma, of uterus, 758, 762
Adenoma, thyroid, 762
Adenosine
phosphatase, and myocardium, 640
triphosphatase, inhibition of, *139*
Adenylate kinase, *139*
Adrenal gland
congestion of, in Chagas' disease, 1038–1039
cortex of
and hypertension, *144*
and lupus erythematous, 131
and measles, *143*
and pheochromocytoma, 628
and renal tubular reabsorption of sodium, 1030
and sympathetic nervous system, *144*
function, in family of rheumatic subject, *1010–1011*
tumor removal from vicinity of, 629
Adrenalectomy
and blood pressure of hypertensive disease, *144*
and serum lipid levels, 492
Adrenalin
blood flow after, in hand, *148*
and hemodynamics, *649*
test, contraindication for in angina pectoris, 429
Aerosol and edema, *635*
African, hypertension in, 19–20
Age (of subject)
and anastomosis for pulmonary stenosis, 516–517
and anemia, with coronary artery disease, 429
and anginal syndrome, 228
and angina pectoris, 425, *926*
and anomalies
coronary, 805
death due to, 801–805
pulmonary venous connection, 203
and aorta
coarctation of, 602–605
elastic properties, postmortem, *498*
regurgitation, *911–912*
sinus aneurysm, 116
and arteriosclerosis, 386
of coronary arteries, 103
and intra-atrial block, 1074
and atherosclerosis, *291*, 485, 706–708
aneurysms of, *309*
coronary, 365–371
and bacterial endocarditis, *883*
and blood pressure, *971–972*
and bronchiectasis, 281
and bulbar conjunctiva, 389
and cardiovascular
accidents, *139*
fatalities in farmers, *975*
renal diseases, *1006*
and carotid sinus massage, 1105–1106
and Chagas' disease, 1037–1039, 1044–1046, 1050–1058
and clearing factor, *496–497*
in coarctation, appraisal after operation, 807
coexistence of gallbladder disease and angina pectoris, 427
and common atrioventricular canal, 203
and congenital tricuspid stenosis in adult, 412–421
and conversion of atrial fibrillation, 573
and coronary embolism, 1160–1163
and desaturated blood supply to coronary arteries, 270
and diabetes mellitus, 386–396
and vascular degeneration, 473
elderly
blood pressure and posture in, *990*
heart disease in, *138*
magnitude of QRS and T vector, 101
refractory congestive heart failure in, *140*
subacute bacterial endocarditis in, *631–632*
and electrocardiographic findings, 100–103
P-R interval, *636*
QRS, T and U axis, *299*
and electrolyte complication, *140*
and emphysema heart, 269–273
and fibroelastosis, 412–421
and heart disease, kyphoscoliotic, and failure, 274
and heart size after pulmonary valvulotomy, 12–15
and hypertension, 17–23, *146*
responses to tilting, 410
and kidney reabsorption, 4–5
and left axis deviation in pulmonary disease, 241–249
and lipid deposits in mitral valve, *501*
and lupus erythematosus, 131
and myocardial infarction, *634*, *926*
mortality, *137–138*, *294*
and narrowing of aortic isthmus, 599
nephrotic syndrome, and ACTH or steroid therapy, *972*
and normal aortograms, 597
and nutrition, *291*
and peripheral pulse pressure versus work, 1123–1127
and pheochromocytoma, 623–624
and phlebitis, 472
and pulmonary valvulotomy, 9
and pure left papillary muscle syndrome, 1134
and rehabilitation in arterial artery disease, 474
and rheumatic fever,
ACTH or cortisone for, 44–47
prophylaxis, 1145–1151
and rheumatic heart disease, *970*, *1019*
and right bundle-branch block, 1048
and shunt, left-to-right, 203
and streptococcal infections, 1149–1151
and stroke volume, 250–253

Age (of subject) (*Cont'd*)
and syndrome of precordial pain, *1169–1170*
and syphilitic aortic sinus aneurysms, 121
thyrocardiac, *138*
and vaccination against variola, *138–139*
and Valsalva maneuver responses, 72
and vectorcardiographic findings and interpretations, 100–103
and ventricular
septal defect, death due to, 357–363
systolic pressures, 265
Air
leakage, and Valsalva maneuver, 75
perirenal injection and pheochromocytoma, 627
Ajmaline, *1166*
Albumin
concentration
and growth, *57*
and heredity, 57–59
radioiodine labeled, and cardiac output, 1061, 1066
serum fraction, and Chagas' disease, 1037
Albuminuria, and hypertension, 108–113
Alcohol
and edema, *148*
hyponatremic, *975*
paroxysmal pulmonary, *635*
and water diuresis, 1030
Aldosterone
and hypertension, *891*
and mineral metabolism, 1030
Alkalosis
circulatory responses to, *988*
and mercurial diuretics, *1164*
and potassium, 821
Alligator's heart, 1114–1116
Allylamine, and aortic tissue, *501–502*
Alseroxylon
and angina pectoris, 230
dosage and responses, 232
and chlorpromazine, *1166*
and spinal vasoregulatory systems, *644*
Alternation
of pulmonary and systemic circulation, 163–173
and brachial, independence in each, 164
of pulse pressure, 164
ventricular, 1101
Alternans. *See* Pulsus, alternans
Altitude
and emphysema, 283
and oxygen desaturation, 272
polycythemic response to, 272
Amblyopia, and hypertension, 109, 112
Amebiasis, and emetine toxicity, 36–37
American
hypertension in, 17–23
Indian, and cyanosis, 271
American Heart Association, Inc.
abstracts of papers, *903–1024*
annual meeting, 154–155, 310–311, 476, 656–657, 897, 1183
Achievement Award to, 1184
Ballistocardiographic Terminology Committee, 435–449
technical appendix, 436
Blakeslee Awards, 897–898
Brown Memorial Lecture, 155, 310, *903*
Cardiology, International Congresses of, 156
Cardio-Views Kit, 157
Cerebral Vascular Disease, Second Conference, 477, 1183
Congress of Cardiology, Fifth Inter-American, 156
Committee on Lipoproteins and Atherosclerosis, Report of Cooperative Study, 691–739
conference
adult fibroelastosis with congenital tricuspid stenosis, 412–421
nonspecific pericarditis and myocardial infarction, 874–882
systemic lupus erythematosus, 125–134
Conner Memorial Lecture, 155, 310, *903*
Council on Community Service Education, 154–155, 311, 1183
Council for High Blood Pressure Research, 311, 658–659, 898, 899, 1183
Council on Rheumatic Fever and Congenital Heart Disease, 155, 1183
courses
cardiovascular disease, 156–157
cardiovascular-renal disease, 156
electrocardiography, 898
in internal medicine, 156
in pediatrics, 156
postgraduate for physicians, 660–666
on death rates from cardiovascular disease, 19
education programs, 6–7
scientific and technical, 155
fellowships available
investigatorships, 310, 477
research, 310, 476, 477, 898
research, senior, 659, 898
films "The Secrets of the Heart," 899
Fifth Inter-American Congress of Cardiology, 156, 657–658
Gold Heart Awards, 897
grants-in-aid, 105, 260, 265, 310–477, 657
Life Insurance Medical Research Fund, 311
recipients of, institutions working at, and subjects of studies, 312–318
Inter-American Congress, Fifth, 312, 657
Lasker Award, 897
literature available
"Anticoagulant Therapy," 1184
"Electrocardiographic Test Book," 311
"If Your Child Has Rheumatic Fever," 1184
proceedings of Council for High Blood Pressure Research, 155–156, 311
"World Trends in Cardiology," 658, 899
meetings, 312, 478, 659–660, 899, 1184
new officers of councils and sections, 1183
New England Cardiovascular Society, 898–899
Presidential Address, 3–8
recommendations for control of rheumatic fever, 1145
research grants, 154
United States Public Health Service, 311–312
Scientific Sessions
and 32nd Annual Meeting, 154–155, 310–311, 476, 656–657, 659, 897, 1183
Second Conference on Cerebral Vascular Diseases, 477, 1183
Section on Clinical Cardiology, 154
symposium
on "Cardiac Rehabilitation," 154
on Heart Disease, Eighth Annual, 477
on "Nature of Rheumatic Fever," 1138–1158
Western Cardiac Conference, 477
American Society for the Study of Arteriosclerosis, annual meeting, 506
program and proceedings of tenth annual, 479–505
Aminometramide, side effects of, *907*
Aminophylline
and carbon dioxide
inhalation, *150*
narcosis, 282
and Cheyne-Stokes respiration, *150*
and exchangeable potassium content, 1094
side effects of, *907*
Aminopropionitrile, *499–500*
Aminoquinoline derivative, 1058
Ammonia, blood in congestive failure, *296*
Ammonium chloride
blood acid-base equilibrium after, *152*
and exchangeable potassium content, 1094
Amputation, for gangrene, 412
Amyloidosis, 415
electrocardiography in, *911*
Anasarca, and Chagas' disease, 1037–1039, 1050–1052
Anastomosis
arterial, 538
and renal aneurysm, 532

ateriovenous flow through, in ear, *1173*
Blalock-Taussig, results of, 512–518
end-to-end, appraisal after, 806–814
growth of coronary, and exercise, *930*
intercoronary, *292*
pulmonary
arteriovenous, *960–961*
artery occlusion, 831
stenosis, 512–518
renal and splenorenal, 532–539
subacute bacterial endocarditis after, 516–517
Andromedotoxin, *644*
Androsterone, 368, 371
Anemia
and angina pectoris, 424–429
hemolytic, in systemic lupus erythematosus, 131
and hypervolemia, hemodynamic effects of, *937*
sickle-cell, in Negro children, *653*
and thrombosis of large pulmonary arteries, 770
Anesthesia
and blood pressure, 627
and cardiac arrest, *640–641*
for children, during cardiac catheterization, *650*
and conduction block, *1171*
cyclopropane, and mephentamine, *152*
and electric properties of Purkinje fibers, *1171*
and pheochromocytoma operation, 626–627
in retrograde brachial aortography, 593
Aneurysm
aortic
abdominal, 473–474, *896*
ascending, 120–123
dissecting, in child, 457
excision of, *308*
fenestration of internal wall, 469
homograft, 474
resection of, 474, 534
of sinuses, 115–123
splenorenal arterial anastomosis for, 532, 534
arteriosclerotic abdominal, 473, *896*
arteriovenous of lung, and heart failure, 272
and Chagas' disease, with *Schizotrypanum cruzi*, 1050
congenital, and arteriovenous fistula, 185–187
differential diagnosis, *293*
fusiform or saccular, roentgen finding of, 122
hydrodynamic factors in production of, *147*
myocardial, *968*
renal artery, 532
ventricular, *968*
and Chagas' disease, 1050–1052
of posterior wall, *146*
Angina
abdominal, 426–427
and emotion, 425
and myocardial infarction, *634*
and vaccination against variola, *138–139*
Angina pectoris
and alseroxylon, 230
and anterior chest wall syndrome, *138*
and atherosclerosis, 702, 709, 718, 736–737
and coronary artery
anomalies, 801
disease, 423
differential diagnosis, 422–433
electrocardiographic patterns, 867
and emetine toxicity, 37
and false-negative, false-positive tests, 430
and hypersensitive carotid sinus syndrome, 1104–1112
Metamine in, *646–647*
and nitroglycerin ointment, *139*
nomenclature
and interrelationships, 422–425
problems of, 426
and obesity, *139*
and pure left papillary muscle syndrome, 1134
and *Rauwolfia serpentina*, 227–232
and pre-existing coronary insufficiency, 231
and transaminase values, 798
triethanolamine trinitrate biphosphate in, *646–647*
Master's test, 432
types of tests for, 429–431
versus myocardial infarction, and age, *926*
Angiocardiography
in aortic sinus aneurysms, 115–123
syphilitic, 122
in cardiac septal defects, *1003–1004*
in congenital heart disease, *1023*
in cyanosis, 332
in differentiation of extracardiac from intracardiac densities, 30
in dilatation and effusion, 875–876
hazards, agents used for, 610
and isotope dilution, simultaneous studies of, *920*
in mitral regurgitation, 350, 847–852
in pulmonary coarctation, *135*
sites for, television and motion picture photography for, *1005*
in thrombosis
left atrial, 25–31
occlusion, 780
Angiography
of abdominal aorta, *1180*
in anomalies
aorta-pulmonary communication, 1090–1092
arterial and bronchial, 832–845
drainage into inferior vena cava, 827–828
intracardiac, *931*
renal, *307–308*
vertebral, 610
Angiologist, and cardiologists, 4
Angiosarcoma, of pericardium, 457
Annulus
fibrosis of pulmonary valve, 350
mitral, polar cross fusion of, *977*
Anomaly. *See* malformation
Anoxemia
and chemoreceptors in carotid body, *1171*
death due to after anastomosis, 516–517
and oxygen therapy, 282
and pulmonary artery pressure, 269
Anorexia, and quinidine, 573
Anoxia
arterial
and bone marrow, 271
coronary, *136*
and cardiac muscle sodium uptake, *153*
electrocardiographic evidence of, 431
and hypertension of systemic circulation, 269
induction of and electric alternans, *718*
and myocardial infarction, 423
Ansolysen, 584–591
Anterior chest wall syndrome, *138*
Antibiotics
broad spectrum, and streptococcal infections, 1145
for bronchial and pulmonary infections, 281
and carbon dioxide narcosis, 282
and coronary embolism, 1162
and endocarditis
bacterial, 1162
monilial, *147*
staphylococcal, *954*
subacute, *631–632*
and genitourinary tract infection, 111
in nonspecific pericarditis, 875
and rheumatic fever, 1145, 1162
and systemic lupus erythematosus, 127
Anticoagulant
and carotid artery, *895*
circulating, in lupus erythematosus, 132
contraindications for, *294*
control methods, 480
and standardized clotting time, *921*
and tissue thromboplastin, *1011*
Coumadin, new, *632*
and heparin, *884*
long-term therapy, *979*
and survival, 258
and myocardial infarction, *138*, 254–259, *883–884*, *888*, *992–993*
systemic effects of, *1165–1166*
for thrombosis of internal carotid artery, *895*
Antigens, responses to, and rheumatic fever, 1140–1141

Anuria, krypton 85 for renal flow measurement in, *148*
Anxiety
and alseroxylon, 232
in pheochromocytoma, 622
Aorta
abdominal
angiography of, *1180*
aortography in, 597, 609–610
vena caval grafts, 470
anomalous branches of, 827, 830–831, 837
aneurysm. *See* Aneurysm, aortic
arch, 597, 603–606
interruption of, 608
right sided, 523, 530
ascending, and syphilis, 120–122
atherogenesis, *498*
biventricular, 1114
calcification
and coronary blood flow, 423
disease, 171
and cholesterol, *305*
coarctation of
in adults and infants, 602–605, 608
aortography in, 193, 593, 597, 603–606
and congenital aortic stenosis, 191, 194
and contraindications for surgery, *884*
and coronary sinus, 116
electrocardiography in, 118
and exertion, 196
hemodynamics after, 806
incidence and mortality rates, *939–940*
and interscapular bruits, 117
with ischemic necrosis of extremities, *895*
with patent ductus arteriosus, *136, 932*
and pregnancy, *885, 924*
resection for, 123, 807
surgical correction of infantile, *1181*
and ventricular septal defect, 362
and congenital aortic stenosis, 191
constriction of and narrowing of isthmus, 598
descending
Ivalon tubes for by-pass, *919–920*
poststenotic enlargement, 119
dextroposition of, 522, 1114
diameter of, 352–358
dilatation of, poststenotic, *147*
fusion of right and left, 1114
grafts, types of, 470, *984–985*
implantation of right renal artery into, 537
iliac obstruction, *896*
incomplete supravalvular rupture of wall, *639*
inhibition of cholesterol synthesis in, *1166–1167*
insufficiency of. *See* Insufficiency, aortic
isthmus
at birth, 601
narrowing of, 602, 607
maldevelopment of, 523
mast cells in, *503*
metabolism study, in vitro, 482
nonpenetrating traumatic injury to, *980–981*
outflow tract, 351
occlusion, aortography in, *896*
and papillary muscle syndrome, 1134
postmortem, *498*
pressure measurement, *909*
pseudocoarctation of, 116
and pulmonary artery, *308*
bronchospirometry, 828
communication between, 1090–1092
transposition of, 521, *1180–1181*
regurgitation
and arachnodactyly, 118–119
and hypertention, 122
in young people, *911–912*
resection, and end-to-end anastomosis of, 806–814
response to cortisone and/or cholesterol diet, *303*
retrograde brachial aortography in, 593–612
riding, 1114
septal defect. *See* Septum, aortic defect
size of, and pulse pressure versus stroke work, 1126
stenosis of. *See* Stenosis, aortic
surgical repair, 123
prolonged exposure for, *994*
syphilitic involvement of, 120–123
thoracic
opacification, 597–599
visualization of, 193
roentgenology, in first years of life, 596–597
and syndrome of high interventricular septal defect, 998–999
thrombi, and coronary embolus, 1161
Aortic valve
and aortic sinuses, 115
calcified, and embolus, 1161
commissures of, 420
and coronary embolism, 1161–1162
deformity of
fibroblastic, 420
with ventricular septal defect, *137*
disease of
and angina pectoris, 424
and patent ductus, *971*
fenestrations of, *892–893*
and mitral valve, sagittal section through, 849
prolonged surgical exposure of, *994*
and ventricular septum outflow tract, in situ, 351
Aortitis
and coronary embolism, 1132
giant cell, dissecting hematoma due to, *962–963*
manifestation of, 120
and papillary muscle, 1132
syphilitic, 762
and aneurysm of aortic sinuses, 118, 122
and thrombosis of the large pulmonary artery, 774
Aortography
aorta
arch, 607
coarctation, 193, 593, 597, 603–606
iliac obstruction, *896*
occlusion, *896*
in arteriosclerotic abdominal aneurysm, *896*
in Bing-Taussig anomaly, 597
in infancy, 593, 596
in pheochromocytoma, 627
retrograde
abdominal, as by-product of, 609
brachial, 593–612
and congenital heart disease in infants, *1179–1180*
and unruptured aortic sinus aneurysm, 115
in segmental narrowing, *896*
shunts, liver and pulmonary artery, 185–187
translumbar, 533
fractionation technic in, 467
Appendectomy, and postcommissurotomy, 182
Apresoline
and ganglionic blocking agents for hypertension, *931*
and regitine tests for pheochromocytoma, 625
Arachnodactyly, aortic
regurgitation
cardiovascular alteration due to, *885*
pulse pressure in, 118
roentgenography in, 119
and sinus aneurysms, 116–117
and heart-failure, 123
Argentaffinoma, *642*
Argentina, areas of distribution of *Schizotrypanium cruzi*, 1036–1037
Armed Services, rejections due to hypertensions, 20
Ajmaline, *1166*
Arrhythmias
and angina pectoris, 426, 428
and antiarrhythmic agents, *650*
atrial, *297*
and complete block, 42
conversion and etiology of, 568–571
and atropine, *150*
cardiac, 745–755
and ajmaline and serpentine, *1166*
and cocaine, *650*
and cyclopropane, *644, 650*
external electric current effect on, *1023*
and hypoxia, *303*
and levarterenol, *152*
and levophed, *152*
and vagal stimulation, *303*
in Chagas' disease, 1046, 1055
and coronary artery disease, 423
and diphenyl butylamine, *646*
and epinephrine, *650*
first heart sound in and digitalis, *1170*

Flaxedil averted, *150*
and mitral commissurotomy, *143*
and myocardial infarction, *634*
anticoagulant therapy, 256
sinus
false alternans during, 165
and rhythm, *148*
and sodium lactate, *1168*
d-tubocurarine prevented, *150*
ventricular
and complete block, 42
and decamethonium, *150*
during quinidine therapy, 761
Arsenobenzol, 1058
Arterenol
constriction, in vascular beds, *944–945*
in myocardial infarction, *952*
Arteriography
cerebral, and Urokon, 596
femoral, fractionation technic in, 467
and occlusion of small vessels, 1084–1089
types of graph in, *984–985*
Arteriosclerosis
and aging, 103, 386
and intra-atrial block, 1074
aortic, *894*
coronary artery
and angina pectoris, 423
electrocardiography in, 103
and heart attacks, 3–4
due to hypercholesterolemia and hypervitaminosis D, *1009*
and hypoxia test, *292*
and intercapillary glomerulosclerosis, 386
mortality rates, in Chicago, *1006*
peripheral, serum lipoproteins, *496*
pulmonary, 277
obliterative, 276
and pulsus alternans, 167
and quinidine therapy, 758, 762
and *Rauwolfia serpentina*, 131–132
tissue oxygenation in and lipemia, *964*
and vaccination against variola, *139*
white plaque fibrin thrombi, 483
Arteriosus
ductus
body size and hemodynamics, *135*
closure of, *136*
and heart size, 185–186
obliterated, 522
pulmonary arteries from, 520
patent ductus
and aortic valvular disease, *971*
bifurcated into pulmonary arteries, 523
and congenital aortic stenosis, 194
and coarctation of aorta, *136*, *932*
dilution curves, 209
and exertional dyspnea, 328
and hypertension, 323–340, 787
incidence and mortality, *939–940*
in infants and small children, 192, 602, *632*, *932*
and intravascular pressure, *887*
and retrograde brachial aortography, 593, 603–606
and reversal of shunt, 787
selection for surgery, *916–917*
and sudden death, 331
and truncus communis, *921*
and ventricular septal defects, 359, 362
wide, *135*
truncus
heart sounds and thrills recorded simultaneously, 788
with hypoplastic pulmonary artery, 523
and opacification of aortic arch, 608
and pulmonary hypertension, 338
Arteritis
coronary, and thrombosis, *139*
giant cell, *962–963*
and inflammatory reaction in lupus erythematosus, 130
necrotizing and renal insufficiency, 486
Artery
anastomoses, splenorenal, 532–539
anomalous. *See* Anomaly
aorta-pulmonary, communication through lungs, 1090–1092
axillary, 597
blood pressure. *See* Blood pressure
and cephalic vessels, 116
oxygen content, 1070
and pulsus alternans, 164–172
retrograde aortography, 593–601
brachial, pressure
and congenital aortic stenosis, 196
and quinidine, 166, 168
tracings, 193, *949*
branched, homograft, *1182*
bronchial
in arteriovenous fistula, 1090–1092
Condorelli's, blood flow through, 1077
coronary. *See* Coronary artery
dilution curves and "anomalous drainage," 212
disease
and coronary blood flow, 423
and digital gangrene, 1085
obliterative, grading of in extremities, 923–924
and rehabilitation, 474
femoral
blood pressures, 807, 810
occlusion of, 770
pulsus alternans in, 173
systolic pressure in, 168–169
thrombosis of, 770
homografts, in peripheral arterial lesions, *1181*
hypertrophy of intramyocardial, 1050–1052
intercostal, 597
lesions, in lupus erythematosus, 129
mammary
implantation for coronary insufficiency, 1012
internal, 597, 603
mesenteric, resistance to blood flow, *1165*
occlusion, *140*, 417, 473, *913–914*, 1087
parascapular, 597
peripheral
disease, and diet, *499*
embolism management, *963*
ischemia, in heart failure, *140*
occlusion of small, 1084–1089
resistance, after pentolium, 1061–1067
pressure. *See* Pressure
in right-to-left shunt, *136*
prostheses, plastic fabrics as, *1180*
pulmonary. *See* Pulmonary artery
reconstruction, intermittent claudication after, *930–931*
renal, 532–539
rheumatic sera in, *958–959*
sclerotic, and coronary embolism, 1162
subclavian, aortography, 597
systemic, alternation, 164
vertebral, 595, 599
Arthralgia
and disease activity, 1154–1158
and lupus erythematosus, 133
Arthritide, and hydralazine, 109
Arthritis
and disease activity, 1154–1158
ethylenediamine tetracetic acid for, *1176–1177*
hypertrophic, 798
and lupus erythematosus, 133
and intermittent febrile episodes, 125
and rheumatic disease, *1177–1178*
rheumatoid
and false positive syphilis test, 132
and liver enlargement, 127
and systemic lupus erythematosus, 127–132
transaminase value in, 798
Aschoff body
and disease activity, 1142
fibrosing, 419
survival, in heart muscle, 1154
Ascites
and ascitic fluid, 417
formation of, *893–894*
and hypophysectomy, *141*
Asian, hypertension in, 17–23
Aspirin
in rheumatic fever, 44
and tissue metabolism, *1166*
versus cortisone, 3 OH-2 phenylcinchoninin, 1157
Asthenia
and hypertension, 109, 111
neurocirculatory, *299*
Asthma
bronchial, and coronary ostia anomalies, 801
and coronary artery disease, 423

Asthma (*Con'td*)
in emphysema heart, 277
Atelectasis
in lupus erythematosus, 132
of newborn
and cardiac changes, *137*
and survival, *137*
Atheroma
electron-microscopy of, *634*
and hypertensive pulmonary disease, 337
and thrombus, 770–772
Atheromatosis, aortic intima in, *978*
Atherosclerosis
and acid mucopolysaccharides, *481*
aortic
and in arterial wall, 417
in Chagas' disease, 1050–1052, 1058
susceptibility to, strain differences, *498*
carotenoid pigments in, *912*
dissociation of estrogenic and lipid altering effects, *489–490*
and embolism, 1162
and cholesterol, *481*, *491*, *502*, 691–739
coronary, *294*, *499*, *634*, *983*
in Chagas' disease, 1050–1052, 1058
and dietary fat, *499*
estrogen therapy for, and fertility, 366
and insulin, *492*
and intramural hemorrhages, *486*
in male castrates, *490*
method for detection of, *504*
and myocardial infarction, *634*
serum proteins, lipids, and lipoproteins in, *914–915*
and survival rate, *634*
and diet
and cholesterol feeding, *502*
protein as possible factor, 489
and estrogen, 365–366, *491*
fertility after, 366
and hypercholesterolemia, *497*
lipemia clearing defect in, *502–503*
and lipoproteins, report of cooperative study of, 691–739
measurement of
atherogenic index, 715–722
serum lipids, 491
mucopolysaccharides, 480–481
and myocardial infarction, *294*, *634*
new events, classification of, 700–703, 709
in New York Clothing Industry, *485*
premature, in diabetes, *473*
and progeria, *473*
radioiodine therapy, *491*
renal arteries, 1050–1052
serum lipid fractionations in, *500*
sitosterol in treatment of, 81
and symmetrical digital gangrene, 1085
and thromboangiitis obliterans, *500*, *966*
and thrombosis, *634*
trends in, *291*
and vascular lesions, 485
Atresia
and Blalock-Taussig anastomosis, 512–518
congenital, *136*
multiple anomalies, 530
pulmonary, *945–946*
of venous ostia of heart, *632*
mitral, *136*, *632*
pulmonary, 530, *633*, 775
blood vessels, 333
defects, 468
tricuspid, *632*
anastomosis, 512–518
and venous anomalous return, 530
Atrioventricularis communis
anomalous venous return to, 530
normal aortograms in, 597
Atrium
arrhythmia. *See* Arrhythmia
cardiac catheterization, 1090–1092
contraction
"isometric," *153*
premature, and pulsus alternans, 168
dilatation of, 278, 417–420
dissociation, and prolonged P waves, 1077
enlargement, 417, 767
in aortic stenosis, 193–195
in mitral disease, 1077
fibrillation. *See* Fibrillation, atrial
flutter, *637*
and antifibrillatory drugs, 142
with atrioventricular conduction, *889*
and Chagas' disease, 1043, 1049
conversion of, 568–581
during heart failure therapy, 1094
esophageal and intracardiac leads in, 451
"focal" origin of, *637*
and fibrillation, 568–581
hemodynamic responses in, *643*
and levarterenol, *152*
reversible change to, with guinidine therapy, 577–578
giant left, and mitral insufficiency, 237
granulomatous formations and Chagas' disease, 1050–1052
and hypertensive pulmonary vascular disease, 323–340
intercommunication between entire, 520
left
drainage of azygos lobe into, 835
enlargement of, and pressures, *1004*
filling defects of, 25–31
and hypertension, 404
intrinsicoid deflections in, *637*
myxofibroma, 467
pressure in, *909*, *1004*
thickening of wall of, 30
thrombosis in, 25–31
vena caval drainage into, 520–521
and mitral valve
commissurotomy, 178–179
regurgitation, 848
stenosis, 403–404
paroxysmal tachycardia and cardiac failure, *151*
premature contractions and false alternans, 165
and retrograde conduction, *143*
rheumatic changes in, 178–181
right
and anomalous pulmonary veins, 200–219
and aortic sinuses of Valsalva, 116
endoelectrogram study, *142*
intrinsicoid deflections in, *637*
oxygen content and pressure in, 1070
pulmonary and right hepatic veins into, 522
septal defects of. *See* Septum, atrial defects
single cavity, 521
and ventricle
connecting systems, *141*, 203–210, 216, 523
synchronization and accrochage, 38–43
Atrophy, testicular, and estrogen, 366
Atropine, and arrhythmia, *150*
Auscultation
gaps, *989*
venous hum in, *1169*
Austin Flint murmur, and mitral stenosis murmur, *999*
Autografts, vena cava, to bridge aortic defects, 470
Avitaminosis, and nutritional disturbances, *631–632*
Ayerza's disease, 271
and heart failure, 338
Azamethonium, and hypertension, *144*
Azotemia
and maglignant hypertension, 105–113
and sodium depletion, 1029
Azygos vein
abnormal drainage, 523
abnormally situated, 1079–1082
distention, 1079–1082

Bacterial endocarditis
and aneurysms of aortic sinuses, 115, 117, 123
in anomalous coronary ostium, 801–803
and antibiotics, *147*, *631–632*, 1162
and aortic regurgitation, 116–117
and cardiac surgery, *926*
and coronary embolism, 1161–1163
in elderly, *631–632*, *883*
fibrinoid degeneration, 419
infiltrative and Chagas' disease with *Schizotrypanum cruzi*, 1050
in mitral valve, 421
monilial, *147*

staphylococcal penicillin and streptomycin for, *954*
subacute
and anastomosis results, 516–517
and coronary embolism, 1161
diagnosis, *631–632*
and erythromycin, *631–632*
listeria monocytogenes as cause of, *631–632*
and pulsus alternans, 1100
terminal, 412–421
and ventricular septal defect, 357, 360
verrucous in lupus erythematosus, 130
Ballistocardiography, *1008*
and anginal cardiogram, 228
in aortic insufficiency, *955*
of circulation, and smoking, *967*
definitions and terminology, 439
in digitalis effect test, *907*
electric correction of, *1002*
nomenclature and conventions, 435–439
pattern due to heart beat, *1020*
in pericarditis, 880
and potassium intake, 62–68
and *Rauwolfia serpentina* study for angina pectoris, 230
systems and methods, *889*
aperiodic, 442–446
direct body, 446–448
high frequency, 439–441, *1006*
low frequency, 441–442
wave form of force, *987*
Banthine, and atrial fibrillation, *142*
Barbiturates, metabolic effect of, 384
Beat
and blood pressure, 749
in brachial artery and pulsus alternans, 164
extrasystolic, and emetine toxicity, 33
heart, *1020*, 1104–1112
postextrasystolic and pulmonary, and false alternans, 165
single ectopic, to electric stimuli, 745
supraventricular premature and quinidine, 573–574, 581
ventricular
and external stimulus, 747–749
premature, and quinidine, 573–574, 581
and retrograde aortography, 611
Benadryl, and atrial fibrillation, *142*
Benzodioxane and blood pressure, 624–625
in malignant hypertension, 111
Bing-Taussig anomaly, 597
Biopsy
lung, in ventricular septal defect, *905*
pericardial, in pericarditis, *147*
rheumatic heart tissue, reaction of sera from, *958–959*
testicular, after estrogen therapy, 369
Blalock-Taussig anastomosis, 512–518
Bleeding. *See* Hemorrhage
Block
adrenergic effect of, by chlorpromazine, 383
alveolar capillary, 273
anterolateral peri-infarction
and left axis deviation, 247
QRS vector in, 238
unipolar deflections, 246
atrioventricular, 41
and atherosclerosis, 734
in Chagas' disease, 1043, 1046, 1050–1052
congenital, *981*
defined, 1106
electrocardiographic patterns in, 40–43
and independence between atria and ventricles, 40–43
and massage of carotid sinus, 1104–1112
nodal, and fibrillation, *1014–1015*
and quinidine, 573
and sodium lactate, *1168*
autonomic, and blood pressure, 155
bundle-branch
after adrenolytic drugs, 616
and anterior necrosis, 1053
and atherosclerosis, 702, 709, 718, 734
bilateral, *890–891*
complete, 1048
in Chagas' disease, 1042–1043, 1050–1053
concept of masquerading, *1009*
and death, in anomaly of coronary ostium, 801–803
and hypertrophy of ventricle, *914*
electrocardiographic patterns, 42, *141*, 233, 243, 277–279, 549, 796, 867
incomplete, *141*, *233*, 278, *994*, 1050–1052
linear time-scale plot, 564–565
and myocardial infarction, 795, *888*
and intra-atrial block, 1076
and left axis deviation, 233, 243
with pulsus alternans, 168, 171
transaminase versus electrocardiography, 796
in valvular regurgitation, 1070
ventricular contraction, *915*
ventricular gradient, *298*
ventricular hypertrophy, *914*
in young, *993*
carotid sinus, 464
conduction, *1171*
dibenzyline, duration of, *1166*
ganglionic
bisquaternary, new series for, 639
and cardiac output, 1061–1067
and cardiovascular system, *144*
for elderly hypertensive, *146*
for hypertension, and Apresoline, *931*
and malignant hypertension, 105–113
and pentolinium, 1061–1067
heart, 118
atrioventricular synchronization in, 39
and failure of idioventricular pacemaker, *891*
and syphilis, 122
and sodium lactate, 464
and stimulation, electric, 748–749
intra-atrial, 1073–1077
and arteriosclerosis, 1074
intracentricular
and atherosclerosis prediction, 702, 709, 718, 734
intraventricular, 1076
in Chagas' disease, 1042–1043
peri-infarction, 238–241, *944*
postinfarction, 549
pulmonary artery
blood, cyanosis, 1090–1092
embolization, *961*
of venous inflow during Valsalva maneuver, 75
Blood
acid-base
and ammonium chloride, *152*
and ammonia levels, *296*
arterial
in anomalies, 219, 828–829
pH, and hypertension, 589
and polycythemia, *136*
buffer base, 589
capillary, and cyanosis, 271
carbon dioxide content, 589
circulating
anoxia; erythropoietic substances, 272
and serotonin, 161
trypanosomes, 1035, 1036, 1042
coagulation time, and optical density, 855–856
concentration and intracranial pressure, 627
dilution curves in
anomalous drainage, 205–219
pulmonary shunt, 219
whole, *937*
distribution of, and venous tourniquets, *939*
gas analysis, 266
and altitude changes, 283
glucose levels in, during forearm exercise, *1016*
intracardiac, and magnitude of surface vectors, *977*
lactic dehydrogenase activity in, *1173*
diseases, and digital gangrene, 1085
lipemia, clearing factor in, *498*
in lymphoma, 627
lipid levels and weight reduction, *645*
new pump, *928*
oxygen content, 362
and aortic insufficiency, *137*
and chlorpromazine, 382
and wide patent ductus, *135*
pulmonary artery, 193
oxygen saturation, *136*
and intracardiac defects, 332–333
as perfusing fluid and ventricular work, 1126

Blood (*Cont'd*)
pericardial, retained, postoperative reactions to, *948*
pH, *148*
and carbon dioxide, 282
and cardiac arrest, 642
in heart failure and lung disease, 266
and hypothermia, 475
and myocardial contractility, *1172*
and ventricular fibrillation, 475
protein changes in and lupus erythematosus, 132–133
quantitative calculation of, 200–219
quinidine concentration and toxicity, 575–576, 579
recirculation
of desaturated arterial, 269–270
through lungs, 832
red cells
and aging in, diabetes mellitus, 390
after anastomosis, 514
and cardiac changes, 272, 280
and cation movement after Andromedotoxin, *644*
and cold storage, *644*
in cor pulmonale, 284
and extravasation in myocardium, 1058
and intravascular changes, 391
in renal insufficiency, 627
and catecholamines, 614
sedimentation rate, in Chagas' disease, 1037
in splenic circulation, *136*
supply
in arteriovenous fistula, 1090–1092
to intra-abdominal viscera, 532
urea nitrogen retention and hexamethonium, 108
and variation of antidiuretics, daily, *149*
viscosity, 284
versus flow in polycythemia, *136*
white cell
in systemic lupus erythematosis, 125
in transmural myocardial infarction, 792

Blood flow
and anomalies
arterial and bronchial, 828
congenital, 423
pulmonary venous connection, 200–219
from aorta to lungs and continuous murmur, 514
arterial, 1077
capillary, 395, *1174*
and cardiac septal defects, 200–219, *1003–1004*
in congenital malformations, 195
in diabetes mellitus
and aging, 391
capillary and venule, 395
cerebral, 384
and blood pressure, 383
and chlorpromazine, 380, 382
and heparin, *149*
collateral to myocardium, *969*
common atrioventricular canal, 203
and contraction wave, *153*
coronary
and angina pectoris, 424
and aortic disease, 423–424
in aortic insufficiency, *987–988*
and arterial disease, 423
and arteriosclerosis, 423
and cardiac arrhythmias, *922*
and congestive failure, 424
during extracorporeal circulation, *917–918*
in hyperthyroids, 90–98
and hypoxia, *292*
and metastatic tumors, 423
and methoxamine, *139*
and nitroglycerin, *1002*
and norepinephrine, *139*
and oxygen content, *642*
after sympathectomy, 470
and vasoxyl, *139*
direction and amount, 1090–1092
and ductus diameter, *135*
and emphysema heart, 270
and epinephrine, *139*, *1165*
in extremity
and body posture, *1171*
and smoking, *967*
measurement, direct, *1005–1006*
and mixing, in central circulation, *920*
myocardial, and anoxia, 424
and norepinephrine, *1165*
oxygen saturation, pH during extracorporeal circulation, *974–975*
and posture of limb, *305–306*
peripheral, *302*
pulmonary, 200–219, *1174*
and circulation time, 214
and common atrioventricular canal, 203, 218
in cor pulmonale, *137*
of cyanotic infants, 530
impaired, 530
in polycythemia, *136*
to pulmonary veins, 1090–1092
and shunt, left-to-right, 203
through manifold, *1175–1176*
in valvular regurgitation, 1070
and wide patent ductus, *135*
and pulsations, resonance of, *969*
quantitative estimation of pulmonary and systemic, 214–219
renal, 587, 589
in anuria, *148*
and hydrazinophthalazine, *146*
resistance to, 4
reversal of, 603
through ductus, 608
self-regulation of, 466
skin and muscle, in hyperthyroidism, 97
systemic, 214–215, 1070
and anomalous connections, 203–218
in vascular bed of hypertensive, 269, 332, 1066–1067
venous, and breath holding, 169

Blood pressure
and adrenolytic drugs, 612–620
age, and sex, *971–972*
in ambulatory patient, 1061–1067
in American and foreign-born, Asian, Negro and white, 17–23
and anesthesia, 627
and aneurysmal dilatation of aortic sinuses, 117
and angina pectoris, 425
arterial, 585, 587
and cerebral blood flow, 383
and chlorpromazine, 380
and necrosis, 337
and alseroxylon, 230
and arteriovenous fistula of renal vessels, 185–187
and autonomic blockade, 155
central and peripheral, recording of, 1118
and congenital aortic stenosis, 190
control of, 5, 868–873
and coronary circulation, *1011*
cuff, responses to, *939*
diastolic
and benzodioxane, sodium amytal, 111
and coarctation of aorta, 118
and diet, *145*
and electron gun "therapy" with, 261
and epinephrine, *638*
after externally paced beats, 749
and extracellular sodium and potassium, *938*
of extremities
and aortic sinus aneurysm, 116
differences in arms, 626
and fasting, *145*
femoral artery, after coarctation, 807–808
and flow from aorta into communicating vessels, 1090–1092
and ganglionic blocking agents, *144*
and heart work, 1125, 1127
and hexamethonium, *142*
and/or hydralazine, 108–113
hydrostatic change due to gravity, 407
and hypertension, 4
benign, and reassurance therapy, 260–264
malignant, 107–113
pulmonary vascular, 337
and shock, 4
in infants
with coarctation of aorta and patent ductus, *932*
flush method for, *975*
and left ventricular strain pattern, 614
and adrenolytic drugs, 620
and levarterenol, *152*
lupus erythematosus, 125, 128
methods, for cardiac output, versus Evans blue dye, *1174*
and mitral commissurotomy, *142*
and muscular activity, *149*
after myocardial infarction, *138*, *140*
and pericarditis, 874–876

and narrowing of aortic isthmus, 598
and norepinephrine, *648*
and obesity, *139*
after pentolinium, 1061–1067
in pheochromocytoma, 622
and piperoxan, 223
postural
in aged, *990*
and azamethonium, *144*
and cardiac output, 1066–1067
and ganglionic blocking agents, *144*
and hexamethonium, *144*
and potassium depletion, 62, 65
and SU 3088 for hypotension, *144*
tilting, 407
and potassium deprivation, 62, 65
and pulsus alternans, 173
range of, in Framingham study, *957–958*
and regitine, 615–616
response to noise and sounds, *302*
and serotonin, *145*
and sodium tolerance, *145*
and stroke volume, 1117–1118
systolic
and coarctation of aorta, 118, 121
and measles, *143*

Blood vessels
and aging, 388
communications in lungs, 1090–1092
coronary, in congenital cardiovascular malformations, *136–137*
fibrinoid substance in and lupus erythematosus, 130
fragility of small, in diabetics, 386
heart and, 4
large thin-walled, and Chagas' disease, 1058
of limbs, drainage of, *1171*
and meperidine and/or aminophylline, *150*
pulmonary, in hypertension, 332–333

Blood volume
in bronchial and arterial anomalies, 828–829
central sodium dihydrocholate in estimation of, *951*
circulating responses to reduction in, *1021*
pulmonary
anomalous pulmonary venous connection, 218
in atrial septal defect, 218
in mitral stenosis, *986–987*
and pulmonary artery occlusion, *963–964*
quantitative estimation of, 214
and pulsus alternans, 171

Body
age. *See* Age (of subject)
build
and coronary artery disease, *932–933*
and electrocardiography, *916*
and QRS complex in left axis deviation, 235–237
carbon dioxide balance sheets, *306*
composition, *930*
and corticotropin for rheumatic fever, *905–906*
fat content and excess of sodium and water, 1029
fluid volume and aldosterone, 1030
hematoxylin of disseminated lupus erythematosus, 130
nutritional state of and metabolism of myocardium, 97
position of
and chest pain, 874–875
and hand blood flow, *1171*
size of
and airway resistance, *929*
and heart volume, *1173*
and pulse pressure, stroke work, 1126
and stenosis in infant, 194
surface area
in coarctation appraisal after operation, 807
Q waves versus epicardial responses to, *996*
and prediction of stroke volume, 250–253
torso shape, and vectorcardiographic computing systems, 83–88
total
oxygen consumption, 585
perfusion, in aortic valve surgery, *994*
weight
and atherosclerosis, *291*
and blood lipid levels, *645*
in coarctation appraisal after surgery, 807
in congestive heart failure, 1093–1098
and conversion from atrial fibrillation to sinus rhythm, 578
and correction of intracellular depletion of potassium, 1097
and diet, *634*
and dosage of Diodrast, 596
and exchangeable potassium content, 1094, 1095
gain during infancy, 189
and heredity, 55–59
hydralazine, and hexamethonium, 111
and left axis deviation, 235
and lipid levels, *645*
reduction, dietary fat and serum levels of β-lipoproteins, *1012–1013*
and serum sodium concentration, 1097
and surgery for congenital aortic stenosis, 197

Bone
marrow, in erythropoiesis, 271–272
retardation in lupus erythematosus, 126

Bradycardia
and amplitude of Qa wave, *142*
and potassium depletion, 65–66
sino-atrial
after carotid sinus massage, 1104–1112
defined, 1105
sinus, and sodium lactate, *1168*

Brain
abscess, after anastomosis, 516–517
and chlorpromazine, 380
hemodynamics in and exercise in aortic stenosis, *718*
infarction, technics for experimental, *896*
metabolic turnover in, 5
oxygenation, and meperidine and/or aminophylline, *150*
reserpine action in and serotonin, *1175*
stem, cephalic, and stress, 156
thrombosis, 774
vascular disease, 743
and anticoagulants, *973*

Breath
holding of, and ventricular alternans, 169, 171
shortness of, 189
and congenital aortic stenosis, 194, 198
and drainage of right lung into inferior vena cava, 827
and pulmonary valvulotomy, 9
and surgery for congenital aortic stenosis, 197

Breathing
and aching pain in lower left chest, 880
capacity and dyspnea, 268
and false alternans, 164
mechanics, and heart failure, 281
positive pressure, 281–282

Bronchiectasis
pulmonary blood vessels in, 333
in young subjects, 281

Bronchitis
and airway resistance, *929*
and thrombosis, 766
pulmonary arteries, 774–776

Bronchodilators, 281, 282

Bronchography, in bronchial and arterial anomalies, 828–845

Bronchopneumonia
death due to, 762, 1038–1039
and quinidine therapy, 758
terminal, and Chagas' disease, 1050–1052

Bronchospasm, 281

Bronchus
arrangement of, 829–835, 838–844
cancer of, 774
diverticula, 830, 834, 838–844
hyparterial right upper lobe, 842
obstruction of, due to pulmonary artery anomalies, *921*

Brucella abortus vaccine, 1141

Buerger's disease, and atherosclerosis, 737

Buffer
base, whole blood, 589
intracellular, *304*
phosphate pH, 57

Buffy coat, of heparinized blood, 130

Bufotenine, and hallucinations, 162

Bulbar conjunctiva, 386
Bundle-branch block. *See* Block, bundle-branch
Bundle of His, pressure on by syphilitic aortic sinus aneurysm, 121
Burger triangle, *1023*
Burn
epicardial, and late mortality, *962*
and transaminase value, 798
Bursitis
and angina pectoris, 426, 428
and rheumatic disease, *1177–1178*

Cachexia, in Chagas' disease, 1038–1039, 1050–1052
Cairivibograph, *305*
Calcification
of aorta, 120–123
of aortic valve, 193
in hearts with mitral stenosis, 404–406
of left atrium and diagnosis of thrombus, 25, 30
of mitral valve, 181–182, 402
Calcinosis
and chelation, *1176–1177*
ethylenediamine tetracetic acid for, *1176–1177*
Calcium
and arrhythmia conversion, *148*
ground substance, as cation exchange resin, 821
metabolism, *1176*
myocardial transfer of, *952*
Calcium ion
binding to meromyosin, *976–977*
and conduction block, *1171*
and electric properties of Purkinje fibers, *1171*
Cancer. *See* Carcinoma
Capillary
changes in diabetes, 394
and aging, 388
in bulbar conjunctiva, 388
distribution of flow in, 1173
fragility, due to salicylate therapy, *1168*
hemoconcentration in and hypertension, *934–935*
in hemorrhagic shock, *147–148*
permeability to protein
in congestive failure, *991*
pulmonary blood flow, *1174*
thrombi, in lupus erythematosus, 129
Carbohydrate, myocardial metabolism and hyperthyroidism, 93–94, 96
Carbon dioxide
arterial, in heart failure and lung disease, 266
body content in congenital heart disease, *306*
and chlorpromazine, 382
conventional bath, *295*
elimination of and oxygen administration, 282
and exercise in mitral stenosis, *466*
and hypertonic sodium bicarbonate, *1176*
Carcinoma
argentaffin, and heart disease, *648–649*
bronchogenic, and arteriosclerosis, *894*
of bronchus, 774
and death due to anomaly of coronary ostium, 801–803
of the lung and thrombosis, 766
metastatic sigmoid, 804
of prostate, *144*, 256
of rectum, 256
of stomach, 775
Cardiac arrest
as adjunct in intracardiac surgery, *964–965*
and anesthesia, *640–641*
and blood pH, *148*, *642*
complete atrioventricular, 464
during exchange transfusion, *301*
heart massage and adrenalin for, *301*
in irreversible failure, 196
pacemaker in, external electric, *640–641*
recovery during extracorporeal circulation, *917–918*
resuscitation from, 754
sino-atrial
after carotid sinus massage 1104–1112
defined, 1104
terminal and molar sodium lactate, 464
and cardioangiography, 852
Cardiac block. *See* Block
Cardiac index
in coarctation appraisal after operation, 807
after pentolinium, 584–590, 1061–1067
in pulsus alternans, 170–171
in valvular regurgitation, 1070
Cardiac output
and atrial dilution curves, 212–219
in congenital aortic stenosis, 196
and coronary blood flow, 93, 95, 196
and cyclopropane, *301*
and digitalization, 166
and ganglionic blocking agents, 1061–1067
and heart failure, *140*
and muscular exercise in athletes, *1171*
and peripheral cyanosis, 333
postoperatively and infundibular stenosis, 197
in pregnancy, *1174*
in polycythemia, *136*
postoperative, coarctation of aorta, 811–812
and pulsus alternans, 168
and quinidine, 166, 168
sodium dihydrocholate in estimation of, *951*
and telangiectasias, cerebral vessels, *295–296*
and thiopental sodium, *301*
and timing for operation, 198
and tissue energy metabolism, *956*
and vasodepressor syncope, *933*
and ventilation in poliomyelitis, *301*
Cardioangiography. *See* Angiocardiography
Cardiologist
nuture of, 3–8
pediatric, radiographic technics versus fluoroscopy, 509
and skin, 475
Cardiomegaly
with congestive failure in newborn, *296*
and hypertension, 108–112
Cardiopneumogram, investigations, *307*
Cardiovascular disease, 3–8
and anticoagulant drugs, *895*
familial, and myocardial infarction, *634*
fatalities, and age in male farmers, *975*
hypertensive
and conversion of atrial fibrillation, 573
and etiology, 568
in myocardial infarction, *634*
and posture, *1001*
and pulsus alternans, 163
and renal disease, in Chicago, *1006*
and thrombosis, 766
trace metals in, 155
Cardiovascular system
abnormalities of
and circulating catecholamines, 615
and potassium depletion, 60–69
adjustments by, and splanchinic circulation, 155
alterations in Marfan's syndrome, *885*
anomalies of, 520
bulbar regulation of, 156
and chlorisondamine, *639*
congenital malformations, *136–137*
damage to, and diet, *503*
and Digoxin, *140–141*
and Ecolid, *639*
and exercise, *894*
function after, *296*
and ganglionic blocking agents, *144*
hypertensive disease of, 155, 177
and mechanical force of heart, *894*
and metabolic disturbances, 60–69
of newborn infant cardiovascular status of normal, *904–905*
and pentolinium, *998*
and resperine, 156
syphilitic involvement of, 119–122
status of, *951*
and ventricular septal defect anomalous, 987
position of, 361
Carditis, rheumatic
in Chagas' disease, 1053

factors determining hormone therapy results, 44–47
subclinical, *1179–1180*
Carotid artery
chemoreceptors in, and anoxemia, *1171*
internal, and anticoagulant drugs, *895*
pulsations of and congenital aortic stenosis, 190
and retrograde brachial aortography, 595–597
thrombosis of, in childhood, 895
Carotid sinus
blood pressure, and norepinephrine, *648*
hypertension
and constriction of, *923*
and curare, 464
massage, responses to, 1104–1112
occlusion of, *893*
sensitivity to sodium lactate, *1168*
stimulation
cardioinhibitory effects of, 1104–1112
electrocardiograms after, *951*, 1104–1112
pulmonary blood pressure after, *893*
veratridine, and potassium for, *1165*
Casein and hypercholesteremia, 488
Catecholamine, 614–618
Catheter, location of, and anomalous drainage, 210
Catheterization, cardiac, *147*
anesthesia for children during, *650*
aorta - pulmonary communication, 1090–1092
aortic stenosis, *942*
and mitral, *904*
and arteriovenous fistula, 1090–1092
in bronchial and arterial anomalies, 828
and congenital aortic stenosis, 193
in diagnosis, *474*
of congenital aortic stenosis, 196, 198
and drainage of right lung into inferior vena cava, 827
and hemodynamics in pregnancy, *303*
idiopathic dilatation of pulmonary artery, *301*
in infancy, *633*
after mitral commissurotomy, 179–180, 182
"oxygen jump" during, *1173–1174*
in wide patent ductus, *135*
and pressure recordings, *643*
pulmonary
coarctation, *135*
valvulotomy, 14–15
right and left heart simultaneously, *935*, *995*
and shunt in erythrocytosis, 280
in ventricular septal defect, 362
Cation, and aldosterone, 1030
Caucasian, hypertension in, 17–23
Cell
aortic mast, *503*
blood counts, and cyanosis, 10–11
epithelial, after aortography, 611
giant
aortitis of, *962–963*
multinucleated, 1050
electric alternans at membrane level, *718*
infiltration
and Chagas' disease, 1056–1058
of polymorphonuclear, 125, *138*
Leydig, and estrogen, 369, 371
monocytoid, and Chagas' disease, 1040
overhydration, and absolute excess of water 1029
permeability of boundaries to water, 1030
potassium during electric activity *304*
Central nervous system
and chlorpromazine, 380
and congenital aortic stenosis, 198
and oxygen supply to cerebral tissue, 194
and surgery, for congenital aortic stenosis, 197
symptoms, and congenital aortic stenosis, 189
Cephalin flocculation tests, in systemic lupus erythematosus, 132–133
Cerebrovascular disease
and heparin, *149*
studies in, *896*
Cerebrovascular system
accident
and/or coronary thrombosis, *139*
and pulmonary thrombosis and aminophylline, *150*
Chagas' disease 1035–1059
Chest
of angina pectoris, 424–425
beat, with electrodes in, 748
in Chagas' disease, 1038–1039
expiratory position of and polycythemia, 279
growth of and cardiothoracic ratio after valvulotomy, 13–15
left pleural effusion in, 413
pain
and aortic regurgitation, 117
and aortic stenosis, 190, 198
cardiac origin, *138*
of chest wall syndrome, *138*
during congestive failure therapy, 1094
of coronary failure, 423
and coronary flow, 194
and death due to anomalies of coronary ostia, 802
and emetine toxicity, 33–37
and heart failure, 117
hypertrophy of left ventricle, 194
in myocardial infarction and pericarditis, 874
due to myocardial ischemia, 194
and pulmonary hypertension, 274–275, 329
and Tietze's syndrome, *910–911*
and thrombosis of pulmonary arteries, 770
and ventricular aneurysm, *293*
position of left ventricle in, and cardiac conditions, 233
and surgery for congenital aortic stenosis, 197
after valvulotomy, 12–15
wall, vibrations of, 788–789
Cheyne-Stokes respiration, and aminophylline, *150*
Child
anesthesia for, during cardiac catheterization, *650*
cardiac chamber enlargement, 116, 123
electrocardiography in, 118
cardiothoracic ratio after pulmonary valvulotomy, 13–15
congestive heart failure in and digoxin, *979–980*
and Chagas' heart disease, 1058
conjunctival vascular bed of, 388
and dilatation of aorta, 599
dissecting aneurysm in, 457
heart disease in school program for, *990–991*
hyponatremia in after surgery, *950*
injury to soft palate area in, *895*
innocent systolic murmurs in, *655*
liver enlargement in, 127
lupus erythematosus in, 125
nail changes, 128
nephrotic syndrome in ACTH or steroid therapy for, *972*
postoperative ambulation, 197
patent ductus arteriosus in, 602, *632*, *932*
and pulmonary stenosis, 192
pheochromocytoma, 454
prophylaxis against streptococcal infection in rheumatic, *1020–1021*
pulmonary coarctation in, *135*
pulmonic-systolic murmur in, *1170*
retrograde brachial aortography in, 593
rheumatic
hormone dosages in treatment for, 44–47
recovery of, 1154
rheumatic fever,
incidence of, 127, *989*
and prolonged residence in Miami, Florida, *995–996*
sickle-cell anemia in, *653*
streptococcal infections, 1145
China, hypertension in, 20
Chloride
barium, arryhthmia due to, *646*

Chloride (*Cont'd*)
and cholesterol level in liver, *1172*
and diuretic activity, *149*
excretion, 588–590
and mercurials, *149*
reabsorption and proximal tubular inhibition, *151*
serum concentration, 589
toxicity of, 501
urinary, in geriatrics, *140*
Chordae tendineae, tensing of, *1169*
Chlopromazine
and blood pressure, 383
and gastric secretion, *643*
metabolic effect of, 384
peripheral adrenergic blocking effect of, 383
and serotonin, 162
Chlorine ion, binding to meromyosin, *976–977*
Chlorisondamine, *639*
Chloroquine, 128
Cholecystectomy, and postcommissurotomy, 182
Cholecystitis, and transaminase value, 798
Cholestanol, 3*β*, and metabolism of cholesterol, 485
Cholesterol
and atherosclerosis, *481*, *491*, *502*, 691–739, *970*
coronary, *499*, *983*
biliary tract lesions and gallstones after, 484
in blood, 481
in butter and corn oil, 484
capacity to handle exogenously fed, *497*
and chloride levels, *1172*
dietary
and hypothyroidism, 344–347
lesions due to, 484
lipid and phospholipid response to, *303*
and serum protein, *962*
sensitivity to, *922–923*
and thyroxine analogue, 491
and estrogen, 366, 371
and atherogenic diet, 489
excretion of in hypothyroidism, 347
feeding, in shell parakeet, *497*
hepatic synthesis, in hypothyroidism, 347
in idiopathic hyperlipemia, *502*
intake and lipids of connective tissue, 487
intravenous tolerance test, *496*
and lipoprotein
as indices of atherogenesis, 691–739, *970*
serum fractions, 367
measurement methods, results appraisal, 696–700
metabolism, *654–655*
and 3 *β*-cholestanol, 485
and nicotinic acid, *494–495*
and phospholipid
during growth, 57
patterns in plasma, *305*
synthesis, *305*
reduction, *495–496*, *1166–1167*
serum
during growth, 57
in normal adults, *304*
and sitosterol, 78–81
biliary and dietary absorption after, 81
in liver, 344, *1172*
and tissue-lipid accumulation, *305*
total body
control of levels, *305*
heredity factors, 57–59
after myocardial infarction, 371
Cholinergics, dilator responses to, *944–945*
Cholinesterase, and acetylcholine effects on heart, 646
Chorda, in mitral stenosis study, 399–402, 404
Chorea
and disease activity, 1154–1158
and lupus erythematosus, 133
Chylomicron, and heparin, *149*
Cineangiocardiography
infundibular dynamics in valvular pulmonary stenosis, *918*
and syndrome of congenital absence of spleen, 524
Circulation
alternation in pulmonary and systemic, 163–173
anomalous drainage from each lung, 218
bronchial collateral to lungs, 333
catecholamines and adrenolytic drugs, 614
central blood flow and mixing in, *920*
cerebral
and Neo-Iopax, 596
and opaque medium, 601
collateral
and dilated descending aorta, 119
and patent ductus arteriosus, 604
of portal system, 1080
and recovery of cyanosed and anesthetic digital skin, 1089
and common atrioventricular canal, 200–219
control system and balance in, 5
coronary
and blood pressure, *1011*
impaired, and atherosclerosis, 423
digital
and arm position, *305*
in hypertension, as guide to drug therapy, *973–974*
dynamics and appraisal of coarctation after operation, 806–814
and external stimulation during sinus rhythm, 750
in ether narcosis, *300*
exclusion of right ventricle, *304*
extracorporeal, *917–918*
and surgery for congenital aorticopulmonary septal window, *923*
after ganglionic-blocking agents, postural influences on 1066–1067
hemodynamics and surgery for perforated aneurysms, 123
hypertension of lesser and Priscoline, 285
and hyperthyroidism, 97
interatrial and interventricular communications, 200–219
in kyphoscoliosis, *935*
left atrial time and thrombus, 31
in myocardial infarction, *140*
and nurture of cardiologist, 3–8
after pentolinium blood shifted from pulmonary to peripheral, 1061, 1066
peripheral
and dimethyl-amino-propyl-N-chlorophenothiazin, *645*
and N - methyl - piperidyl - 3 - methyl phenothiazin, *645–646*
portal pulmonary venous drainage into, 520–521
and pressure changes, 173
in mitral insufficiency, *966–967*
pulmonary
in mitral disease and hydrazinophthalazine, *1177–1178*
and occlusion of carotid arteries, *893*
vasomotor activity in, *990*
respiratory, *300*
responses to acidosis and alkalosis, *988*
and smoking, *463*, *967*
splanchnic, in cardiovascular adjustments, 155
splenic, *136*
systemic
and epinephrine, *151–152*
and norepinephrine, *151–152*
passive congestion in and Chagas' disease, 1046
time
anomalous pulmonary venous connection, 218
in appraisal of coarctation after operation, 812
in atrial septal defect, 203, 218
common atrioventricular canal, 203, 218
and conversion from atrial fibrillation to sinus rhythm, 578
after pentolinium, 1061–1067
and potassium depletion, 62
sodium dihydrocholate in estimation of, *951*
transcoronary, *943*
and Valsalva maneuver, 74
and unilateral pulmonary hypoxia, 463
visceral, in lupus erythematosus, 130
Cirrhosis
and arteriosclerosis of aorta, *894*
bronze, myocardial lesions, 457
cardiac, 412–421
and jaundice, *297*
Climate
and hypertension, 20
and mortality rate in myocardial infarction, *634*

Clubbing
of fingers
in erythemia, 280
in lupus erythematosus, 125
in pulmonary hypertension, 330
and toes, 524
Coagulation
of blood, 479
after fatty meal, 854–858
in Chagas' disease, 1037
defects, in systemic lupus erythematosus, *291*
and hypothermia, *632*, *959*
and lipemia, 855–856
and plasma lipids, 479
standardized and control of anticoagulant therapy, *921*
whole blood times
and dietary fat, 854–858
standardized methods, 479
Coarctation
of aorta. *See* Aorta, coarctation of
pulmonary, *135*
surgical correction of and diastolic pressure changes, 810
Coccidioidomycosis, and arterial necrosis, 337
Colic, and hematuria, 185–186
Colon
ascending, persistence of dorsal mesentery of, 523
jejunum and ileum situs inversus of, 521
mobility of, 521
perforated sigmoid, 804
rectosigmoid, mucosal ecchymoses in, 112
transverse, 520
Coma, in thrombotic occlusion, 773, 779
Commissure
involvement of, 399–402
in mitral stenosis, 403–406
and thrombosis in pulmonary arteries, 770
Commissurotomy
mitral, *308*
and coexisting aortic valve lesions, *1010*
complications after, *1014*
and cortisone cardiac rheumatic lesions, *1177–1178*
electrocardiac changes in, *142*
embolus during, 181–182
fatigue level after, 176
follow-up of status after, 175–182
hemodynamic changes after, *927*
rheumatic changes after, 178–179
postcommissurotomy syndrome, *307*
systolic thrill and murmur after, 197, 471
tricuspid, 470
Compensation law and heart disease, *654*
Concato's disease, polyserositis, 416–417
Conduction
atrioventricular
and atrial flutter, *889*
after carotid sinus massage, 1104–1112
in Chagas' disease, 1042, 1048
and external cardiac stimulation, 750
in rheumatic fever, 1147
slowing, 1106
concealed arteriovenous, 890
defects
defined, 1105–1106
with pulsus alternans, 168
retrograde, *143*
to atria, *143*
time
atrioventricular, in emetine toxicity, 36
ventricular, cooling and rewarming, *148*
ventricular
in left bundle-branch block, 243
and ventricular excitability, *148*
volume, potential disturbances, *305*
Congestion
in Chagas' disease, 1046, 1050–1052, 1058
and exchangeable sodium, 1094
after mitral commissurotomy, 181
pulmonary
and abnormally situated azygos vein, 1080
cause of death with ventricle septal defect, 357
in fibrinous pneumonitis, 112
and pure left papillary muscle syndrome, 1134
Congo, hypertension among natives, 20
Connective tissue
and fibrinoid substance in disseminated lupus erythematosus, 130
in fibroelastosis and tricuspid stenosis, 420
lipids of
and cholesterol intake, 487
in cornea and vascularization, 487
proliferation of interstitial and Chagas' disease, 1040
protein components and mucopolysaccharides, *972–973*
rheumatic sera in, *958–959*
septa and lobular architecture, 417
Conn's syndrome, with severe hypertension, *891*
Conus
and ostium, 419
papillary muscle, 350–356
Convulsions
and absolute excess of water, 1029
death due to in Chagas' disease, 1038–1039
and lupus erythematosus, 133
epileptiform, 131
Cor biloculare
and absence of spleen, 522
with ostium atrioventriculare commune, 521
Cornea, vascularization, 487
Coronary artery
anomalous, *136*, 801–805
absence of right, 521
aortic sinuses, and valves, 115–116
arteriosclerosis of
detection, 4
and electrocardiographic age trends, 103
atheromatous plaque and Chagas' disease, 1050–1052
atherosclerosis, 702–714, 718, 736–737
and blood lipid levels, 725–726
and embolism, 1162
and estrogen, 365–366
serum proteins, lipids and lipoproteins, *914–915*
blood flow
and cardiac arrhythmias, *922*
and cardiac output, 93, 95, 196
and chest pain, 194
and hypoxia, *292*
calcareous mass and embolus, 1161
desaturated blood supply to in older subjects, 270
disease, *996–997*
in American soldiers killed in Korea, *291*
disease of
and angina pectoris, 423–424
and anterior chest wall syndrome, *138*
and anticoagulant therapy, 257
Beck operation for, *965–966*
and bundle-branch block, *925*
and cardiac asthma, 423
and Chagas' disease, 1050–1052
and coronary failure, 423
c-reactive protein and transaminase in, *963*
death due to and geographic differences, *932–933*
and emetive toxicity, 37
hypertensive, 762
and intra-atrial block, 1077
and left axis deviation, 233, 238–244
and low fat diet, *499*
physically active workers with, *635*
and "pseudo angina" or "atypical angina," 424
and pulsus alternans, 1099–1101
and *Rauwolfia serpentina*, 227–232
surgical treatment for, *293*, *965*
and thrombosis of pulmonary arteries, 774
transaminase assays in, 790–799
embolism, 1159–1163
failure, defined, 423
insufficiency of
and blood flow, *139*
and Chagas' disease, 1058
mammary artery implantation for, *1012*
and papillary muscle syndrome, 1131

Coronary artery (*Cont'd*)
myokinase activity of and drugs, *139*
narrowing of and exercise, *930*
obliterative changes of in Chagas' disease, 1058
occlusion
fibrillation after, *1014–1015*
intercoronary anastomosis after, *292*
and myocardial infarction, *292*
and sudden death, *294*
and syphilitic aortic sinus, 121
opacification of and normal aortograms, 597
ostium of left, 351
sclerosis of, and atherosclerosis, 702, 709, 736–737
thrombosis of, *138*, 770
and atherosclerosis, 702, 709, 736–737
Coronary sinus
arterial oxygen difference and glucose, lactic and pyruvic acid, 96–97
arterialization of, artery ligation after, *137*
intrinsicoid deflections in, *637*
Cor pulmonale
and alveolar-arterial gradient, 274
and blood red cell levels, 284
and anomalous arterial distribution, 804
and cyanosis at birth, *137*
electrocardiographic finding, 122
and erythrocytosis with lung disease, 280
and exchangeable potassium content, 1094
and heart failure, 281
management of, 280–285
in newborn, *137*
and noradrenalin, *649*
and papillary muscle syndrome, 1131–1132
and pulmonary
destruction, *633*
thrombosis, 776
and pulsus alternans, 167, 171
and response to Valsalva maneuver, 74–76
and right ventricular hypertrophy, 278
and systemic hypertension, 280
x-ray configuration, 277
Corticosteroids, and anterior chest wall syndrome, *138*
Corticotropin
and anterior chest wall syndrome, *138*
after hypophysectomy, *141*
inflammatory response to, 281
and rheumatic disorders, *1177–1178*
for rheumatic fever
body composition changes after, *905–906*
and myocardial infarction, *650*
and carditis, 44–47
and valvular heart disease, 1146, 1156
and steroid therapy of nephrotic syndrome, *972*
Cortisone
and aspirin in heart failure, 1157
and/or cholesterol and phospholipid turnover, *303*
in lupus erythematosus, 125–127
and rheumatic disorders, *1177–1178*
for rheumatic fever
and carditis, 44–47
and valvular heart disease, 1146, 1156
Cough
in heart failure, 412
and systemic lupus erythematosus, 125
Crista supraventricularis, and ventricular septal defects, 350–356, 362–363
Curare, 464
Curettage, of uterus, and postcommissurotomy, 182
Cyanosis
adult fibroelastosis with congenital tricuspid stenosis, 421
at birth
and anomalous coronary ostia, 802
and cor pulmonale, *137*
of "black cardiacs," 271
and blood flow direction, 1090–1092
coronary artery anomalies, 801–804
death due to in congenital mitral atresia, *136*
and dyspnea, *885*
in heart failure, 270–271, 338
in lung disease, 268
in hypertensive pulmonary vascular disease, 333
and occlusion of
peripheral arteries, 1084–1089
thrombotic, 779
and pulmonary
hypertensive disease, 330–332, *885*
valvulotomy, 9–10, 13–15
and syndrome of congenital absence of spleen, 524
Cyclopropane
and cardiac arrhythmias, *644*, *650*
and cardiac output, *301*
concentration of and myocardial function, *1172*
Cylindruria, and hypertension, 111
Cysteine, and heart force, *640*

Deafness, and quinidine, 573
Decamethonium, and arrhythmia, *150*
Decholin circulation times for assessing status of cardiovascular system, *951*
Desoxycorticosterone acetate
and cortisone, *296*
and estrogen, 368, 371
and heart failure, *296*
nephrosclerosing action of, *144*
Desoxyribonucleoprotein, abnormality in disseminated lupus erythematosus, 130
Dextran
changes in serum proteins produced by, *640*
and hemorrhagic shock, *639–640*
Dextrocardia, *632*
and aortic arch, 520–521
and drainage of right lung into inferior vena cava, 827
Diabetes mellitus
and adrenal cortex hormones, *144*
aging in, and red cells, 390
and angina pectoris, 425
angioscopic changes, 386
and arteriosclerosis, 386, 472–473
and conjunctival vascular bed, 387
with Kimmelstiel-Wilson disease vectorcardiography in, 52
and lipfanogen-antilipfanogen balance with insulin, *498–499*
and myocardial infarction, *634*
and vascular disease
and hexosamine, *912*
premature, 473
retinal abnormalities, 953–954
Diamox
for congestive failure and exchangeable potassium content, 1094
and emphysema heart, 282
metabolic effects of, *1168*
Diasthesis, hemorrhagic, and salicylate therapy, *1168*
Diarrhea, and quinidine, 573
Diatrizoate sodium, and retrograde brachial aortography, 596
Dibenzyline
blockade by duration of, *1166*
and electrocardiographic responses, 616
and heart rate, 616
and uremia, 615
Dicumarol
for myocardial infarction, long-term therapy, 254–259
and surgery, *883*
Diet
and atherogenesis, 489
and blood pressure, *145*
and cardiovascular damage, *503*
casein in, and hypercholesteremia, 488
cholesterol in and concentrations after, 57, 484, 491
and hypothyroidism, 344–347
lesions due to, 484
lipid and phospholipid response to, *303*
and serum protein, *962*
and eosinopenia, *145*
and fasting, *145*
fatty food
and argentaffinoma, *642*
and atherosclerosis, *499*
and blood coagulation, 854–858
and heart rate, *145*
and hepatic renal damage, *503*
high-fat, high-cholesterol, *922–923*

high-fat, high-protein, *488*
and hormone imbalance, coronary atherogenesis, *983*
and lipoprotein concentrations, *57*
low-fat, and artery diseases, *499*
low-salt, after mitral commissurotomy, 177
for postcoronary patients, *634*
rice, in hypertensive vascular disease with papilledema, *143*
Diethanolamine salt, *919*
Diethylamide, lysergic acid, 162
Diethyl ether
concentration of and myocardial function, *1172*
negative inotropic effects of, *650–651*
Digitalis
and apical diastolic gallop, 168
ballistocardiogram in test for effect, *907*
and bilateral alternans, 166, 169
for cardiac failure due to congenital aortic stenosis, 189
and cardiac work, *894*
for congestive failure, 281
and exchangeable potassium content, 1094
electrocardiography, 793
atrial premature systoles, *890*
and emphysema heart, 282
and first heart sound in arrhythmia, *1170*
and geriatric patient, *140*
and hypothermia, *1167*
intoxication, *917*
and intracellular potassium, *640*
and papillary muscle syndrome, 1131
and intra-atrial block, 1076–1077
after mitral commissurotomy, 177
and pulmonary pressure, 281
and pulsus alternans, 166
and/or quinidine
for atrial fibrillation, *1016*
in congestive heart failure, 818
Digitoxin
for congestive heart failure, 1094, *1167*
and exchangeable potassium content, *647*, 1094
Digoxin
and cardiovascular function, *140–141*
for congestive heart failure
and exchangeable potassium content, 1094
in infants and children, *979–980*
right-sided, *140–141*
and pulsus alternans, 166, 169
and renal hemodynamic function, *140–141*
and sodium excretion, *140–141*
Dilatation
aneurysmal
of aortic sinuses, 117–122
and cardiac chambers, 116
diffuse, and syphilis, 120
muscular pulmonary arteries, 333
of aorta
and age of child, 599
ascending, 193–195
poststenotic, *147*
and post-traumatic aortic insufficiency, *639*
and aortogram, 598
cardiac, and pericardial effusion, 875–876
in Chagas' disease, 1046, 1050–1052, 1056, 1058
and concentric hypertrophy, 277–279
congenital and sudden death, 331
and heart enlargement in Chagas' disease, 1046
left ventricle hypertrophy of, 376
plastic, in isolated hearts, *300*
of pulmonary artery
cardiac catheterization in, *301*
and sudden death, 331
varicose, 417
Dimethylamino-propyl-N-chlorophenothiazin, 645
Diodrast, and retrograde brachial aortography, 595–596
Diphenhydramine, *142*
Diphenyl butylamine, *646*
Diphtheria
and myocarditis, 457
toxoid, and rheumatic fever, 1141
Diuresis
and benzodioxane, in pheochromocytoma, 221–226
and chloride, *149*
and geriatric patient, *140*
mercurial
and acid-base balance, *1164*
and chloride, *149*
in congestive heart failure, 1094, *1168*
molecular hypothesis for, *910*
Neohydrin as, *889*
renal site of action of, *149*
after mitral commissurotomy, 177
and piperoxan in pheochromocytoma, 221–226
proximal tubule as site of action, *149*
and quinidine, 579
sodium in, *149*
water, *149*
Diverticulitis, and thrombosis, pulmonary, 774
Diverticulum
bronchial, 830–844
retroesophageal aortic, 599–606
Ductus
arteriosus. *See* Arteriosus, ductus
diverticulum, 599, 601
malignant, 603
Duodenum
liver, and stomach anomalies, 520
pancreatic duct opened separately into, 521–522
and situs inversus of viscera, 521
of triatomid bugs parasite development in, 1037
ulcer, perforated, 801
Dyscrasia, erythropoiesis, and polycythemia vera, 280
Dyspnea
and adult fibroelastosis, 421
and angina pectoris, 426, 428
and congestive failure, 412
exchangeable potassium content, 1094
and coronary
anomalies, 801–804
insufficiency, 423
and cyanosis, *885*
and digitalis for pulmonary disease, 281
in emphysema, 274
and erythrocytosis, 279
on exertion
cardiothoracic ratio after valvulotomy, 13
in Eisenmenger's complex, 329
after pulmonary valvulotomy, 10
and hypertension, 109
pulmonary, 274
and pure left papillary muscle syndrome, 1134
and quinidine, 579
in rheumatic heart disease, *985*
and rupture of aortic sinus aneurysms, 122–123
and stenosis
aortic, 194, 197
mitral, 302
tricuspid, 421
and subacute bacterial endocarditis, 117
and thrombosis of pulmonary artery, 770, 778–779
and vital capacity, and heart failure in lung disease, 267–268

Ear, hemorrhage due to anticoagulant, 257–259
Ebstein's anomaly, *913*
diagnostic sign, 415
of left atrioventricular valve, *633*
tricuspid valve in, 417
Ecchymoses, and anticoagulant long-term therapy, 257–259
Ecolid
and malignant hypertension, 108–109
pharmacology of, *639*
Edema
adult fibroelastosis with congenital tricuspid stenosis, 421
due to aging in diabetes mellitus, 390
and alcohol, *148*, *635*, *975*
and Chagas' disease, 1037, 1039, 1050, 1058
and heart failure, 412
due to *Rauwolfia serpentina*, *635*
therapy for, and exchangeable sodium, 1094
drainage of massive, *295*
hyponatremic, alcohol in therapy of, *975*
in lupus erythematosus
angioneurotic, 132
inflammatory, 130

Edema (*Cont'd*)
pulmonary
and absolute excess of water, 1029
antifoaming agents in, *148*
and congenital aortic stenosis, 194
and coronary artery disease, 423
death due to, 112, *633*, 762
and estrogen, 366
and hypersensitive carotid sinus syndrome, 1104–1112
intravenous calcium in, *946*
after myocardial infarction, *140*
paroxysmal, *635*
and quinidine therapy, 758
in rheumatic heart disease, *985*
valvulotomy, 11
and ventricular defect
death due to, 357
in infancy, 361
Effusion
pericardial, *149*
and myocardial infarction, 875–876
simulation of and dilatation of heart, *147*
subepicardial fat in diagnosis, *1179–1180*
pleural, *652*
left, 413
right, 417
Einthoven triangle, versus Burger triangle, *1023*
Eisenmenger's complex
and biventricular aorta, 1114
defined, 338
and hypertensive pulmonary vascular disease, 323–340
and intravascular pressures, *887*
Electrocardiography
abnormalities
associations with, 1134
and atherosclerosis prediction, 702, 709, 718, 734–737
in emetine toxicity, 33–37
after adrenolytic drugs, 619
age trends, 101
in Italian populations, 103
of alligator's heart, 1114–1116
ambiguities of nomenclature, 244
amplitude
alternate systolic, ventricular vascular system, 173
of P wave, after mitral commissurotomy, 177
of U wave, in hypopotassemia, *1007*
in amyloidosis, *911*
in aneurysms, unperforated aortic sinus, 118
syphilitic, 122
anginal syndrome, 228
Rauwolfia serpentina, 230
angina pectoris, 103, 230, 425, 867
aortic heart disease
arterial hypertensive, 867
and papillary muscle, 1132
in assessing cardiac status, 870
of arteriosclerosis, 103
and atrioventricular synchronization, 38–43
and atropine, *146*
axis deviation
and anomalous coronary ostium, 801–803
and pulsus alternans, 171
axis deviation, left, 233–249
peri-infarction block, *944*
QRS, *889–890*
terminal QRS, 242–244
axis deviation, right, 122, 278
and body build, 916
"masquerading" pattern, *1009*
QRS complex responses, *142*
in bundle-branch block, *141*, 243, 277–279, 796, *914*
after carotid sinus stimulation, *951*, 1104–1112
in Chagas' disease, 1038–1052
in congenital aortic stenosis, 193, 196
contiguous bipolar, and time of arrival of activation, *141*
in coronary
artery anomalies, *136*, 800–803
disease, 423, 790–799
insufficiency, 423, 793, 867
occlusion, *292*
after dibenzyline, 616
and digitalis, 793, *890*
electrode placement and result variations, 558–566
in emphysema, 277–279
and epinephrine, 614, 821
in erythropoiesis, 280
and exercise-induced angina pectoris, 432–433
experimental survival after centigrade, *637*
and external electric
and pacemaker, 749
stimulation, 746–755
failure of correlation in electrolyte imbalance, 815–823
of healthy children, analysis of P-R interval in, *636*
and heart
block, 118
congestive failure, *636*, 818
disease, 297, 864–867, 1131–1132, *1169*
enlargement of, 118
mobility, *297*
position of, 243, *636*
in hypertension
arterial, 1132
norepinephrine-induced, *146*
pulmonary idiopathic, 331
hypertrophic myocardium R wave pattern in, 277–279
lead
amplitude and age, 101
and electrode placement, 556
multiple, and depolarization, *637*
number recorded, 551, 553
pulsus alternans, during exercise, 172
sagittal, in two-dimensional homogenous model, 49
systems, comparison of, *953*, *997–998*
twelve, and angina pectoris, 425
lead, esophageal
and cavitary, for auricular activation study, *637*
and intracardiac, in atrial flutter, 451
lead, precordial
and arrival time of activation, *141*
horizontal plane, and age trends, 101
morphologic types of negative U waves, 867
QRS duration, in incomplete bundle-branch block, *141*
and R′ deflections, 244
site for recording of, 246
of left ventricle
infarction, 540–554
strain pattern, 619
in malignant hypertension with renal azotemia, 110–113
"masking" and pattern of myocardial infarction, 795
of mediastinopericarditis, *297*
mitral
commissurotomy, *142*, 177–178, 182
insufficiency, 867, *956–957*, *1169*
surgery, *956–957*
muscular tremor, typical patterns of, *638*
in myocardial infarction, *140*, 237–249, *292*, 540–544, 798, 867, 876–877, 1132
myocardial ischemia, 793–794
ST-T wave, 794, 798
of myocardium, after caustic substances, 451
in neurasthenia, 818
and norepinephine, *146*
in operable heart disease, 595–596
pacemaker
cardiac, 636
idioventricular, *891*
intrinsic sino-atrial, 747–750
in palpitation, *152*
in papillary muscle syndrome, 1129
paresis after poliomyelitis, *638*
patent ductus arteriosus with pulmonary hypertension, 326
in pericarditis, 876–880
or myocardial anoxia, 414
in pleuropericarditis, *297*
and potassium
depletion, 66–69
serum concentration, 818–823
P-R interval
after carotid sinus massage, 1107–1112
and emetine toxicity, 33–35
rheumatic fever and hormone dosage, 45
and Scilla, *151*
P wave, 767
after carotid sinus massage, 1107–1112
in intra-atrial block, 1073
in cardiac amyloidosis, *911*
after mitral commissurotomy, 177

in pulmonary
disease, 277–278
embolism, 472
hypertensive heart disease, 277
valvulotomy, 11–12, 15
Q-FA$_s$, time and pulsus alternans, 168–169
QRS, 244
criteria for infarction, 234
duration, and quinidine, 573–574, 581
and emetine toxicity, 33–35
and position of heart, 243
in hyperpotassemia, *143*
interval and left axis deviation, 233
in lead I or V$_6$, *143*
left axis deviation, *889–890*
of left ventricular hypertrophy, 234–236
QRS complex, *142*, 246
in left ventricular hypertrophy, 236–237
after mitral commissurotomy, 177
and pulsus alternans, 168–169
and sodium depletion, 66, 69
and ventricular tachycardia, *984*
QRS forces
in anterolateral peri-infarction block, 238
and left axis deviation, 237–241
QRS and T waves
in cardiac amyloidosis, *911*
and cardiac enlargement, 374–375
"Q wave" patterns
and left axis deviation, 239
and myocardial infarction, 798
and ST segments in anomalous coronary artery, *136*
due to ventricular scars, *996*
of pulsus alternans, 170–171
and quinidine, 577–579
control of tachycardia, ventricular, 761
myocardial toxicity, 573–574, 581
R wave and bundle-branch block, 277–279
and regitine, 616
ST and T wave, 617–618
in renal insufficiency, 614
after retrograde aortography, 611
in rheumatic fever, *906*, 1146–1147
in scarlet fever, and arthralgia, 1146–1147
and sinus rhythm with ventricular extrasystoles, *143*
and smoking, *967*
S-T junction and atherosclerosis prediction, 734
S-T segment
in aneurysms of posterior wall, *146*
in emetine toxicity, 33–36
and oxygen differentials in heart, *915*
in pericarditis, 878–879
S-T segment, T wave, and myocardial infarction, 793
myocardial necrosis, 798
in left ventricular hypertrophy, 237
U wave responses to potassium concentrations, 66–69
S wave
in hyperpotassemia, *143*
in lead I or V$_6$, *143*
in subendocardial ischemia, 793
in thrombotic occlusion of pulmonary artery, 773, 780
in toxic myocarditis due to common cold, *147*
T wave, and electrolyte disturbances, *143*
T-U tract, 861, 865–867
T wave
in emetine toxicity, 33–36
in hyperpotassemia, *143*
inversion, and atherosclerosis, 734
and S-T segment, renal insufficiency, 614
unstability of, *911*
unipolar technics, *297*
United States survey of, *947*
U wave
amplitude, *1007*
definitions and limits, *297–298*
negativity, 859–867
and T-U segment, 1129–1136
types of, 861–867
ventricle
infarction of lateral wall, 545
and quinidine, 573–574, 581
versus transaminase assays
in coronary artery anomalies, 790–799
myocardial infarction, 796–799
versus vectorcardiography
lead-field concept, 48–54
lead systems for, *953*
variability of linear time-scale curves, 559
in ventricular hypertrophy, *891*
Electrokymography
in congenital heart disease, *887*
in hypokalemia study, 61–62, 65
Electrolyte
complications, in geriatrics, *140*
disturbances
and emetine toxicity, 36
after mitral valve surgery, *927–928*
and T wave, *143*
excretion, 588–590
and hypophysectomy, *141*
imbalance
electrocardiogram in, 815–823
and rice diet, *143*
pattern in malignant hypertension disorder, 818
serum values
in electrocardiograms and hypokalemia, 818–823
during therapy of congestive failure, 1094
and water
exchanges, *940*
excretion, in hypertension, *955*
metabolism in hypertension, *892*
Electrophoresis
in elderly, and serum lipids, *494*
in estrogen therapy for coronary atherosclerosis, 367–370
in idiopathic hyperlipemia and fat ingestion, *502*
of lipoproteins moving boundary, *497–498*
Embolectomy, right foot, 412
Embolism
and atrial fibrillation, 757–763
and cardiac condition, 412
cerebral
and anticoagulant therapy, mortality after, 256
and pulmonary artery thrombosis, 770
coronary, 1159–1163
mortality rate, 1162
femoral artery lumbar sympathectomy, 412
during mitral commissurotomy, 181–182
in mitral stenosis and thrombus in left atrium, 30
paradoxical, 416–417
peripheral arterial, *963*
pulmonary, 277–279, 472, *994*, *1016–1017*
and anomalous coronary arteries, 801–804
blockage in, and death, *961*
and Chagas' disease, 1050–1052
and Chagas' disease with *Schizotrypanum cruzi*, 1050
and lung disease, 266
and pulmonary vasoconstriction, 161
and serotonin, *893*
transaminase in, 796–797
and quinidine, 575, 579–581, 757–763
and rheumatic heart disease, 577
into right leg, 421
and sudden death, 757–763
systemic, 572, 770
and thrombus differentiation, 1159–1162
Emetine, toxicity, 33–37
Emphysema
electrocardiography in, 277–279
heart, 266–271
and mountain sickness, 280
postural drainage in young subjects, 281
pulmonary
and left axis deviation, 241–249
and pulsus alternans, 171
and response to Valsalva maneuver, 74
radiologic picture, 276–277
and responses to altitude, 283
and thrombosis, 776
Employment, for cardiacs, *654*
Encephalitis
in Chagas' disease, 1038–1039
hypertensive, 107
post-vaccination, *139*
Encephalmyocarditis, virus infection in childhood, *652*
Endocardium
elastic membranes and vessels in, 418
parietal and Chagas' disease, 1056
Endocrinium, *971*

Endoelectrography, right atrial, *142*
Endothelium
regeneration of, 487
rheumatic sera and heart tissue in, *958–959*
Endotoxin
bacterial versus shock syndrome, *1024*
in group A streptococcal lysates, *1007*
lipopolysaccharide and gram negative bacteria, *1008*
Environment
geographic differences and deaths from coronary artery disease, 932–933
and hypertension, 20–23, *145*, *299*
Eosinopenia
and diet, *145*
due to histamine, *1177–1178*
Ephedrine, *152*
Epicarditis
and Chagas' disease, 1050–1052
Epicardium
lymphocytes and plasma cells in, and Chagas' disease, 1056–1058
vectors from, and QRS interval, 238
Epilepsy
Jacksonian, 117
and leukopenia, lupus erythematosis, 128
Epinephrine
adrenal, 281
antidiuretic action of, *1164*
posthypophyseal, 214–226
blocking pressor effect of, 624–625
blood pressure responses to, *638*
cardiovascular manifestations of discharge, *151*
and cation movements of red cells, *644*
circulating action of, 233
coronary blood flow after, *139*
electrocardiographic alterations induced by, 614, 821
and extrasystole, *152*
heart muscle absorption of specific avidity of, *645*
inhibition of renal function by in pheochromocytoma, 224
and mechanical left ventricle, *151–152*
and mesenteric resistance, *1165*
and paroxysmal hypertension, 622
responses to in vascular beds, *944–945*
secretion of and pheochromocytoma, 626
and systemic arterial pressure, *299*
in urine, 627
and ventricular arrhythmias, *150*
versus mephentermine or ephedrine, *152*
Epiploicum, and situs inversus of viscera, 521
Epistaxis
and anticoagulant long-term therapy, 257–259
and aortic disease, 117
and congenital aortic stenosis, 190
Ergometry, direct stimulation, intermittent claudication by, *930–931*
Ergonovine, stress test, *1006–1007*
Erythemia
of digits, 190
and lung disease, 266
marginatum
and disease activity, 1154–1158
rheumatic fever, 45
and systemic
hypertension, 280
lupus erythematosus, 128–129
Erythrocyte
cation transfer in and cardiac glycosides, *644*
intravascular aggregation and age, 391–393
sedimentation rate
rheumatic activity, 1154
transmural myocardial infarction, 792
Erythrocytosis
with arterial desaturation, 280
and arterial oxygen saturation, 271, 280
and dyspnea, 274
in emphysema heart disease, 270–273
and heart failure, 272
internal oxygen transport in, 270
Erythropoiesis, and desaturation of arterial blood, 271, 280
Esophagus
and congenital aortic stenosis, 193
and angina pectoris, 426–427
electrodes in and supraventricular beats versus ventricular, 748
intrinsicoid deflection in, *637*
varices of distal, classification of, *894*
Estrogen
and atherosclerosis, *491*
coronary, *294*, 365–371
and cholesterol, 366, 371, 489
and pulmonary edema, 370
and vasomotor instability of menopause, *638*
Estrone, derivative. *See* SC-6924
Ethylenediamine tetra-acetic acid
and arrhythmias, *148*
chelating action of, *1176–1177*
Etiocholanolone, excretion of, and estrogen, 368–371
Exercise
angina pectoris induced by, 432–433
and cardiovascular function, *296*, *894*
and coronary arterial anastomosis after coronary arterial narrowing, *930*
forearm, blood glucose levels after, *1016*
and gas exchange, 268
and heart failure, *296*
and mitral stenosis, 466
muscular and cardiac output, *1171*
after pericarditis, 877
and pulmonary hemodynamics in left-to-right shunt, *916–917*
and pulsus alternans, 172, 1099–1103
and renal function, *296*
in supine position, *149*
tolerance
and angina pectoris, 425, 429–431
and cardiorespiratory performance, 73–76
and fatigue, 176, 189, 194–197
after pulmonary valvulotomy, 9
and surgery for congenital aortic stenosis, 197
and work capacity in cardiacs, *966*
Expirogram, in heart disease, clinical value of, *654*
Eyeground, after rice diet, *143*

Fallot's pentalogy, 468
Fallot's tetralogy
differentiation for, 332
and intravascular pressures of pulmonary artery, *887*
oxygen saturation and hemoglobin concentration, *136*
pulmonary blood vessels in, 333
Fat
degeneration and Chagas' disease with *Schizotrypanum cruzi*, 1050
deposit in cells and ground substance, *501*
dietary
and argentaffinoma, *642*
and blood coagulation, 854–858
and lipemia, 855–856
and lipid serum level, *499*
sensitivities to, *922–923*
and tissue lipids, *488*
and weight reduction, *1012–1013*
and phospholipid synthesis, *305*
and serum lipoproteins
in idiopathic hyperlipemia, 502
and lipids, in coronary atherosclerosis, *499*
spacing of, and familial hyperlipemia, *494*
Fatty acids
with coronary disease, *499*
and lipid transport, 484
and serum concentration responses, *641*
and sitosterol, cholesterol absorption after, 81
Femoral artery. *See* Artery, femoral
Fetus, azygos vein in, 1080
Fever
and disease activity, 1154–1158
intermittent, and chest pain, 874–875
and lupus erythematosus, 125, 133
postoperative, mitral commissurotomy, 181
Fibers
of atheromata as fibrin, *634*

myocardial and Chagas' disease, 1035, 1040, 1050–1052
contractile power of, 173
Purkinje, *1171*
ventricular, 194
electric alternans in single, *960*
Fibrillation
atrial, 762
and antifibrillatory patent drugs, *142*
in Chagas' disease, 1043, 1050–1052
cholinergic factor in, *644*
digitalis and/or quinidine in, *1016*
and diphenhydramine, *142*
and embolism, 757–763
of first heart sound, *1170*
and flutter, 568–581
with heart disease in congestive heart failure, 818
and hypertension and intra-atrial block, 1074
and intra-atrial block, 1076
and mitral commissurotomy, 177–182
and its perpetuation, *997*
and quinidine, 177–182, 568–581, 758, 761, *1003*, *1016*
and response to Valsalva maneuver, 74
and strophanthin-K versus tryptamine-strophanthidin, *151*
termination of by countershock, 752
and thrombus, 31, 770
and thyrotoxicity, *138*
and atrioventricular nodal blockade, 1014–1015
ventricular
and atherosclerosis prediction, 702, 709, 718, 734
and auriculoventricular nodal block, *1014–1015*
and blood pH, 475
death due to, 762
with electric currents to, 745–755
and electric defibrillation, 745, *962*
after hypercapnia, *647–648*, *984*
and quinidine, 573, 758
termination of by countershock, 745, 752
Fibrin
collagen, *634*
thrombi in, 483
Fibrinogen
polymerization test in nonspecific myocarditis and pericarditis, *938*
and prothrombin time, *632*
serum level, in lupus erythematosus, 132
Fibrinolysin, responses to, *919*
Fibrinolysis, pyrogen induced, *959–960*
Fibroelastosis
with congenital tricuspid stenosis, 412–421
and normal aortograms in, 597
Fibrosis
adventitial, 333
beryllium, and heart failure, 274
of central and sublobular veins, 417
and Chagas' disease with *Schizotrypanum cruzi*, 1050–1052, 1056–1057
and cortisone, 281
endocardial, 1050, 1056–1057
interstitial "diffusion capacity" in, 273
of lung fields in systemic lupus erythematosus, 126
mural thrombosis, 412–421
"parietal block" secondary to, 243
and pulsus alternans, 171
myocardial, *138*, *979*, 1057
and left axis deviation, 247
perivascular and pulmonary hypertension, 269
pulmonary, 1050–1052
and left axis deviation, 241–249
subendocardial, 1050–1052
tubular cells, 371
Fibrositis, and rheumatic disease, *1177–1178*
Fiedler's myocarditis
idiopathic death due to, 579
simulating pericardial effusion, *147*
Fistula
aorticopulmonary, *308*
arteriovenous
and blood supply, 1090–1092
cerebral, *296*
of renal vessels, 185–187, 538
cardioaortic and pulmonary hypertension, 338
tracheoesophageal and ventricle septal defect, 358
Flaxedil, protection against ventricular arrhythmias by, *150*
Fluid
at bases, and azygos vein distention, 1081
body, and hyponatremia, 1031
after mitral valve surgery, *927–928*
extracellular volume
ionic exchanges, *304*
measurement of, *1173*
sodium, potassium concentration in and blood pressure, *938*
hemorrhagic, in pericardial effusion, *149*
mechanical removal of, *295*
pulsating, resonance of, *969*
Fluoroscopy, in posterior wall aneurysm, *146*
Foramen ovale
patent, and coronary embolism, 1159–1163
and situs inversus of viscera, 521–522
Foreign-born, hypertension in, 17–23
Framingham study
blood pressures in, *957–958*
coronary heart disease, *926*
Frank precordial system, normal, QRS loop three dimensionally with, *999*
Frank-Starling Law, and pulsus alternans, 173
Freon, and edema, *148*, *635*
Gallbladder
disease of, and nitroglycerin, 425
and syndrome of congenital absence of spleen, 521, 524–529
Ganglion
autonomic
nerve impulses in and serotonin, 162
and SU 3088, *144*
blockade, in malignant hypertension, 105–113
blocking agents
for hypertension, *144*
in malignant hypertension with azotemia, 105–113
and regitine test for pheochromocytoma, 625
tolerance to, *965*
celiac, 622
Gangrene
amputation for, 412
of feet and legs, walking in treatment for, *936*
of left foot, and thrombosis of pulmonary arteries, 770
symmetrical digital and occlusion of small arteries of extremities, 1084–1089
Gas
alveolar concentration changes and blood, 269
blood, and chlorpromazine, 382
exchange, and vascular bed expansion on exercise, 268
Gastrectomy, and antibiotics, *147*
Gastrointestinal tract
and anticoagulant therapy, 257–259
congestion in, 417
disorders and thrombosis, 766
function of
and chlorpromazine, *643*
and reserpine, *643*
and syndrome of congenital absence of spleen, 524, 526, 529
thickening of serosa, 417
Geriatrics
and bacterial endocarditis in patients over 50, *883*
and nutrition, *291*
and nutrition for cardiac patients, *631–632*
See also Age (of subject), elderly
Gitalin, toxicity of, *917*
Globulin
blood sera fractions in Chagas' disease, 1037
gamma
concentration changes and growth, 57
fraction, and lupus erythematosus, 132
and rheumatic sera, *959*
serum level in lupus erythematosus, 132–133
Glomerular filtration rate, 587
and Digoxin, *140–141*
after hypophysectomy, *141*

Glomerulonephritis
in Chagas' disease, 1050–1052
hemolytic streptococci from, *949*
hemorrhagic, and piperoxan, 222
in kidneys, and lupus erythematosus, 130
and malignant stage of hypertension, 106
and respiratory infections, 881
Glomerulus
and death due to pulmonary edema in hypertension, 112
lesions of, 392
Glucose
and arterial-coronary sinus oxygen difference, 96–97
arterial metabolism and hyperthyroidism, 93–94
blood levels from antecubital vein during forearm exercise, *1016*
tolerance in adrenal insufficiency versus lupus erythematosus, 128
Glutathione, *640*
Glycosides
and cation transport, *644*
and protein
in myocardial infarction, *494*
serum, *912*
Goldblatt kidney, hypertension, 536
Gradient
alveolar-arterial
in carbon dioxide narcosis, 282
in left heart, *642–643*
oxygen tension, 266, 269
postoperative and infundibular stenosis, 197
systolic, 193, 196
time of election for operation, 198
ventricular
in bundle-branch block, *298*
in hypertension, *298*
and QRS complex versus T wave, 102
spatial, after hexamethonium, *142*
Graft
aortic
and arteriographs, *984–985*
homologous, *1181*
autogenous, and hypercholesterolemia, *639*
experimental vascular, 469
pericardial valve for mitral insufficiency, *908*
thrombosis of, 532
Granuloma
formation, in Chagas' disease, 1050
and periarteritis nodosa, *653*
Ground substance, as cation-exchange resin, 821
Growth
changes in serum protein pattern during, 57
development, 189
embryologic and congenital malformations, *1015*
of new hair, and estrogen, 366
and pericardial autografts, 469
and surgery for congenital aortic stenosis, 197
Guerreiro-Machado's reaction, 1053
Guillain-Barre syndrome, respiratory problems in, *652*
Gynecomastia, and estrogen, 366–370

Headache
and aortic disease, 117
of hypertensive and electron gun therapy, 262
paroxysmal frontal with emesis and syncope, 111
in pheochromocytoma, 622
and quinidine, 573
Heart
and acetylcholine-cholinesterase system, *646*
activity correlation by limb and precordial systems, 83–88
alligator, 1114–1116
alveolar-arterial oxygen pressure gradient of, *642–643*
anatomic findings in Chagas' disease, 1038–1039
anomalies
developmental, *295*
and pulmonary drainage, 827
and splenic agenesis, 520–530
and survival, 196
after antihypertensive regimens, 113
atrioventricular connecting system of, *141*
auscultation, venous hum in, *1169*
beat
and ballistocardiographic patterns, *1020*
and hypersensitive carotid sinus syndrome, 1104–1112
blood flow in, *153*
cairivibograph, 305
calcified valve and coronary embolism, 1161
and carbon dioxide conventional bath, *295*
cardiothoracic ratios after anastomosis, 514
catheterization
right and left simultaneously, *995*
television and motion picture photography for, *1005*
changes of electric events in and age, 101
congenital malformation
and anomalous venous drainage, 200–219
and embryologic growth rates, *1015*
incidence and mortality rates of, *939–940*
versus atelectasis-cor-pulmonale lesion-complex, *137*
contrast material in, *931*
coronary attacks, 3–4
cyanotic disease, 524
damage to
and coronary embolism, 1162
due to rheumatic fever, and hormone therapy, 44–47
dextroposition, 836
and size of right lung, 830
dextroversion of, *886*
diagrams of sections of, 542, 544–548
electrocardiogram of an alligator, 1114–1116
electromotive forces, 241
use of lead-field concept and vectorcardiography for, 48–54
and embolization, 412
and emetine toxicity, 33–37
emphysema, 266–271
and lung disease, 266
enlargement of, 171, 520, 762, 827
and abnormally situated azygos vein, 1080
in Chagas' disease, 1046, 1050–1052
and congenital aortic stenosis, 190–195
due to cor pulmonale, *137*
in Eisenmenger's complex, 325
and fatal congestive heart failure, 373
and hormone dosage for rheumatic fever, 45
in idiopathic pulmonary hypertension, 328
in patent ductus arteriosus, 326
and pulmonary hypertensive heart disease, 277, 327
and pure left papillary muscle syndrome, 1134
and quinidine therapy, 758
roentgen finding of, 118, 122
and response to Valsalva maneuver, 75
single ventricle, 521
after valvulotomy, 12–15
ventricular septal defect, 324
and external electric currents, 745–755
fetal development of, 530
fibrinoid lesions, *925–926*
function
and arrhythmias, 423
and cardiac asthma, 423
and pressure, *140*
and valvulotomy, *942*
great vessels
schematic diagrams of, 525, 527, 528
and syndrome of congenital absence of spleen, 520–530
and hyperpotassemia toxic effects, *909–910*
hypoxia test for arteriosclerotic, *292*
involvement
in Chagas' disease, 1037, 1044–1046
in lupus erythematosus, 130
and artificial hypothermia, *1172*
beating, and norepinephrine, *912*
perfused, and iodoacetate, *304*
kidneys, and brain reintegration of, 4
lead-field concept and vectorcardiography, 48–54
lesions in
ischemic myocardial, 1058
and lupus erythematosus, 129

rheumatic, 420
streptococcal, *933*
and symmetrical digital gangrene, 1085
in leukemia, *652*
heart-lung preparation and anesthetics, *1172*
force, 189
mechanical, *894*
massage and adrenalin for cardiac arrest, *301*
methoxamine effects on, *1017*
mobility electrocardiographic study, *297*
muscle. *See* Muscle, of heart
in muscular dystrophy, 474
myosin in, *940–941*
nicotine effects on, *1017–1018*
nonpenetrating trauma to, *146*
open surgery, *1023*
oxygen consumption in hypoxia, *292*
oxygen differentials in, *915*
pain
daily report card, 228–230
See also Chest, pain
phonocardiography, *967–968*
position of
and electrocardiogram, 243, *636*
postmortem appearance, 768
postoperative reactions to retained pericardial blood, *948*
premature contraction and sodium lactate, *1168*
pressure
on chambers of, by aortic sinus aneurysm, 123
pulse recording in, *943*
protein, quantitative determination of, *1174*
range of normal in athletes, *1018*
response
in hyperthyroidism, 97–98
supraventricular, 748–749
revascularization of in coronary artery disease, *137*
rupture of, *961–962*
eight hours after myocardial infarction, *138*
shape in syphilitic aortic sinus aneurysm, 122
size
and angina pectoris, 425
and arteriovenous fistula, 185–187
and azygos vein distention, 1081
in congenital aortic stenosis, 194
after mitral commissurotomy 178, 182
postoperative changes in, 513–514
after pulmonary valvulotomy, 12–15
radiologic evidences of, 577
in rheumatic heart disease, 573
and roentgenology, 807
in Brazil, 1035
in Chagas' disease, 1050–1052
stab wound of, with delayed hemopericardium, *653*
in Stokes-Adams disease, *647*
stroke volume, Starr's equation for, 250–253
surgery
and angiocardiographic diagnosis, 25
and bacterial endocarditis, *926*
in systemic lupus erythematosus, 126
timing of electrical and mechanical events of, *1171–1172*
vagal inhibition of and pH changes, *642*
venous, return to and anomalous pulmonary vein connections, 201
venous vessels of and ischemic myocardial lesions, 1058
and ventricular septum defect, 356–359
vibogram, *305*
volume determination, *1173*
weight
in Chagas' disease, 1050–1052, 1056
and left axis deviation, 235, 241–249
QRS complex, 235–237
and ventricular hypertrophy, 236–237, 339
work
and antithyroid drugs, 1154
bed and chair regime for, *634*
capacity, and exercise tolerance, *966*
and cardiovascular efficiency, *894*
decreasing of, 1154
estimation of, 1117–1127
in hot and humid environments, *917*
as mechanical force, *894*
and obesity, *139*
and psychiatric evaluation, *956*
and pulse pressure, 1118, 1125

Heart disease
acquired thrills in, 784–789
acyanotic congenital and anomalies, 212, 802
aortic
and arterial hypertension, 867
and papillary muscle, 1132
and argentaffin carcinoma, *648–649*
arteriosclerotic
and coronary anomalies, 801–803
death in, 762
and exchangeable potassium content, 1094
and interrelationships, 422
and pulsus alternans, 171
and quinidine therapy, 758
and response to Valsalva maneuver, 74–76
serum lipid response to beta sitosterol in, 77–81
with atrial fibrillation in congestive heart failure, 818
brachial artery tracings in, 195
cardiac thrills in graphic registration of, 784–789
and cardiologist, 3–8
Chagas', 1035–1059
in children, school program for, *990–991*
cholesterol and lipoprotein elevations in serum, 724
congenital
angiocardiograms in, *1023*
angiography in, *931*
anomalies of coronary ostia as cause of death, 801
associated with pregnancy, *885–886*
carbon dioxide content in, *306*
classification of, *949*
cor biloculare type, 530
coronary blood vessels and myocardium in, *136–137*
cyanotic, 749
and dosage of Diodrast, 596
electrocardiography in, 1132
and etiology, 568
and papillary muscle syndrome, 1131
partial situs inversus, 522
pulmonary vascular tree in, *903*
and response to Valsalva maneuver, 74–76
sensitivity of respiratory center in, *306*
and thrombosis, 766
values of shunt in, *136*
and venoarterial shunts, 273
coronary, *926*
cholesterol and lipoprotein in, *970*
and conversion of atrial fibrillation, 573
detection of latency, 8
electrocardiographic findings in, 1132
mortality and geographic differences, *932–933*
operative risk, 471
susceptibility, *304*
cyanotic and Eisenmenger's complex, 338
decompensated, 73
and response to Valsalva maneuver, 74–76
degenerative in older subjects, 270
electrocardiographic study, after surgery, *297*
forced expiration in, *654*
hypertensive
calcium in pulmonary edema due to, *946*
hypertensive
and coronary anomalies, 801–804
death in, 762
pulmonary, 269, 274
pulmonary function in, *922*
and pulsus alternans, 167, 1102
response to Valsalva maneuver, 74–76
screening tests for, 454–455
and idiopathic cardiac enlargement, 377
incidence of obesity in, *139*
kyphoscoliotic, cardiorespiratory involvement in, 274
mitral, 862–863
and electrocardiography patterns, 864–867

Heart disease (*Cont'd*)
mortality rates in Chicago, *1006*
operable, radiologic aspects of, 593–612
organic paroxysmal supraventricular tachycardia complicating, *951*
papillary muscle in, 1132
parasitic, Chagas' heart disease as reversible type of, 1058
and phlebitis, 472
and pregnancy, *959*
management of, *655*
prevalence of, *988*
in Pittsburgh, *1007*
psychiatric and work evaluation in, *956*
psychotic disturbances with, *985–986*
pulmonary
and airway resistance, *929*
hypertensive, 265, 276
and thrombotic occlusion, 766
and pulsus alternans, 167, 1099–1103
rheumatic, 569, 762, 1144
and age, morbidity, *970*, *1019*
alternans in, *637*
and anomalies, 801–804
and antibiotics, 1162
breathing high oxygen mixtures in, *985*
in congestive heart failure, 818
and conversion of atrial fibrillation, 573–581
and coronary embolism, 1162
and cortisone, *1177–1178*
death due to, 762
differentiation from syphilitic aortic sinus aneurysms, 122
and etiology, 568
and exchangeable potassium content, 1094
hypertensive, *922*
and intra-atrial block, 1074, 1077
multivalvular, 470
myxofibroma of left atrium, 466–467
prednisone in, *933–934*, *1177–1178*
and pulsus alternans, 167, 171
and quinidine therapy, 758
and response to Valsalva maneuver, 74–76
screening for, *652–653*
secondary to pulmonic valvular regurgitation, 1069–1072
senile, and emphysema heart, 273
and streptococcal infection, 1144
syphilitic, 762
and coronary embolism, 1162
and exchangeable potassium content, 1094
and intra-atrial block, 1077
thyrotoxic
and conversion of atrial fibrillation, 573
and etiology, 568
and Valsalva maneuver false phase II responses to, 72–76
valvular,
and angina pectoris, 426, 428
and corticotropin, 1146
and pulsus alternans, 167
and streptococcal infection, 1146
variation in antidiuretic substance, *149*
work capacity, versus disability and exercise tolerance, *966*
Heart failure, 189, 779
and abdominal distention, 412
and abnormal azygos vein, 1080
and aortic regurgitation chest pain due to, 117
and arachnodactyly, 123
and arterial oxygen desaturation, 270
in arteriovenous aneurysms, 272
and aspirin, 1157
and Blalock-Taussig anastomoses, 517
and carbon dioxide baths, *295*
and cardiac output, *140*
congestive, 762
abnormal expirograms in, *654*
and acetyl-digitoxin, *1167*
and aminophylline, and/or ammonium chloride, 1094
and angina pectoris, 424–428
and anticoagulant therapy, 256
and arteriovenous fistula, 1090–1092
atrial fibrillation in, 818
and azygos vein, 1079–1082
and blood ammonia, *296*
and body weight, 1093–1098
and Chagas' disease with Schizotrypanum cruzi, 1050–1052
and coarctation of aorta in infancy, 606
and congenital mitral atresia, *136*
and convulsions, 1038–1039
and coronary anomalies, 801–804
and coronary artery disease, 423
C-reactive protein in serum of, *888–889*
deaths due to, *136*, 339, 357, 762, 801–803, 1038–1039
digitalis in, 818
and digitoxin, *1167*
and Digoxin, 1094
Digoxin in infants and children, *979–980*
and diuretics, *1168*
electrocardiography in, 818
and exchangeable potassium content, 1094
and first heart sound, *1170*
heart disease in, 818
in humid environment, *917*
and hypertensive pulmonary vascular disease, 330
and idiopathic pulmonary hypertension, 329
and liver enlargement, 127
and myocardial infarction, *634*
and negative electrocardiogram, *636*
and Neohydrin, *889*
permeability of capillaries to protein in, *991*
and phlebotomy, *296*
and prednisone, *1177–1178*
prevention of, *906*
and pulsus alternans, 168, 171
and quinidine, 579–581, 758, 818
refractory, in elderly, *140*
and mercurial diuretics, *1168*
and renal insufficiency, 409
response to Valsalva maneuver, 73
rheumatic fever and hormone dosage, 45
in thrombotic occlusion of pulmonary artery, 773, 779
and thyroxicity, *138*
and venous congestion of legs, *296*
and conversion of atrial fibrillation, 579–581
in the rheumatic, 572
due to cor pulmonale, *137*
in costophrenic angle and size of azygos vein, 1081
and cyanosis, 268–271, 338
and nocturnal cough, 412
death due to in Chagas' disease, 1038–1039
and Digoxin, *140–141*, *295*
and dyspnea, 412
and edema, 412
electric and mechanical systole during fasting in, *890*
in emphysema and internal oxygen transport, 270
and erythrocytosis, 272, 279
and erythropoiesis, 280
exchangeable potassium content of the body, 1093–1098
hemodynamic patterns in, *1000*
and hypothermia, *1167*
due to hypoventilation of obesity, *1003*
hypoxic, *292*
intractable, and amyloidosis, 416
ischemic, *140*
and lung disease, 265–285
and malignant hypertension, 110–113
myocardial transfer of potassium and sodium after acetylstrophanthidin in, *952*
and occlusion, arterial, *140*
and orthopnea, 412
plasma proteins, electrophoresis in, *295*
in polycythemia vera, 272
and post-traumatic aortic insufficiency, *639*
and pulmonary function, *922*
hyaline membrane in newborn, *300*
hypertensive disease, 269–273, 284
renal function in and posture, *974*
and response to Valsalva maneuver, 72–76
and rheumatic heart disease, 577
and sinus rhythm, 579
stage of, and pulsus alternans, *993*

and surgery for congenital aortic stenosis, 197
for mitral insufficiency, *956–957*
in syphilitic aortic sinus aneurysm, 121
and rupture, 122
variation in antidiuretic substance, *149*
Heart rate
and adrenolytic drugs, 616
and alseroxylon, 230
and dibenzyline, 616
and diet, *145*
and fasting, *145*
and filling time, diastolic, 169–170
and pulsus alternans, 171
and obesity, *139*
and postural change, 466
in pulsus alternans, 170–171
and regitine, 616, 619
response
to serotonin, *145*
to tilting, 407
sino-atrial, slowing, 1105
and ventricular filling, *643*
Heart sound
diastolic rumble at apex, 789
first
and digitalis, *1170*
frequency range, 789
in mitral stenosis, *301*, *1170–1171*
production of, *1168–1169*
and second, in Chagas' disease, 789
frequency range of vibrations, 789
in hypokalemia, 62, 65
reduplication of, *152*, *153*
second
and congenital aortic stenosis, 190, 194
in emphysema heart, 275
after mitral valvulotomy, *141*
in pulmonic stenosis, *137*
in pulmonic valvulotomy, 11
reduplication of, *153*
snapping, 275
splitting of, *135*, *153*
in thrombotic occlusion, 773, 779
in valvular stenosis, 196
splitting of, *1169*
synchronization in fragments, 42–43
third, 789
after mitral valvulotomy, *141*
and thrills recorded simultaneously, 784–789
valvular snap, 789
Hematemesis, and salicylate therapy, *1168*
Hematocrit, 587
plasma concentration and toxemia, *934–935*
postoperative anastomosis, 515, 518
and pulsus alternans, 170–171
Hematoma
dissecting and aortitis, *962–963*
hemorrhage, and anticoagulant long-term therapy, 157–159
Hematuria
and anticoagulant long-term therapy, 257–259
and hypertension, 111–112
and lupus erythematosus, 133
and renal colic, 185–187
Hemiparesis, and quinidine, 758, 762
Hemiplegia
with atrial fibrillation, rehabilitation after, *896*
complete left, after mitral commissurotomy, 181
and diodrast, following retrograde aortography, 611
and thrombosis of pulmonary artery, 770
Hemodynamics
after adrenalin, *649*
and anomalous pulmonary venous drainage, 200–219
and Ansolysen, 584–591
after aortic and valvular surgery, *909*
and atrioventricular block, congenital complete, *981*
basic, *643*, *982–983*
of blood flow and anomalous pulmonary venous connections, 200–219
cardiac
and hypervolemia, *937*
in mitral valve disease, *944*
and norepinephrine during pulmonary arterial constriction, *937*
and tolazoline, *991–992*
in cardiorespiratory disorders, 274
cardiovascular and pentolinium, *998*
cerebral
and chlorpromazine, 380
and reserpine and/or hydralazine, *896*
and thorazine, 380
circulatory, and surgery for perforated aneurysms, 123
after circumferential suture of mitral ring, *956–957*
and coarctation of aorta, 806
after digitoxin, 466
of emphysema heart, 267, 270
of erythropoiesis, 280
in estimation of size of ductus, *135*
of heart failure, 267, *1000*
of interatrial communications *1175*
in kyphoscoliosis, 267
after mitral commissurotomy, *927*
in mitral stenosis, 267
and myocardial
fibrosis, *979*
infarction, *140*
responses to hyperthyroidism 90–98
in obesity, 267
after pentolinium, 584–590, 1061–1067
in polycythemia vera, 267
of pregnancy, *303*
in pulmonary
arteriovenous fistula, 1090–1092
hypertensive heart disease, 267
and left-to-right shunt, *916–917*
in pulmonocardiac syndrome, 267
renal
and cardiovascular response to exercise, *296*
and Digoxin, *140–141*
after ostium atrioventriculare commune, *965*
in restrictive pulmonary disease, *969–970*
and salicylate, *991*
and shunt, 1090–1092
in silicofibrosis erythremia, 267
splanchnic and hepatic ischemia, *640*
suprasternal puncture technic for, *307*
systemic, 155
and thermal radiation, *1164–1165*
and valve obstruction, *950*
of vasodepressor syncope, *933*
Hemoglobin
and arterial oxygen saturation, 272
cellular production and emphysema, 272–273
concentration
in emphysema heart, 273
in hyperthyroidism, 92
and polycythemia, *136*
in pulmonary atresia, *136*
in heart failure and lung disease, 266
levels after anastomosis, 515, 518
in malignant hypertension with renal azotemia, 110, 112
unoxygenated, 271
Hemopericardium, after myocardial infarction, *633*
Hemophilia, 801
Hemoptysis
and anticoagulants, 257–259
congestive, death due to, 339
in Eisenmenger's complex, 329
due to mitral stenosis, *1176*
in patent ductus arteriosus, 329
in pulmonary
hypertensive disease, 329
occlusion, 773, 779
thrombosis, 770
in ventricular septal defect, 329
Hemorrhages
and aging in diabetes mellitus, 390
and anticoagulants, 256–259
and arterial pressure, 283
from bronchial tree, 1090–1092
and carbon dioxide retention, 283
and cardiorespiratory function, 283
cerebral
and coronary artery anomalies, 801–804
and malignant hypertension, 107, 113
delayed, from heart wound, *653*
diathesis, and salicylates, *1168*

Hemorrhages (*Cont'd*)
epistaxis, and anticoagulant therapy, 257–259
in erythrocytosis, 274
gastrointestinal and hypertension, 112
of gums, 257–259
intramural in coronary atherosclerosis, 486
and oxygenation, 283
pulmonary, due to mitral stenosis, *1176*
and quinidine, 758, 760
retinal, and pressor response after tilting, 409
Hemorrhoids, and anticoagulant therapy, 257–259
Hemorrhoidectomy, and posteommissurotomy, 182
Heparin
and anticoagulant, *884*
claudication and intermittent, 472
clearing factor activated by, *496–497*, *498*
and lipemia serum concentration, *641*
for myocardial infarction, *295*, *883–884*
serum phenol turbidity test, *493*
tolerance
and fatty meal, 854–858
and prothrombin time, *649–650*
Hepatomegaly
and Chagas' disease, 1037
in congenital mitral atresia, *136*
as cortisone side effect, 127
Hepatitis
after anticoagulant therapy, 256
in Chagas' disease, 1038–1039
Heredity
and cholesterol concentration, total body, 57–59
and hypertension, *145*
of obesity, 55–58
Hernia
diaphragmatic, 774
hiatus, 426, 427
inguinal, 521
Herpes zoster
and angina pectoris, 426
and peripheral vascular spasm, 379
Hexamethonium
and blood pressure, 383–384
and nitrogen retention in malignant hypertension, 108–113
and cerebral hemodynamics, 383
ganglion-blocking action, tolerance to, *299*
and hydrazinophthalazine, *146*
for hypertension, 108–113, *931*
and/or hydralazine, *144*
and/or pentolinium, 108, 112, 589–590
and work of the heart, 1154
Hexosamine, in degenerative vascular disease and diabetes, *912*
Histamine
and airway resistance, *929*
eosinopenia, due to, *1177–1178*
and rheumatic disorders, *1177–1178*
tests with, 622, 624–626
Homograft
aortic, 474
and hypercholesterolemia, *639*
arterial
branched, *1182*
in peripheral arterial lesions, *1181*
for atherosclerotic abdominal aortic aneurysm, 473
for thrombosis of renal arteries after, 533
Hormone
adrenal
and hypertension, *144*
and insulin after dietary cholesterol, 492
antidiuretic secretion of, 1030
and dietary imbalance, coronary atherogenesis, *983*
dosage in treatment of rheumatic carditis, 44–47
growth and hypophysectomy, *141*
and myocardial infarction, *294*
pituitary and ascites formation, *141*
thyroid heart response to, 98
Hydralazine
and arthritides, 109
for elderly hypertensive, *146*
for hypertension, *928*, *931*
and hexamethonium, *144*
malignant, 105–113
and regitine tests for pheochromocytoma, 625
and/or reserpine, *896*, *928*
Hydrazinophthalazine
and ganglionic blocking agent in hypertension, 113
and pulmonary circulation in mitral disease, *1177–1178*
in vascular hypertension, *146*
Hydrocarbon
epinephrine, in ventricular arrhythmia, *150*
inhalation of, *150*
Hydrocortisone
in lupus erythematosus, 125–127
and prednisone, 126–127
metabolism of, 465
Hydrogen ion
concentration
in geriatrics, *140*
and myocardial function, *1172*
Hydronatriodyskinesis, relative dilution, 1029
Hydropericardium and hydroperitoneum, in Chagas' disease, 1038–1039
Hydroxytryptamine, 161
metabolism, in heart disease, *648–649*
systemic and pulmonary pressor response to, *145*
Hyperadrenalism, after steroid therapy for rheumatic fever, *906*
Hypercapnia
ventricular fibrillation after, *984*
and hyperkalemia, *647–648*
Hypercatecholemia, and renal insufficiency, 614–620
Hypercholesterolemia
and atherosclerosis, *497*
and dietary casein, 488
and hyperlipemia, *642*
and hypervitaminosis D, arteriosclerosis due to, *1009*
idiopathic coagulation in, 479
serum lipids and nicotinic acid, *495*
and transplants, *639*
Hyperemia
and edema of lung and Chagas' disease, 1039
reactive
to cyanosis or gangrene, 1084–1089
in forearm, 466
of vessels at the corticomedullary junction, 417
Hyperkalemia
carbonic anhydrase inhibitor in treatment of, *1167*
cardiac effects of, *148*
serum electrolyte values in electrocardiograms and, 819–823
and ventricular fibrillation after hypercapnia, *647–648*
Hyperlipemia
familial, spaced fat feeding for, *494*
and hypercholesterolemia, *642*
iodiopathic
coagulation in, 479
and fat ingestion, *502*
in vitro effect of soybean phosphatides on lipoproteins in, *504*
Hyperlipoproteinemia, and high potency B complex and C vitamins, *982*
Hyperosmolarity syndrome, and electrolyte pattern disorder, 818
Hyperplasia
of coronary arteries and Chagas' disease, 1050–1052
in erythropoiesis, 280
intimal, and Chagas' disease, 1050
lymphoid, of spleen and Chaga's disease, 1039
and portal hypertension, 417
Hyperpotassemia
cardiotoxic effect of and molar sodium lactate, *909–910*
and papillary muscle syndrome, 1131–1132
Hypertension
and adrenal
cortex, 144
regeneration, 455
and aldosteronism, *891*
and amblyopia, 109, 112
in American and foreign-born Asian, Negro and white, 17–23
and anginal syndrome, 228
and angina pectoris, 424–425
and antihypertensive drugs, 156, 868–873
and aorta
anastomosis of, 123
heart disease, 867
arterial

and adrenalectomy, *299*
and angina pectoris, 424, 867
and coronary insufficiency, 1131
in electrocardiographic pattern, 867, 1132
hemidecorticate, *299*
and papillary muscle syndrome, 1131
reassurance in management of, 260–264
and renotrophine, *144*
and atrial
enlargement, 1077
thickness, 404
and blood pH, 589
blood pressure in, 4
and ganglionic blocking agents, 1066–1067
and cardiovascular system, 171
and carotid sinus area constriction, *923*
and catecholamine, 614
with cerebral vascular disease, *896*
and Conn's syndrome, *891*
control of, 105–113
coronary arteries, *292*
anomalies, 801–804
development of, 532
drug therapy in, *144*, 465, *928*, *931*
digital circulatory testing as guide to, *973–974*
and environmental condition, *299*
geographic origin, 17–23
and epinephrine, 622
after ephedrine, *152*
after mephentermine, *152*
of extremities and aortic sinus aneurysms, 116
fatigue
electron gun "therapy," 262
pulmonary heart disease, 274
and ganglionic blocking agents, 1061–1067
in geriatric patient, *146*
heart disease, *946*
and coronary anomalies, 801–804
and pulsus alternans, 1099–1103
and heart failure, pulmonary function in, *922*
and hydrostatic alterations of pressure during tilting, 407
and hydralazine, *896*
after infarction, *138*
and intra-atrial block, 1074
and Inversine, *645*
left ventricular
hypertrophy with, 52, 242–244
thickness, 404
malignant, 615–616
electrocardiogram in, 818
and periarteritis nodosa, 454
and renal azotemia, 105–113
rice diet in, *143*
and measles, *143*
and Mecamylamine, *645*
and reserpine, *999–1000*
and myocardial infarction, *634*
and nitrogen retention, 105–113
noradrenalin excretion in urine of, *639*
and norepinephrine, 622
induced by, *146*
paroxysmal, 622
and malignancy in tumors, 628–629
pentolinium tartrate for, 584–591
and phenochromocytoma response to piperoxan, 221–226
portal
azygos vein distention, 1080–1082
and splenorenal shunt, 532
postural and potassium deprivation, 62, 65–69
after pregnancy, 131
pressor and depressor responses in, 407–410
and tilting, *945*
pulmonary, 193
in mitral stenosis, 334
in vascular disease, 334–336
and quinidine, 758, 762
pulmonary, 274–275, 277–279
idiopathic, 323–340
and complications, *1018*
and cyanotic cardiac lesions, *885*
defined, 323
electrocardiographic pattern in, 331
and emphysema triad, 269–273
newborn lung, *300*
and patent ductus, 195, 334, 338, 608, 787
and pulsus alternans, 167
and septal defect, 361
and sudden death, 331
and surgery for congenital aortic stenosis, 197–198
and tolazoline, *991–992*
vascular disease, 323–340
venous capillary pressure, 193
and ventricular hypertrophy, 265
and wide patent ductus, *135*
and *Rauwolfia serpentina*, 131–132, 454, 464–465, *639*, *896*
renal functions, of and piperoxan, 222
and renotrophine, *143–144*
and resistance, in congenital aortic stenosis, 195
serotonin, *145*
and antiserotonins, *1018–1019*
and sodium
serum concentration, *892*
tolerance and Pitressin, 455
surgically treated and pheochromocytomas, 629
sustained, 623, 628–629
and regitine, 629
systolic and syphilitic aortic sinus aneurysm, 121–122
tests for pheochromocytoma, 624, 629
and toxemia of pregnancy, *934*
and vaccination against variola, *139*
and vascular disease, 323–340
venous, and ascites formation, *141*
water and electrolyte
excretion in, *955*
metabolism, *892*

Hyperthyroidism
in cardiacs, and life span, *138*
hemodynamic myocardial responses to, 90–98

Hypertrophy
and aortic sinus aneurysms, 116
electrocardiography in, 118
syphilitic, 122
cardiac
and hypertension, 112
enlargment in, 14
and Chagas' disease, 1050–1052
and congestive heart failure, 377
idiopathic ventricular and pulsus alternans, 167, 171
left ventricular
with aortic stenosis, 52
and congenital aortic stenosis, 196
electrocardiography pattern in, 867
with hypertension, 242–244
and left axis deviation, 235, 238–249
in mitral stenosis, 404
negative U wave, 862
and pulsus alternans, 171
and strain, 863, 867
transaminase versus electrocardiography in, 796
medial, in Chagas' disease, 1050, 1058
myocardial and pleuropericardiomediastinitis, 457
renal and renotrophine, *144*
right ventricular, 326, *1014*
in congenital mitral stenosis, *136*
electrocardiographic pattern, 278, 331, 867
in emphysema heart, 275, 277–279
and left axis deviation, 241 249
and strain, 865
vectorcardiogram versus electrocardiographic pattern of, *891*
ventricular, 420
and arrival time of activation, *141*
and coarctation of aorta, *136*
and congenital aortic stenosis, 194
and death due to anomaly of coronary ostium 801–803
electrocardiographic evidence of, 577, 767
and intra-atrial block, 1076
after mitral commissurotomy, 178, 182
and papillary muscle syndrome, 1131
and right bundle-branch block, *914*
and strain, 793
and surgery for congenital aortic stenosis, 197
in thrombotic occlusion of pulmonary artery, 773, 779
vectorcardiographic diagnosis of, *890*

Hypervagotonia
and atrial fibrillation of arrhythmia, *142*

Hyperventilation
and postural hypotension in hypokalemia, 65, 68
and anxiety, 65
and pulmonary hypertensive heart disease, 268–269
Hypervitaminosis D, and hypercholesterolemia arteriosclerosis due to, *1009*
Hypervolemia, hemodynamic effects of, *937*
Hypocalcemia, cardiac effects of, *148*
Hypochloremia, and sodium depletion, 1027–1031
Hypocholesteremia
and diethanoline salt of camphoric acid ester of α,4-dimethylbenzyl alcohol, *919*
and sitosterol, *911*
Hyponatremia
adaptation, 1030–1031
in children after surgery, *950*
edematous states, alcohol in therapy of, *975*
and mitral valve surgery, *309*
relative dilution, 1029
water and electrolyte distribution disorders, 1027–1031
Hypophysectomy
and blood pressure, *144*
after electrolyte excretion, *141*
Hypoplasia of right inflow tract with fibroelastosis, 420–421
Hypopotassemia
cardiovascular phenomena during and metabolic disturbances, 60–69
electrocardiography in, *978*
and electrolyte imbalance, 818–823
and U wave amplitude, *1007*
due to potassium depletion intermittent muscular paralysis with, 60–69
and papillary muscle syndrome, 1131
Hypoproteinemia, and papillary muscle syndrome, 1131
Hypoprothrombinemia, and hemorrhagic complications after anticoagulant therapy, 254, 257–259
Hypospermatogenesis, and estrogen therapy, 369
Hypotension
and cerebral blood flow, 384
and heart work, 1154
neurogenic and hormonal, *303*
and quinidine, 573
and sodium depletion, 1029
Hypothalamus
medullary, and rauwolfia alkaloids, *644*
posthypophyseal system and epinephrine, *1164*
Hypothermia
and acetylcholine, *889*
in aortic replacement, 474
artificial and isolated heart, *1172*
and clotting time, *959*
and digitalis, *1167*
and heart failure, *1167*
and leukopenic, thrombocytopenic effects, 631–632
of ventricle, *148*
and pH in excitability cycle, 475
and repair of septal defect, *1181*
in surgery, 468–469
for congenital aorticopulmonary septal window, *123*
Hypothyroidism
cholesterol concentration and sitosterol, 344–347
Hypoventilation
and carbon dioxide narcosis, 282
of obesity, heart failure due to, *1003*
Hypoxia
and catecholamines, 618
and cardiac arrhythmia, *303*
myocardial, and adenosinephosphatase, *640*
unilateral, and pulmonary circulation, 463
Hysterectomy, and postcommissurotomy, 182

Idiopathic heart enlargement syndrome, 373–377
Ileum, jejunum and colon situs inversus of, 521
Indian, American, hypertension in, 19–20
Infant
anomalies in
of left coronary artery, *136*
of pulmonary venous drainage, 913
aorta
arch, 362, 599
congenital stenosis, and body weight, 189
aorta, coaretation of
and blood pressure, 932
homologous grafts for, *1181–1182*
and patent ductus arteriosus, *932*
aortography in, 593, 596
and Chagas' heart disease, 1058
blood pressure in, *932*
flush method for, *975*
cardiac catheterization in, *633*
in cyanotic heart disease, 749
congenital abnormalities
absence of spleen, 520
of heart, *939–940*, *1179–1180*
mitral atresia, *136*
electrocardiogram in, *939*
patent ductus arteriosus in, *632*
pericarditis in, acute benign, 457
pulmonary artery
congestion, 361
hyaline membrane, *300*
and septal defects, 354–356
and reserpine administered ante partum, *646*
ventricular septal defect, 350–363, *1022–1023*
death due to, 633
edema in, 361
tissue involvement in, 354–356
and traeoesophageal fistula, 359

Infarction
anterolateral
as cause of left axis deviation, 238–241
and Chagas' disease with *Schizotrypanum cruzi*, 1050
anteroseptal, and thrombosis, pulmonary, 770
apical or apicolateral, 548–551
and arterial hypertension, electrocardiography pattern, 867
cardiac, with cerebrovascular accidents, *139*
cerebral, experimental, *896*
and electrocardiographic patterns, 540–554, 867
precordial T waves, *888*
and intestinal infections, *292*
myocardial. *See* Myocardial infarction
pulmonary, 777–778, 782, *980*
and angina pectoris, 426
and Chagas' disease, 1039, 1050–1052
death due to, 762
and exchangeable potassium content, 1094
and quinidine therapy, 758
and transaminase value, 798
renal and splenic, 1050–1052
subendocardial, definition of terms, 540
ventricle
lateral wall, 540–554
Infection
antibiotics for
bronchial and pulmonary, 281
endocarditis, *147*, *631–632*, *954*, 1162
genitourinary, 111
lupus erythematosus, 127
in Chagas' disease 1044, 1050–1052
intestinal and infarction, *292*
pharyngeal, *1177–1178*
cardiac lesions in, 457
pulmonary, 281
and lupus erythematosus, 126–127
respiratory and wide patent ductus, *135*
Schizotrypanum cruzi, 1035
streptococcal
pharngeal, *1177–1178*
prophylaxis and treatment of, 1144–1151
and rheumatic fever, *995*
and symmetrical digital gangrene, 1085
and transaminase value, 798
upper respiratory, after pericarditis, 881
Injury
myocardial, and papillary muscle syndrome, 1131
nonpenetrating traumatic, to aorta, *980–981*
renal artery and splenorenal arterial anastomosis, 532
transaminase value, 798
Insufficiency
adrenal
of hypertensive disease, *144*
and systemic lupus erythematosus, 128

adrenocortical and hydrocortisone, 628
aortic, 762
ballistocardiography in, *955*
and combined ventricular septal defect, *137*
and coronary blood flow, *987–988*
due to fenestrations of cusps, *892–893*
graded, 468
heart sounds and thrill, simultaneous recording, 785
myocardial metabolism in, *987–988*
and papillary muscle syndrome, 1131
post-traumatic, and cardiac failure, *639*
and pulsus alternans, 171, 1099–1101
and response to Valsalva maneuver, 75
and staphylococcal endocarditis, *954*
and surgery, for congenital aortic stenosis, 197
and syphilis, 120–122
and thrombosis of pulmonary arteries, 770
arterial, in heart failure, *140*
cardiac
and postoperative hyponatremia, *309*
Valsalva maneuver as method for diagnosis of, 72–76
cerebral vascular and hypotensive agents, *896*
coronary
and aortic stenosis, 196
and atherosclerosis, 702, 709, 718, 736–737
and chest pain, 423
electrocardiographic patterns in, 423, 867
and hypertension, *292*
internal mammary artery implantation for, *1012*
interpretation of term, 423
and myocardial revascularization, *970–971*
and nitroglycerin ointment, *139*
and obesity, *139*
pre-existing, and rauwolfia, 231
transaminase versus electrocardiography for, 793, 798
death due to, in ventricular septal defect, 357
intermittent, of internal carotid arterial system, *895*
mitral valve, 279, *309*, *925*
and atrioventricular ring suture, *1182*
death due to, 762
electrocardiography in, 867, *956–957*, *1169*
evaluation of, *1021–1022*
and giant left atrium, 236–237
heart sounds and thrills, 785
and hypertension, 404
after mitral commissurotomy, 178, 182
pericardial valve grafts in, *908*
polar cross fusion of mitral annulus for, *977*
and pulsus alternans, 171
and quinidine therapy, 758
and response to Valsalva maneuver, 75
spring valve for, 468
suprasternal pressure curves, *307*
surgical correction of, 470, *956–957*
suture of fibrous ring, *1182*
myocardial
and anticoagulant therapy, mortality after, 256
and pulsus alternans, 1099–1103
and ventricular alternation, 1101
pulmonary, *641–642*
after valvulotomy, 11
renal, 615–616
and blood catecholamines, 614–620
and blood pressure, 627
and malignant hypertension, 105–113
and necrotizing arteritis, 486
tricuspid, 786
valvular indicator-dilution curves, *960*
and unidirectional blood flow, *153*

Insulin
and adrenal hormones after cholesterol feeding, 492
clearance, 587
and coronary atherosclerosis, *492*
and lipfanogen-antilipfanogen balance in diabetes, *498–499*

Intestine
cholesterol absorption in and sitosterol, 347
development of, 530
in small, *305*
incomplete rotation of, 521

Inthiopental, and cardiac output, *301*

Intima
aortic, *978*
phospholipid composition, 482
calcium deposits in and syphilis, 120
thickening of
and Chagas' disease, 1058
and pulmonary hypertension, 265–266

Inversine
as hypotensive agent, 109, *645*
and reserpine, *999–1000*

Iodoacetate, and isolated perfused heart, *304*

Iodomethamate, 596

Iodopyracet, 595–596

Ischemia
and arterial necrosis, 337
cerebral and thrombosis of the pulmonary artery, 778–779
hepatic and splanchnic hemodynamics, *640*
in left foot due to arterial embolus, 770
left ventricular, 103
myocardial
angina pectoris, *293*
and Chagas' disease, 1058
and congenital aortic stenosis, 194
electrocardiogram in, 793–794
and infarction, 423
and papillary muscle syndrome, 1129–1131
surgical approaches, *1008*
and occlusion of small peripheral arteries, 1084–1089
renal
and hydrazinophthalazine, *146*
and splenorenal arterial anastomosis, 537
subendocardial electrocardiogram in, 793

Isopropylarterenol, vasodilation after, *944–945*

Italian parentage and atherosclerosis, 485

Ivalon, tubes for by-pass, *919–920*

Jacksonian epilepsy and aortic disease, 117

Japan, food conditions in, and hypertension, *299*

Jaundice
in cardiac failure, *297*
and pulmonary
embolism, 797
thrombosis, 770

Jejunum, colon and ileum, situs inversus of, 521

Jewish parentage and atherosclerosis, 485

Joint
effusions, and disease activity, 1154–1158
manifestations
in lupus erythematosus, 125, 131–132
after mitral commissurotomy, 181

Ketosteroid excretion and estrogen, 368–371

Kidney
adenocarcinoma of and hematuria, 185–187
anuric, oxygen consumption of, *148*
and arteriovenous fistula, 185–187, 538
arterial blood supply to, 532
aspiration biopsy, *300*
azotemia of, and malignant hypertension, 105–113
blood flow measured with krypton, *148*
cell damage, transaminase value, 798
and Chagas' disease with *Schizotrypanum cruzi*, 1050–1052
and cholesterol, *305*
congestion, 417, 1038–1039
damage
due to diet, *503*
and hypercatecholemia, 614
diabetic lesions in, 386
disease of, 1050–1052
and acetozoleamide, *1167*
failure
death due to, 532

Kidney (*Cont'd*)
and water excess, 1029
and malignant hypertension, 109–113
fatty degeneration, 1038–1039
filter and excretion of water by, 4
function
after antihypertensive regimens, 113
in heart failure, *974*
after hydrazinophthalazine, *146*
and piperoxan, 221–226
and rice diet, *143*
glomeruli microaneurysms in, 394
hemorrhage, and anticoagulant therapy, 257–259
and hypertension, *143–144*
and adrenolytic drugs, 614–620
malignant, 111
obstruction due to, 536
insufficiency, 614
and blood pressure, 627
and catecholamines, 614–620
and necrotizing arteritis, 486
and nitrogen mustard, *1167*
and blood pressure control, 106–113
hyperpotassemia due to, *143*
and mercurial diuretics, *149*, *151*
polycystic
death due to, 358
roentgenologic diagnosis, 108
renin distribution in, *981–982*
and splenorenal anastomosis, 532, 538
tuberculous, 1050–1052
urea excretion by, *976*
vascular beds, 185–187, 392
Kimmelstiel-Wilson disease
diabetes with, vectorcardiography in, 52
with renal insufficiency, 618
and thrombosis, 775
Kyphoscoliosis
circulation and respiration in, *935*
and left axis deviation, 241–249
and lung disease, 266

Lactate
and cardiotoxic effect of hyperpotassemia, *909–910*
cardiovascular responses to, *1168*
dehydrogenase activity in blood, *1173*
metabolism, 93–97
and potassium tolerance, *945*
Laennec's cirrhosis, and arteriosclerosis of aorta, *894*
Leriche's syndrome, 532
Lesion
and adrenal regeneration, 455
of angina pectoris, 426, 428
biliary tract and gallstones, 484
cardiac
congenital, 827
cyanotic, *885*
fibrinoid, *925–926*
after pharangeal infections, 457
streptococcal, *933*
and stroke, *139*
cardiovascular, 455
of Chagas' disease, 1042, 1050–1052
coexisting aortic valve and mitral commissurotomy, *1010*
of diabetes and aging of, 394
digital, and gangrene, 1084–1089
of fibrinous pneumonitis, 107
of hypertensive pulmonary vascular disease, 338
of lupus erythematosus, 130–133
myocardial
in bronze cirrhosis, 457
infarct, 545
pleural, and pericarditis, 876
pulmonary
and pericarditis, 876
resolution of, *137*
and valve regurgitation, 1071
renal, 455
rheumatic
and bacterial infections, 1138, 1151
and cortisone, *1177–1178*
prophylaxis, *1020–1021*, 1144–1151
skin, 127
stenotic, genesis and progression, 483
syphilitic, 1050–1052
valvular
and atrial fibrillation, 572
and thrombotic occlusion, 773–779
vascular
and atherosclerosis, 485
in diabetes, 394
Leukemia
and arteriosclerosis of aorta, *894*
death due to after anastomosis, 516–517
heart in, *652*
Leukocytosis
and Chagas' disease, 1037
and erythrocytosis, 280
and myocardial infarction, *635*
polymorphonuclear, 876
and rheumatic valvulitis, 421
and systemic lupus erythematosus, 127
Leukopenia, 128
Levarterenol, and cardiac arrhythmia, *152*
Levophed
and arrhythmias, *152*
in myocardial infarction, *952*
and shock, *1015*
Ligamentum arteriosum, 598
Lipemia
clearing factor
in blood, *498*
defect, in atherosclerosis, *502–503*
production in pancreas, *493*
and ingestion of cream, 855–856
serum concentration, *641*
and tissue oxygenation in arteriosclerosis, *964*
Lipfanogens, and lipoproteins, *504–505*
Lipid
of aorta
and allylamine, *501–502*
metabolism, in vitro, 482
of connective tissue and cholesterol intake, 487
deposits in aortic cusp of mitral valve, *501*
of hyperlipemic serum and serum water, *1174*
levels
in atherosclerosis, 725–726, *914–915*
coronary heart disease, 691–739
in degenerative vascular disease, 484
after dietary fat, *499*
and weight reduction, *645*
measurement of, predictive ability of, 710–713
metabolism, *499*
mobilization factor, *493–494*
partition, *303*
serum
and adrenalectomy, 492
in arteriosclerotic heart disease, 77–81
in coronary atherosclerosis, *499*, *914–915*
in elderly, *494*
in experimental athergenesis, 491
fractionations in atherosclerosis, *500*
after myocardial infarctions, 371
and sitosterol, 344, 346
total and beta sitosterol therapy, 78–81
transport, 484
Lipoprotein
alpha- and beta-fractions
and estrogen, 367
after sitosterol therapy, 78–81
and atherosclerosis
coronary, *499*, *914–915*
report of cooperative study of, 691–739
and cholesterol
in coronary heart disease, 715
and estrogen therapy, 371
in idiopathic hyperlipemia, *502*
as indices of atherogenesis, *970*
electrophoresis of moving boundary, *497–498*
and heparin, *149*
and hereditary obesity, 56
and lipfanogens, *504–505*
lipid fractions after beta sitosterol therapy, 80
nomenclature, 695–696
plasma lipase, and lipemia clearing factor, *498*
serum
concentrations of during growth, 57
and high fat meal, *499*, *502*
in hyperlipemia, *504*
patterns, 56–59, *494*
in peripheral arteriosclerosis, *496*
regulation of, *305*
and weight reduction, *1012–1013*
in South African Bantu, *992*
standard measures, 714–715
Listeria monocytogenes, *631–632*

Liver
cardiac fibrosis of, 417
in Chagas' disease, 1038–1039, 1050
and cholesterol, *305*
chloride level in, *1172*
and/or cortisone in diet, *303*
after sitosterol, 80, 344–347, *1172*
congestion, 1038–1039
and true cardiac cirrhosis, 421
damage, due to diet, *503*
duodenum and stomach anomalies, 520
enlargement of, 1046
with cortisone therapy in systemic lupus erythematosus, 127
fatty degeneration in Chagas' disease, 1038–1039, 1050–1052
function, 1037
in coronary atherosclerosis, *499*
and gallbladder, levoposition of, 521
ischemia of and splanchnic hemodynamics, *640*
"pulsating," *1171*
and situs inversus of viscera, 521
size of, 522–523
after pulmonary valvulotomy, 11, 15
and syndrome of congenital absence of spleen, 520–530
vascular abnormalities in, 185–187
Lobectomy
for aneurysm of pulmonary artery, *896*
for aorta-pulmonary communication, 1090–1092
Lobeline, and serotonin, 161
Low-salt syndrome, 1027–1028
Lung
abscess in, and coronary embolism, 1161
accessory lobes of and absence of spleen, 521–530
alveolar spaces of, and focal necrosis, 112
anomalies
bronchial and arterial, 826–845
venous connections, 200–219
venous drainage, *884*
arteriovenous
anastomosis, *960–961*
communication, 1090–1092
arteritis of, 265
atelectasis of, due to cor pulmonale, *137*
azygos vein, abnormal drainage, 523
situation, 1079–1082
blood from each, quantitative estimation of, 200–219
cancer of, and pulmonary thrombosis, 776
and Chagas' disease with *Schizotrypanum cruzi*, 1038–1039, 1050–1052
circulation time, 203, 215
drainage, *884*
into inferior vena cava, 826–845
and cholesterol, *305*
diffusion surface of on exercise, 269
diseases of, 338
and carbon anhydrase inhibitor, 282
electric conductance in advanced, 241
and heart failure, 265–285
granulomatous, and diffusion capacity, 273
emboli of multiple, repeated, 266
fetal, development of, 530
fields, 132, 767–768
insufficiency due to valvulotomy, *641–642*
left
four distinct lobes of, 523
as mirror image of right, 521
and left-to-right shunt in atrial septal defect, 200–219
vascularity of and pulmonary hypertension, 323–340
stenosis, *137*
and ventilation during open thoracotomy, *641*
Lupus erythematosus, 125–134
and blood coagulation, *291*
cell phenomenon, 133
and hydralazine, 109
chronic course of and previous illnesses, 130–134
disseminated
fibrinoid material in, 129
and malignant hypertension, 107–113
with renal involvement, *1167*
roentgen findings, 467
Lymphadenitis, 1050–1052
Lymph node
and azygos vein, 1082
in Chagas' disease, 1037–1039, 1050–1052
Lymphoma
and blood, 627
and arteriosclerosis of aorta, *894*

Magnesium ion, binding to meromyosis, *976–977*
Malaria, and Chagas' disease, 1050–1052
Malformation
abdominal artery, 520
aorta-pulmonary communication, 1090–1092
aortic arch, 607
arterial and bronchial, 826–845
atrial defect, 359
and cardiac catheter, 332
azygos vein, 1079–1082
Bing-Taussig, 597
cardiovascular
in Marfan's syndrome, *885*
and pulmonary vascular tree, *903*
and ventricular septal defect, 332, 357–363, *987*
central nervous system, 358
congenital
in cardiovascular system, *136–137*
and embryologic growth rates, *1015*
hemodynamic responses, *1175*
in infants, *1179–1180*
coronary artery, 423
anoxia, *136*
and ostia, 801–805
and developmental arrest, 530
exstrophy of bladder, 358
gastroenteric, and congenital absence of spleen, 520–530
of heart, *633*
classification of, *949*
and hypertensive pulmonary vascular disease, 339
postoperative results, 513
predictable pattern of, 530
pulmonary, *885–888*
stenosis, 1070–1071
venous connection, 200–219
renal artery, 538
tracheoesophageal fistula, 358–359
Malignancy
of bacterial endocarditis after cardiac surgery, *926–927*
of pheochromocytomas, 622
in hypertension, 454, 615–616, 818
and renal azotemia, 105–113
and transaminase valve, 798
Marfan's syndrome
angiographic versus electrocardiographic findings in, 118
cardiovascular alteration in, *885*
Master's test, for angina pectoris, 430–433
Measles, and hypertension, *143*
Mecamylamine
blood pressure and nitrogen retention after, 109
for hypertension, *645*, *931*
and hydralazine, 109
and reserpine, *999–1000*
and hydralazine for hypertension, 109
Mecholyl
and atrial fibrillation, *644*
tests with, for pheochromocytoma, 624
Meckel's diverticulum, of the abdominal viscera, 523
Mediastinopericarditis
electrocardiographic study, after surgery, *297*
and myocardial hypertrophy, 457
Medulla
adrenal, and epinephrine, *151*
hypothalamic, and rauwolfia alkaloids, *644*
Megaesophagus, in Brazil, 1035
Megaphen, and peripheral circulation, *645*
Melena, and salicylate therapy, *1168*
Meningitis, death due to after anastomosis, 516–517
Meningoencephalitis, and Chagas' disease, 1037
Menorrhagia, and quinidine therapy, 758, 762
Mental health
confusion, and absolute excess of water, 1029
in coronary artery disease and *Rauwolfia serpentina*, *232*

Mental health (*Cont'd*)
and malignant hypertension with renal azotemia, 111
and rauwolfia, *647*
Meperidine, *150*
Mephentermine, as antifibrillatory drug, *152*
Mercaptomerin
and bicarbonate threshold of proximal tubule, *151*
radiomercury-labeled studies with, *905*
rectal absorption of, *651*
Mercury, *150*
Meromyosin, binding of calcium, chlorine and magnesium ions to, *976–977*
Mersalyl, and concentration of sulfhydryl cells, *1166*
Mesentery
abnormal attachments, 530
dorsal, maldevelopment of, 522
elongation of, and cecum mobility, 523
Metabolism
calcium, *1176*
cerebral
and hydralazine and/or reserpine, *896*
oxygen, and Thorazine, 380
cholesterol, *654–655*
3*β*-cholestanol, 485
and nicotinic acid, *494–495*
disturbances
cardiovascular responses, 60–69
and papillary muscle syndrome, 1131
in ether narcosis, *300*
and hydrocortisone, 465
and hypertension, 584–591
inhibitors and substrates and carotid chemoreceptor activity, *1171*
of lipid, and atherosclerosis, 714–724
myocardial
and hyperthyroidism, 90–98
and nitroglycerin, *1002*
of nicotinic acid and lupus erythematosus, 128
and pentolinium, 584–590
of reserpine, *645*
tissue anaerobic and cardiac output, *956*
Metamine, in angina pectoris, *646–647*
Metaraminol, and shock, *1015*
Methacholine
dilator responses to, *944–945*
tests with for pheochromocytoma, 624
Methoxamine
cardiac effects of, *1017*
rhythm, *644*
coronary blood flow after and blood pressure, *139*
Microscopy, capillary, in rheumatic fever, *1177–1178*
Mitral valve
aortic cusp of lipid deposits in, *500–501*
atheromatous plaque, in Chagas' disease, 1050–1052
calcified and thrombosis of large pulmonary arteries, 770
cardioangiography in assessment of, 852
chordae tendineae, 420
circumferential suture of ring for insufficiency, *956–957*
and coronary embolism, 1161
disease, 762
hemodynamic and volumetric change in, *944*
and hydrazinophthalazine, *1177–1178*
left atrial pressure measurement of, 471
and left ventricular hypertrophy, 277–279
reoperation for, 469
in thrombotic occlusion of pulmonary artery, 773, 779
endocarditis of posterior leaflet, 419
fibroblastic deformity of, 420
insufficiency. *See* Insufficiency, mitral valve
involvement with regurgitation, 413
measurement of in mitral stenosis, 403–404
opening snap of, *152*
after mitral valvulotomy, *141*
rheumatic fibroblastic deformity of, 419
stenosis of. *See* Stenosis, mitral
surgery, 285
electrolyte and fluid disturbances after, *927–928*
hemiplegia following, 469
pericarditis following, 881
and ventricular septal defect, 359
Monge's disease, 280
Mononucleosis, infectious, and pericarditis, 881
Morphine, metabolic effect of, 384
Morphology, of negative U wave, 859–867
Mortality
in anomalies of coronary artery, 801, 803
in Chagas' disease, 1038–1039, 1044
cardiovascular in male farmers, *975*
and excision of arteriosclerotic aneurysms, *309*
in hypertension and age of subject, 18
late, and epicardial burns, *962*
and malignant hypertension with renal azotemia, 106–113
due to myocardial infarction, *137–138*
and climate, *634*
after coagulant therapy, 255
in coronary artery anomalies, 801, 804
and rupture of ventricular wall, 544–545
and nitrogen retention, 107–113
postoperative
and anastomosis, 516–517
after mitral insufficiency, 176
rates
cardiovascular-renal disease, in Chicago, *1006*
after coronary artery ligation, *137*
in myocardial infarction, *137–138, 635*
after transventricular pulmonary valvulotomy, 15
sudden death
in coronary embolism, 1161
in quinidine therapy, 757–763
syndrome of congenital absence of spleen, 530
Mountain sickness, and arterial desaturation, 280
Murmurs
adult fibroelastosis with congenital tricuspid stenosis, 421
apical systolic phonocardiography in, *998*
auscultation of and background noise, *946*
Austin Flint versus mitral stenosis, *999*
continuous after anastomosis, 514
and death due to anomalies of coronary ostia, 803
diastolic
and aortic insufficiency, 195
and aortic stenosis, 190
basal, frequency range of vibrations, 789
of mitral stenosis, *1170*
postoperatively, 197
duration of illness prior to, versus dosage of hormone therapy, 44–47
extracardiac venous hum, *1169*
Graham-Steel and pulsus alternans, 171
heart, 189
and aortic sinus aneurysms, 117, 123
in hypertensive pulmonary vascular disease, 331
and pulmonary valvulotomy, 11, 15
holosystolic, 1070
interscapular and hypertension, 117–118
normal, 1090–1092
and postcommissurotomy, 177, 182
pulmonic-systolic in children, *1170*
in thrombotic occlusion of pulmonary artery, 773, 779
in rheumatic carditis, and hormone therapy, 44–47
simultaneous recording of, 784
systolic, 195, 779
and aortic stenosis, 190
in congestive heart failure, 1046
due to cor pulmonale, *137*
frequency range of vibrations, 789
harsh, and aortic stenosis, 195
and hypokalemia, 62, 65
innocent, in child, *655*
in mitral commissurotomy, 471
postoperatively, 197
in pulmonary hypertension, 275–276

in thrombotic occlusion of pulmonary artery, 773, 779
and unruptured aortic sinus aneurysms, 117, 121
systolic-diastolic in wide patent ductus, *135*
typical, in congenital aortic stenosis, 194
Muscle
blood flow and pentolinium tartrate, 590
of heart
Aschoff body in, 1154
and catecholamine absorption, 615
and epinephrine, *645*
function, and glutathione, *640*
and hypertension, *292*
isolated sodium content of, *1174*
and norepinephrine, *645*
oxygen supply of, *139*
sodium in, *153*
and uremia, 618
energy output and exercise, *149*
failure of and sodium uptake, *153*
glycerol-extracted trabecular in failing myocardium study, *910*
loss of substance and Chagas' disease, 1040
mammalian ventricular, threshold of irritability of, *640*
papillary
and aorta enlargement, 1134
of conus, and right ventricle outflow tract, 350
and aortitis, 1132
and glutathione, *640*
and strophanthin K versus tryptamine - strophanthin, *151*
syndrome of, 1129–1136
paralysis, and potassium concentration, 60–69
tremor interference in vectorcardiographic computing systems, 88
ventricle
rhythm and contractile force in, *1175*
involvement in coronary embolism, 1161
weakness
and hypokalemia, 60, 65–69
and neurasthenia, 818
Muscular dystrophy, heart in, 474
Myocardial infarction, *293*
and ACTH, *650*
and age in male, *926*
age and mortality in, *137–138*
and angina pectoris, 426
and anterior chest wall syndrome, *138*
anterolateral
negative U wave, 865
reflected in linear time-scale plots, 563–564
anteroseptal
negative U wave, 861, 865–867
and pleural effusion, 880
anticoagulants for, *294*, *888*, *992–993*
and arrhythmia, 256
and congestive heart failure, 256
and atherosclerosis, 702, 709, 718, 736–737
atypical, *138*
basilar rales in, *138*
and bundle-branch block, 795, *888*
cardiac rupture eight hours after, *138*
complications after, *929*
and coronary artery
anomalies, 801–804
disease, 423
thrombosis, *634*, 1162–1163
death due to rupture of the left ventricular wall, 544–545
differential diagnosis in and nonspecific pericarditis, 874–882
in Egypt, seasonal incidence, *292*
electrocardiographic findings, *140*, 237–249, *292*, 540–544, 798, 867, 876–877
and papillary muscle in, 1132
and electrophoretic patterns of proteins, lipoproteins and glycoproteins, *494*
and emetine toxicity, 33–37
endocrine influences in, *971*
and endocrinium, *971*
and glycoprotein pattern, *494*
hemodynamics after, *140*
hemopericardium complicating, *633*
and heparin, *883–884*
index rating, *294*
and intra-atrial block, 1076
and left axis deviation, 237–249
and left bundle-branch block, *888*
Levophed therapy in, *952*
and malignant hypertension, 110, 113
mortality, *294*, 762
in Negro, *634*
and nonspecific pericarditis, 874–882
and occurrence of coronary anomalies, 805
painless, in psychotics, *635*
physical exertion after, *635*
postcommissurotomy, 182
posterior linear-time scale plots, 563–564
postoperative, *958*
prior to anginal syndrome, 228
pulmonary edema due to, calcium in, *946*
and pulsus alternans, 171
and quinidine therapy, 758
and response to Valsalva maneuver, 74
in sedentary workers, *635*
and septum involvement, 39–43
and serotonin, 161
and serum enzyme content, *968*
alterations, *1022*
spontaneous cardiac rupture after, *138*
and sudden death in syphilitic aortic sinus aneurysm, 121
surgery as risk after, 471
survival rates, 254–259
and thrombosis of the large pulmonary arteries, 775
and thyrotoxicosis, *957*
and transaminase, *635*, 790–799
and vaccination against variola, *138–139*
Myocarditis
and Chagas' disease, 1040, 1050–1052
granulomatous form of, 1056–1058
due to common respiratory viruses, *1001*
death due to, 762
in diphtheria, 457
and emetine toxicity, 37
Fielder's, simulating pericardial effusion, *147*
after group A streptococcal pharyngeal infections, *1177–1178*
interstitial and lupus erythematosus, 130
in newborn, *892*
nonspecific fibrinogen polymerization test in, *938*
rheumatic, 412–421
toxic, due to common cold, *147*
and transaminase value, 798
ventricular gradient in, *298*
Myocardium
and adenosinephosphatase, *640*
blood flow
and arterenol versus epinephrine, *944–945*
stimulation of collateral, *969*
catecholamines and adrenolytic drugs, 614–620
in Chagas' disease, 1050–1052
fibrosis, 1056–1058
in congenital cardiovascular malformations, *136–137*
contractility of
and cardiogenic shock, *947*
proteins, *910*
contraction
cyclic variations in, 173
and external electric stimulation, 749–750
failure, 274
fibrosis of, *979*
and potassium depletion, 68
fractionate contractions of, 173
function of and emphysema heart, 267, 270
and heart-lung preparation, cardiac effects of anesthetics on, *1172*
hemodynamic response to hyperthyroidism, 90–98
hypertrophy of
due to cor pulmonale, *137*
ventricle, 195
R wave pattern in, 277–279
involvement of and embolus, 1161
ischemia of and surgery, *1008*
of leishmania bodies and preflagellate forms of *Schizotrypanum cruzi*, 1035–1036
localized destruction of spatial vectorcardiographic response to, *955–956*

Myocardium (*Cont'd*)
metabolism of
in aortic insufficiency, *987–988*
and nitroglycerin, *1002*
and norepinephrine, *146*
revascularization, *970–971*
retroperfusion of, *137*
Schizotrypanum cruzi in, 1035–1059
transfer of calcium, potassium, sodium after acetylstrophanthidin, *952*
ventricular
after digoxin therapy, *140–141*
excitability recovery curve after hypothermia, *148*
hypertrophy of, 376
vectorcardiography after hexamethonium, *142*
Myofibril, contractile skeletal isolation of, *915–916*
Myokinase, inhibition of, *139*
Myomectomy, and postcommissurotomy, 182
Myosin, cardiac, *940–941*
Myxedema, 775
Myxoma
left atrial, 31
and rheumatic myocarditis, 467
and thrombus
differentiation of, 31
pulmonary artery, 770

Nalline, 384
Narcosis
carbon dioxide emphysema heart, 282
and respiratory metabolism, *300*
Nausea
and carotid sinus stimulation, 1110
in pheochromocytoma, 622
and quinidine, 573
Necrosis
arterial, 333
as allergic response, 337
arteriolar and arterial and pulmonary vascularity, 337
hypoxemic and adenosinephosphatase activity, *640*
ischemic, of legs and coarctation of aorta, *895*
and Jaundice of hepatic cells, *297*
of lower extremities walking in treatment for, *936*
myocardial
electrocardiography in, *292*, 796–797
infarction, *635*
and papillary muscle syndrome, 1131
serum glutamic-oxalacitic transaminase in, 790–799
myofibril, *1177–1178*
renal arteriolar and hypertension, 110, 113
and right bundle branch block, 1053
skin after noradrenaline, *648*
Negro
child, sickle-cell anemia in, *653*
hypertension in, 17–23
myocardial infarction in, *634*
Neohydrin, in ambulatory patients, *889*
Neo-Iopax, counterindication for in retrograde brachial aortography, 595–596
Nephrectomy
bilateral, electrocardiographic abnormalities after, 614
preoperative biopsy, *300*
for renal artery obstruction, 536
total, renal hypertension after, 455
Nephritis
and lupus erythematosus, 133
potassium-losing and aldosteronism, *891*
Nephrologist, 4
Nephrosclerosis
arteriolar, 112
and blood pressure following the tilt, 409
and quinidine therapy, 758
death due to, 762
Nephrotic syndrome, and ACTH and/or steroid therapy, *972*
Nervous system
central
and Chagas' disease, 1037
malformations of, 358
and resperine, 156
and serotonin, 162
sympathetic and hypertension, *144*
Neurasthenia, and muscle weakness, electrocardiogram in, 818
Neuritis, and angina pectoris, 426
Newborn
cardiovascular system, status of normal, *904–905*
cerebral arteriovenous, *296*
fistula, and failure, *295*
cor pulmonale in, *137*
myocarditis in, *892*
liver of filled hypochondrium, 521
vascular ring type of respiratory obstruction, *921*
See also Infant
Nicotinic acid
and cholesterol metabolism, *494–495*
deficiency, and lupus erythematosus, 128
intracoronary arterial injections cardiac effects of, *1017–1018*
and lipids in hypercholesterolemia, *495*
Nitrogen
and azotemia, 107–113
fractions of aortae and allylamine, *501–502*
mustard for lupus and renal impairment, *1167*
nonprotein levels, and antihypertensive regimens, 106–113
retention, in malignant stages of hypertension, 105–113
Nitroglycerin
and angina pectoris, *139*, 425
and coronary circulation and myocardial metabolism, *1002*
Nitrous oxide, concentration and myocardial function, *1172*
Nodule
atrioventricular conduction, 1107
blockade, *1014–1015*
fibrosing Aschoff periarterial scars from, 420
persistence, and disease activity, 1154–1158
rheumative fever and hormone dosage, 45
sino-atrial failure of impulse, 1104
Noradrenalin
and blood pressure, *938*
and cor pulmonale, *649*
hand blood flow after, *148*
Norepinephrine
antidiuretic action of posthypophyseal, 214–226
and arterial blood flow, 383
and atropine electrocardiographic changes after, *146*
blocking pressor effect of, 624–625
and blood pressure, *299*, *648*
and carotid sinus
arterial walls, *299*
vasoreceptive walls, *648*
coronary flow after and blood pressure, *139*
hemodynamic effects of during pulmonary constriction, *937*
as humoral mediator, 161
and paroxysmal hypertension, 622
inhibition of renal function by, 224
and isolated beating mammalian heart, *912*
and mechanical left ventricle, *151–152*
and mesenteric resistance, *1165*
and pheochromocytoma, 224, 626
skin necrosis after, *648*
and systemic arterial pressure, *239*
in urine, 627
versus mephentermine or ephedrine, *152*
Nucleic acid, metabolism of and lupus erythematosus, 128
Nurture of cardiologist: Presidential address, 3–8
Nutrition
and aging, *291*
of cardiacs, 631–632
impairment of and coronary heart disease, 423
and metabolism of myocardium, 97
and ischemic lesions, 1058
and obesity, *139*

Obesity
and heart failure, 266–273, *1003*
hereditary, 55–58
incidence of in coronary disease, *139*
and myocardial infarction, *634*
and pheochromocytoma, 627–629

and QRS changes of left ventricular hypertrophy, 236
and work tolerance, *139*
Obstruction
due to abnormality and ventricular septal defect, 362
aortic, 533
aorto-iliac aortography in, *896*
bronchial, due to pulmonary artery anomalies, *921*
in congenital aortic stenosis, 195
site of, 194–196
and sudden death, 198
intestinal
postoperative, 534
and thrombosis of the large pulmonary arteries, 775
in pulmonary valvular stenosis, 266
renal artery and splenorenal arterial anastomosis, 532
vena caval, and azygos vein distention, 1082
Occidental, hypertension in, 20
Occlusion
aortic aortography in, *896*
arterial, 1087
in heart failure, *140*
and lumbar sympathectomy, 473
by thrombus, 417
and Valsalva maneuver, *913–914*
arteriosclerotic by-pass operation in, *1180*
of carotid sinus, *893*
coronary arterial
fibrillation after, *1014–1015*
intercoronary anastomoses after, *292*
and myocardial infarction, *292*
and sudden death, *294*
in heart failure, *140*
of lumen, 333–336, 340
massive thrombotic of large pulmonary arteries, 766–782
of mitral orifice, *142*
peripheral arterial arteriosclerotic, *930–931*
popliteal arterial management of, 473
pulmonary artery
anastomosis after, 831
and blood volume, *963–964*
by laminated organized thrombi, 768
of left, *633*
of small arteries of hands and feet, 1084–1089
thrombotic, 773–779
digital or similar-sized arteries, 1084–1089
fainting in, 773, 779
femoral artery, 770
venous plethysmography, *936*
Oligemia of lung, in mitral stenosis, *1180*
Oliguria, and absolute sodium depletion, 1029
Operation
Beck, for coronary artery disease, *965–966*
for coarctation, appraisal after, 806–814
for coronary artery disease, *965*
See also Surgery
Organ of Zuckerkandl, pheochromocytoma in, 622
Oriental, hypertension in, 20–23
Orthodiagraphy, fluoroscopic examination with for cardiovascular functions study, 61
Orthopnea, and congestive failure exchangeable sodium in, 1094
Osler-Vaquez, primary blood dyscrasia in, 280
Osmolarity
and body composition, *930*
and cellular hypotension, 1030–1031
and concentration of serum sodium, and body composition, *930*
urinary and pentolinium tartrate, 589
Ossification, subcutaneous, in venous stasis, *968–969*
Ostium
anomalies of the coronary, 801
accessory lobe, 523
and conus, 419
persistent atrioventriculare commune, *965*
primum, 522
secundum, *886*
Ouabain, cardiac effects of, *148*
Oxygen
alveolar
content, and tension, 283
pressure gradient, of left heart, *642–643*
arterial
coronary sinus difference, 96–97
and hypertension, 269
mixed venous difference, 585
renal difference, 587, 589
arterial desaturation
and emphysema heart, 269–281
and heart failure, 266–285
and hypertension, 269
arterial saturation, *292*, 381
and arm position, 466
erythropoiesis, 272
in heart failure and lung disease, 266
postoperative anastomosis, 515
after valvulotomy, 10–11, 15
arteriovenous difference
in hyperthyroidism, 92, 97–98
in lung disease heart failure in, 267–268
in valvular regurgitation, 1070
breathing high mixtures in rheumatic heart disease, *985*
cerebral, 380–381
and chlorpromazine, 380
and heparin, *149*
consumption, 92–95, 1070
in bronchial and arterial anomalies, 828
and coronary blood flow, *642*
and heart failure in lung disease, 267–268
and hyperthyroidism, 92, 95
and muscular activity, *149*, 466
and obesity, *139*
and pentolinium tartrate, 584–590
of pulmonary and systemic blood, 214–215
renal, 587, 589
in valvular regurgitation, 1070
content, 1070
in aorta-pulmonary arteriovenous communication, 1090–1092
and atrium cardiac catheterization, 1090–1092
in coronary venous blood after norepinephrine, *139*
in heart failure and lung disease, 266
in pulmonary artery, 1090–1092
of pulmonary and systemic blood, 214–215
in wide patent ductus, *135*
differentials, in heart electrocardiography, *915*
internal transport, in erythrocytosis and heart failure, 270
jump, validity of, *1173–1174*
presacral injection of and pheochromocytoma, 627
tension
in alligator, 1116
alveolar-arterial gradient, 266, 269
of tissues, *903*
transport
in granulomatous lung disease, 273
to muscles, 194
venous saturation, blood flow and pH during extracorporeal circulation, *974–975*

Pacatal, and peripheral circulation, *645*
Pain
chest. *See* chest, pain
and coronary
insufficiency, 423
thrombosis, in psychotics, *635*
in epigastrium in pheochromocytoma, 622
heart
daily report card, 228–230
and palpitation, *299*
and peritrate, *139*
joint
and rheumatic fever, 45
and systemic lupus erythematosus, 125, 127
left shoulder and pleuritic left chest, 876
midabdominal in myocardial infarction, *138*
neck and neo-iopax following retrograde aortography, 611
pericordial
and Chagas' disease, 1050–1052
and electrocardiographic findings, 33

Pain (*Cont'd*)
after mitral commissurotomy, 181
and profuse diaphoresis, 880
syndrome of, *1169–1170*
and syphilitic unperforated aortic sinus aneurysms, 121
in pericarditis
and pleuritis, 876
radiation of, 875
thoracic, after mitral commissurotomy, 181
Palpitation
and death due to anomalies of coronary ostia, 801
heart pain, *299*
relief from, and quinidine, 579–581
Palsy, left phrenic, after mitral commissurotomy, *1014*
Pancreas
cancer of, 774
incompletely developed, 520
and lipemia clearing factor, *493*
and situs inversus of viscera, 521
and syndrome of congenital absence of spleen, 523–529
Pancreatitis
and angina pectoris, 426–427
hemorrhagic, 801
and transaminase value, 798
Panstrongylus megistus, as vector of Chagas' disease in South and Central America, 1036–1037
Papillary muscle syndrome, left and right, 1129–1136
Papilledema
and malignant hypertension, 108, 109
hemorrhagic and exudative retinitis with, 110–113
after rice diet, *143*
Para-amino hippuric acid
excretory clearances of, 463
extraction, 587
Parabiosis, in hypertensives and blood pressure, *144*
Paracentesis, serous fluid drainage after, 415
Paresis, after poliomyelitis, electrocardiogram finding of, *638*
Peizogram, neurotonic, *299*
Penicillin
and aortitis, 123
and endocarditis
bacterial, subacute, 1155
monilial, *147*
staphylococcal, *954*
for rheumatic fever prevention, 1144, 1155
and streptococcal infections, 1139
prevention of, 1144–1145, 1155
Pentaerythritol tetranitrate, and coronary insufficiency, *139*
Pentolinium
cardiovascular
hemodynamics after, 584–591, *998*, 1061–1067
for hypertension, *931*
and/or hexamethonium, 108, 112–113
Periarteritis nodosa
and malignant hypertension, 454
and nasal granuloma, *653*
Pericarditis
acute benign in infancy, 457
and angina pectoris, 426, 428
anticoagulants contraindicated in, 881–882
constrictive diagnostic sign of, 415
electrocardiography in, 878–879
idiopathic simulating acute abdominal disease, *652*
and lupus erythematosus, 130
nonspecific
fibrinogen polymerization test in, *938*
frequency of relapse in, 881
and friction rubs, 874–875
and myocardial infarction, 874–882
premature contraction in, 877
rheumatic
death due to, 762
and hormone dosage, 45
and quinidine therapy, 758–762
due to staphylococcus, penicillin and streptomycin-resistant, *652*
and transaminase value, 798
tuberculous, *147*
Pericardium
angiosarcoma of, 457
autografts, growth of, 469
blood retained in, postoperative reactions, *948*
friction rubs, 874–875
grafts, in mitral insufficiency, *908*
rupture into, *293*
Peritrate, *139*
Pharyngitis, and streptococci, *949*, 1139
Phenindione, as coagulant, *634*
Phenobarbital, and hypertension, *928*
Phenolsulfonphthalein, excretion in malignant hypertension with azotemia, 110
after rice diet, *143*
Phenoxylbenzamine, 465
Phentolamine, tests with, 622, 624–626
Phenylbutazone, and aspirin, 1157
Phenylindanedione
and Dicumarol, *295*
for myocardial infarction, 254
Pheochromocytoma, 622–629, *638–639*
and blood pressure following the tilt, 409
in children, 454
and hypertension, 628
intrathoracic, 622
piperoxan in, renal responses to, 221–226
and regitine, 617, 625
sympatholytic agents, 868–873
Phlebitis, and heart disease, 472
Phlebothrombosis, and lupus erythematosus, 133
Phlebotomy
and death after anastomosis, 516–517
and renal clearances, *296*
Phonocardiography
in apical systolic murmur, *998*
azoulay maneuver in mitral stenosis, *298*
of holosystolic murmur, early and diastolic murmur, 1070
intracardiac, *967*
in mitral disease, *141*
in mitral stenosis, *1168–1169*
in obliterative pulmonary arteriosclerosis, 276
in pulmonic-systolic murmurs in children, *1170*
and "reduplication," *152*
in splitting of heart sounds, *1169*
Phosphatide, *504*
Phosphokinase, *139*
Phospholipid
alpha-lipoprotein
and estrogen therapy, 366, 371
in ideopathic hyperlipemia, *502*
of aortic intima, composition of, 482
and cholesterol, *303*
turnover, *305*
with coronary disease, *499*
metabolism in tissues, *305*
serum concentrations of
during growth, 57
and heredity, 57–59
Photooscillography, in pulsus alternans studies, 163–173
Photosensitivity, and lupus erythematosus, 133
Pigmentation
carotenoid in atherosclerosis, *912*
skin
in adrenal insufficiency versus lupus erythematosus, 128
and estrogen, 366
Piperoxan
antidiuretic effect of, 214–226
and blood pressure, 624–625
and glomerular filtration, 223
and hypertension, 223
in pheochromocytoma, 221–226
Pitressin, and hypertension, 455–456, *938*
Pituitary gland
anterior
and epinephrine, *1164*
and protein-rich diet, *143–144*
and blood pressure of hypertensive disease, *144*
and measles, *143*
Plasma
bicarbonate concentration, 589
carbon dioxide content, 589
cholesterol, *305*
in butter and corn oil, 484
and cortisone, *303*
method for reducing, *495–496*
after sitosterol, 80
and excised tissue water and electrolyte exchanges between, *940*
leakage due to aging in diabetes mellitus, 390
lipase
and lipemia clearing factors, *493*, *498*
pressor amines in and pheochromocytoma, 626

renal flow, 589
and Digoxin, *140–141*
after hypophysectomy, *141*
volume, and pulsus alternans, 171
Plasmin, intravenous, responses to, *919*
Plethysmography
blood flow measured by, *302*
venous occlusion, *302*, *936*
Pleura
calcification, 273
effusion of, 413, 417, *652*
pain, in thrombotic occlusion, 773, 779
Pleurisy
and lupus erythematosus, 131
and pericarditis, 876
after myocardial infarction, 880
Pleuritis
and angina pectoris, 426
fibrinopurulent, in Chagas' disease, 1038–1039
Pleuropericarditis
complication of myocardial infarction, 882
electrocardiographic study after surgery, *297*
after mitral commissurotomy, 181
Pneumonectomy, *308*, 633
Pneumonia
death due to
after anastomosis, 516–517
in anomalies of coronary artery, 804
and lupus erythematosus, 129
and penicillin, 125
lobar, 758, 760
fatal, 762
Pneumonitis
fibrinous, and malignant hypertension, 107, 109–113
and pericarditis, 876
and rheumatic fever, *1179–1180*
Poliomyelitis, cardiac output, and ventilation, *301*
Polyarthritis, and systemic lupus arthritis, 126–130
Polycythemia
and angina pectoris, 423
differential diagnosis, 279–280
and erythremia, 274
and heart failure, 272
and lung disease, 266
arterial oxygen desaturation, 271–272
and morbus coeruleus, *136*
and pulmonary hypertension, 333, 337
primary blood dyscrasia in, 280
Position
arm, and circulation through fingers, *305–306*
and blood pressure
in aged, *990*
and blocking agents, *144*, 1066–1067
of body
hand blood flow, *1171*
in cardiovascular disease, *1001*
and heart rate, 466
and distention of azygos vein, 1082
head-down blood pressure response, 407
and hypertension pressor and depressor responses in, *945*
and magnitude of spatial vectors, 100
and pulmonary hemodynamics in left-to-right shunt, *916–917*
and pulsus alternans, 1099–1103
and renal function in heart failure, *974*
supine, and blood pressure in malignant hypertension, 108, 111
tilt to head-up blood pressure response, 407
in vector analysis, and age trends, 101–103
Postcommissurotomy syndrome, *307*
pericarditis in, 881
Postmyocardial infarction syndrome, *929*
Potassium
ballistocardiography after intake of, 62–68
blood, *143*
in cardiac muscle, *153*
electrocardiography in studies of, 62–69, 818–823
exchangeable content of body in congestive failure, 1093–1098
and digitoxin, *647*
after steroid therapy, *905–906*
excretion, 588–590
in sweat, *1176*
failure of renal conservation of and hypokalemia, 60–69
ground substance as cation exchange resin to, 821
intracellular content
and congestive failure, 1097
versus extracellular, and pH alterations, 821
and molar sodium lactate, *945*
myocardial
and hypopotassemia, *978*
transfer in heart failure, *952*
serum concentration
and digitoxin, *647*
serial electrocardiograms, 818–823
and sodium, 463–464
tissue studies in, *640*
and veratridine, for carotid sinus, *1165*
Precordium
"crista supraventricularis" recorded from, 278
systolic murmurs of and coarctation of aorta, 806
Prednisone
and lupus erythematosus, 126–127
in rheumatic carditis, *933–934*, *1177–1178*
Pregnancy
and cardiac disease, management of, *655*
and coarctation of aorta, *885*, *924*
and congenital
aortic stenosis, 189
heart disease, *885–886*
and coarctation of abdominal aorta, *885*
and heart disease, *959*
hemodynamics in, *303*
hypertension during, 409
pulmonary, *1018*
and postcommissurotomy deliveries, 182
toxemia of and hypertensive vascular disease, *299*
and pyelonephritis simulating, *934*
Premarin, 371
Pressor
amines secretion, 622
and azamethonium, *144*
and depressor responses to tilting, 407–410
and ganglionic blocking agents, *144*
and hexamethonium, *144*
receptor and veratridine, *1165*
released by kidneys, *144*
responses
to catecholamine, *986*
to cold, *144*, 624
to tilting, 407–410, *945*
Pressure
arterial
and congestive failure, *906*
in hyperthyroidism, 92
and pentolinium, 584–590
and piperoxan, 223
responses to Valsalva maneuver, 72–76
and serotonin, 161
versus large and small vein, *1013*
wedge, in hypertensive pulmonary disease, 332
atrial
and anomalous pulmonary venous connection, 203
and common atrioventricular canal, 203
and Digoxin, *140–141*
and fibroelastosis, 420
and heart failure, 1101–1102
shunt, left-to-right, 203
systolic, *153*
during valvotomy, *1181*
versus in mitral stenosis, *1004*
blood. *See* Blood pressure
and blood flow resonance of, *969*
brachial artery
and congenital aortic stenosis, 196
diastolic, alternation in, 164
and oxygen content, 1070
and pseudocoarctation, 117
tracings, 193, *949*
capillary pulmonary, classification of, *894*
central venous and right ventricle, *304*
diastolic
and Ecolid, 109
and electron gun "therapy," 263
in malignant hypertension with azotemia, 110
and prediction of stroke volume, 250–253

Pressure (*Cont'd*)
and syphilitic aortic sinus aneurysms, 121–122
femoral arterial
and hypophysectomy, *141*
and intra-arterial radial, 808
and pseudocoaretation, 117
gradient and response to Valsalva maneuver, 76
and hemodynamics after pulmonary embolism, *994–995*
intra-arterial systolic postoperative, coarctation, 809–810
intracardiac
in atrial septal defect, 203
common atrioventricular canal, 203
and Digoxin, *295*
and pressure amines concentrations, 627
intravascular, and Eisenmenger's complex, *887*
measurements
left atrial, 471
left atrial, left ventricle simultaneously, *909*
peripheral pulse, and stroke volume, 1120–1127
pleural, and breath holding, 169
pulmonary artery, 302, 332–333, 339, 585
and anomalous coronary artery, *136*
and anomalous pulmonary venous connection, 203
and cardiac failure, 1101–1102
and carotid sinus stimulation, *893*
and common atrioventricular canal, 203
in congenital heart disease, *887–888*
and digitalization, 281
and epinephrine, *151–152*
and heart failure in lung disease, 267–268, 276–280
pulmonary arterial
in mitral stenosis, *1004*
and norepinephrine, *151–152*
and pentolinium, 584–590
and pulsus alternans, 167, 170–171
and right ventricular function, 265
and serotonin, *145*
and shunt, left-to-right, 203
and stimulation of carotid sinus, *893*
after valvulotomy, 10
and ventricular septal defects, 358–363
pulmonary wedge, 203
and heart failure in lung disease, 267–268
in mitral stenosis, *1004*
and oxygen content, 1070
recordings during catheterization of cardiac vein, *643*
and respiratory acidosis, *641*
systemic, 170–171
and left ventricular function, 265
pulse, 163
venous, and azygos vein distention, 1082
systolic
alternation in, 164
and electron gun therapy, 263
in hypertension, 18
in malignant hypertension with azotemia, 110–111
systolic and pulse in Chagas' disease, 1058
during thoracotomy, inflation and deflation time ratios and, *641*
transmural, venous-arteriolar reflex to, *1175*
venous, *1013*
in Chagas' disease, 1046
and congestion, *297*
and conversion from atrial fibrillation, 578
and myocardial infarction, *140*
ventricular
end-diastolic, 173, 585
and cardiac enlargement, 14–15
patterns for, *633*
and pentolinium, 584–590
and quinidine, 166, 168
systolic, and digoxin, *140–141*
after valvulotomy, 10, 13–15
volume studies, *300*, *954*
Priscoline, and pulmonary hypertension, *991–992*
Procaine amide, and cardiac arrhythmias, *650*
Progeria, and atherosclerosis, 473
Proliferation, retroperfusion of myocardium due to, *137*
Promonta, and peripheral circulation, *645*
Prostate, cancer of, and anticoagulant therapy mortality after, 256
Prostatectomy, transurethral, nonprotein nitrogen after, 112
Prostheses, arterial, plastic fabrics as, *1180*
Protein
capillary permeability to, in congestive failure, *991*
components of connective tissue and mucopolysaccharides, *972–973*
concentration of total and heredity, 55–59
contractile, of failing myocardium, *910*
c-reactive
in congestive heart failure, *888–889*
in disease activities, *307*, 1154–1158
and myocardial infarction, *635*
and transaminase in coronary artery disease, *963*
dietary
and atherosclerosis, 489
and serum cholesterol, *962*
and tissue lipids, 488
lipids and lipoproteins, in coronary atherosclerosis, *914–915*
and lipoprotein patterns, heredity in establishment of, 55–59
quantitative determination of, *1174*
serum
in diabetes, 395
in erythematosus, 132–133
fractions, electrophoretic, 57
serum pattern
and growth, 57
in myocardial infarction, *494*
urinary, after aortography, 611
volume expansion after Dextran, *640*
Proteinuria, 417
Prothrombin time
and anticoagulant therapy, 256–259
and the fatty meal, 854–858
and heparin tolerance test, *649–650*
and reaction between thrombin and fibrinogen, *632*
Protoveratrine
A versus B, *1019*
and hypertensive disease, 465
Pseudocoarctation
and aneurysmal dilatation of aortic sinuses, 117, 123
electrocardiography in, 118
Pseudodiverticulum, *293*
Psychoneurosis
and angina pectoris, 426, 429
and nitroglycerin, 425
Psychoses
and lupus erythematosus, 133
and painless myocardial infarction, *635*
and quinidine, 758, 762
and reserpine, 463
Pueblo, Colo., rheumatic fever prevention program, *1010*
Pulmonary artery
accessory, 835–844
alternans, and exercise, 1102
and aneurysm of aortic sinuses, 116, 118
and syphilis, 122
angiogram of small right, 837
anomalies
and atrium, 200–219
and bronchial obstruction, *921*
complete drainage, *913*
and dilution curve, 216
of left, 832
left coronary artery from, *136*
venous connection, 200–219, *886–887*
venous return, 826–845
surgery for, 831, *886–887*
and aorta
communication between, *308*
transposition of, *1180–1181*
atretic, 521–523, *633*, 775
blood oxygen
content, 193
and diameter of ductus, *135*
branch, in arteriovenous fistula, 1090–1092
coarctation of, *135*
congestion
and mitral stenosis, *986*
and ventricular septal defect, 361
constriction
and cardiac failure, *296*

and Digoxin, *140–141*
hemodynamic effects of norepinephrine during, *937*
as cordlike structure, 520
coronary circulation origin from, 800
distention of, in heart failure, 1082
and digitalization, pulsus alternans after, 166
disease
electrocardiography in, 238–247
and erythrocytosis, 279
hemodynamics in, *969–970*
management of, 281
and respiratory irritants, 281
embolization, 417, *1016–1017*
block in, *961*
enlargement of
and coarctation of aorta, *136*
trunk of, 827–840
and epinephrine, *151–152*
flow and pressure, 275
hypoplasia of with a patent ductus arteriosus, 523
independent alternation of, 164
infarction of, *980*
infection and coronary embolism, 1161
left, congenital absence of, *885*
and left atrium mitral regurgitation into, 848
and left-to-right shunt through atrial septal defect, 204, 206
ligation of
and pulmonary infarction, 471–472
and total by-pass of pulmonic valve, *308*
main, thrombosis of, 766–769
maldevelopment of, 522
manifold of blood flow through, *1175–1176*
massive thrombosis, *895*
muscular, and hypertension, 334–336
and norepinephrine, *151–152*
outflow of, and coronary venous drainage, *139*
and oxygen content
cardiac catheterization, 1090–1092
and pressure in, 1070
postmortem appearance, 768
pressure. *See* Pressure, pulmonary
pulses in valvular stenosis, *940*
pulsus alternans in during exercise, 172
saturation in and calculation of shunt, *136*
second and third beats in false alternans, 165
size of
after mitral commissurotomy, 178–179
after valvulotomy, 14
stenosis. *See* Stenosis, pulmonary, *941*
thrombosis of, 774
occlusion, 766–782
and transposed aorta, 521
undivided and enlargement of right ventricle, *884*
volumetric changes in
in mitral valve disease, *944*
and pentolinium, 1061–1067

Pulmonary vascular obstruction syndrome, 265

Pulmoncardiac syndrome
and lung disease, 266

Pulsation
of aorta
and hypertension, 118
and ventricular enlargement, *137*
and congenital aortic stenosis, 191
paradoxical and constrictive pericarditis, 276

Pulse
arterial
and aortic stenosis, 188, 196
during electric stimulation, 749
in thrombotic occlusion of pulmonary artery, 773, 779
capsule attachment sensitivity, 789
in cardiac neurotonic amplitude, *299*
carotid pressure, direct recording of, *977*
central venous in thrombotic occlusion of pulmonary artery, 773–779
halving of due to severe alternans, *637*
peripheral and congenital aortic stenosis, 190
pressure
alternation of, 163
and azamethonium, *144*
in arachnodactyly and aortic regurgitation, 118
and cardiac work, 1118
in congenital aortic stenosis, 194
defined, 252
after digitalization, 169
direct recording of, *977*
in exposed heart, *943*
and hexamethonium, *144*
and mitral insufficiency, *966–967*
and quinidine, 166, 168
right atrial and cardiac lesions, *153*
in right ventricle and pulmonary artery, *940*
and stroke volume, 250–253, 1126
during strain of Valsalva maneuver in cardiacs, 72–76
in syphilitic aortic sinus aneurysms, 121–122
time versus pressure ratios, 811
in valvular pulmonary stenosis, *940*
waxing and waning in, 173
and wide patent ductus arteriosus, *135*
rate
and ganglionic blocking agent, *144*
and muscular activity, *149*
after resection of aortic coarctation, 808

Pulsus alternans, 1099–1103
with alternating pulse, *637*
brachial artery, 164, 168, 172
false, 165
cardiocirculatory studies in, 163–173
and congestion, 167
defined, 163
and digitalization, 166–169
after Digoxin, 166, 169
reversal of, after ouabain, *148*
and stage of heart failure, *993*

Pulsus bisectus
halving of pulse, due to severe alternans, *637*

Purpura, thrombocytopenic, in systemic lupus erythematosus, 131–133

Pyelogram, by-product of retrograde aortography, 609

Pyelonephritis
with hypertension aspiration biopsy, *300*
and malignant hypertension, 110, 113
and nitrogen retention, 106
and thrombosis of the large pulmonary arteries, 775
and toxemia of pregnancy, *934*

Pyothorax, in Chagas' disease, 1038–1039

Pyridoxine, and transaminase activity of placenta, *1172*

Pyrogen, fibrinolysis induced by, *959–960*

Pyruvic acid, metabolism, and hyperthyroidism, 94–97

Quick one-stage prothrombin test, *921*

Quinidine
and atrial fibrillation, *1003*
and ajmaline, *1166*
and/or digitalis, *1016*
and cardiac arrhythmias, *650*
as a cause of sudden death, 757–763
and diphenhydramine, *142*
electrocardiographic alterations induced by, 821
and fibrillation after mitral commissurotomy, 177–178, 182
and intra-atrial block, 1076–1077
and pulsus alternans, 166
serum concentration and dosage, 568–581
and toxicity, 573–574
and ventricular arrhythmias, *650*

Race
and aortic sinus aneurysms unperforated, 116
and coronary artery disease, 103
and cyanosis, 271
and hypertension, 17–23
and lupus erythematosus, 131
and mortality rates, cardiovascular-renal diseases, *1006*
and myocardial infarction, *634*
and syphilitic aneurysms, unperforated aortic sinus, 121

Radiation
roentgen, in anterior chest wall syndrome, *138*
thermal
hemodynamics after, *1164–1165*
for herpes zoster, 379
Radioiodine, and atherogenesis, 491
Radiology
cardiovascular diagnostic, 509–511
in erythropoiesis, 280
in hypertensive pulmonary vascular disease, 331
in myocardial infarction, 875
in pericarditis, 875
and pulmonary arterial pressure in congenital heart disease, *887–888*
in pulmonary disease
hypertensive and heart, 276–277
thrombotic, 773, 779
Radiomercury, mercaptomerin labeled with, *905*
Rales
basilar pulmonary, in myocardial infarction, *138*
moist, in lupus erythematosus, 126
Rauwiloid, therapeutic response pattern after, 230
Rauwolfia
and angina pectoris, 227–232
antiemetic activity of, *1166*
and hypertension, 131–132, 454, 464–465, *639*, *896*, *931*
in elderly, *146*
and hypotensive disease, 645
and hypothalamic medullary, 644
and premature ventricular contractions, *647*
reactions to, 231
and regitine test for pheochromocytoma, 625
and reserpine, *639*
and spinal vasoregulatory systems, *644*
therapy with depression and anxiety during, *647*
See also Reserpine
Raynaud's disease
and coronary artery disease, 423
among women, *941*
Raynaud's phenomenon
and lupus erythematosus, 133
and occlusion of small arteries in extremities, 1089
sympathectomy for, *941–942*
Rectum
absorption by, of mercaptomerin, *651*
cancer of, and anticoagulant therapy, mortality after, 256
of triatomid bugs, parasite development in, 1037
Regitine, 616–625
Regurgitation
aortic
and bacterial endocarditis, 116, 123
and chest pain, 117
and pulse pressure, 118
after surgery, postoperatively, 197
and syphilis, 122–123
in young people, *911–912*
and Chagas' disease with *Schizotrypanum cruzi*, 1050
mitral
diagnosis of by cardioangiography, 847–852
and rheumatic carditis, 31
pulmonic valvular, isolated, 1069–1072
tricuspid in Chagas' disease, 1046, 1050–1052
Rehabilitation
and age in arterial artery disease, 474
in hemiplegics with atrial fibrillation, *896*
in hypertensive diseases, 263
Renotrophine, and growth of renal tissue, *143–144*
Rescinnamine, and reserpine, hypotensive effects of, *976*
Resection
of aortic coaretation, 195
appraisal of after, 806–814
Reserpine
activity of, cerebral, *896*
assay of emesis in pigeons for, *644*
and chlorpromazine, *1166*
and electroconvulsive therapy, *646*
and gastric secretion, *643*
and hypertension, *144*, 454, *639*, *928*
and hydralazine, *896*, *928*
and mental patients, 465
metabolism of, *645*, *896*
and newborn infants, *646*
and postural hypotension, *144*
and psychosis, 463
and rauwolfia, *639*
and rescinnamine hypotensive effects of, *976*
and serotonin, 162, *1175*
and SU 3088, *144*
and thyroid function, *648*
See also Rauwolfia
Resistance
airway, and body size, *929*
arteriolar and wide patent ductus, *135*
and blood flow in pulmonary hypertension, 195
cerebral vascular, 381
and heparin, *149*
coronary vascular and hyperthyroidism, 92–93
mesenteric, and epinephrine, norepinephrine, *1165*
outflow and congenital aortic stenosis, 195
peripheral, 585, 608, 1070
and Digoxin, *140–141*
and hypokalemia, 65
and myocardial infarction, *140*
and pentolinium, 1061–1067
postoperative, coaretation of aorta, 807, 811–812
total, 1070
peripheral vascular and potassium intake, 65, 68
pulmonary, 585
and heart failure in lung disease, 267–268
in right-to-left shunt through ductus, 608
pulmonary arteriolar in valvular regurgitation, 1070
pulmonary flow, and ventricular septal defect, 361
pulmonary vascular and tetraethylammonium, *302*
in pulsus alternans, 171–173
renal, 223, 587
and venous-arteriolar reflex, *1175*
Respiration
and alternation, 164, 167
Cheyne-Stokes, and aminophylline, *150*
correction of abnormal, 281
in ether narcosis, *300*
functions, and erythropoiesis, 280
in Guillain-Barre Syndrome, *652*
and hypertonic sodium bicarbonate, *1176*
in kyphoscoliosis, *935*
meperidine and/or aminophylline, *150*
reaction, after retrograde aortography, 611
reserve, and surgery for congenital aortic stenosis, 197
spatial QRS and T vectors after, *1001*
and thoracic disease, 427
vascular ring type of obstruction in newborn, *921*
Respirator, 281, *980*
Respiratory system
and cardiorespiratory disorders, 274
and emphysema heart, 267, 269
and heart failure, 265–285
infection, and myocarditis in, *147*
Retina
cytoid bodies in and lupus erythematosus, 132
diabetic lesions in, 386
glomeruli microaneurysms in, 394
vascular abnormalities in and diabetes mellitus, *953–954*
specific morphology, 392
reactivity after, *1000–1001*
Retinitis
diabetic, in lupus erythematosus, 132
hemorrhagic, and hypertension, 108–112
malignant, 110–113
splanchnicectomy for, 455
Rheumatic fever
antibiotics for, 1145, 1162
antistreptolysin-O titer and hormone dosage, 45
capillary microscopy, *1177–1178*
in children
and prolonged residence in Miami, Florida, *995–996*

and systemic erythematosus, 127
control of primary attacks, *983*
and coronary embolism, 1162
electrocardiographic effects produced in, *906*
and familial susceptibility to group A streptococcal infection, *995*
hemolytic streptococci in, survey of, *949*
hormone dosages for, 44–47
incidence of, *989*
pituitary-adrenal function in families of subjects, *1010–1011*
pneumonitis, *1179–1180*
prophylaxis against streptococcal infection, 1144
in children with, *1020–1021*
Pueblo's prevention program, *1010*
recommended procedures for the prevention of, 1145
recurrences in adult and streptococcal infection, 1151
respiratory infections preceding, 881
steroid therapy for, body changes after, *905–906*
symposium on, 1138–1158
tissue culture studies in, *935*
and transaminase value, 798
treatment, 1153
and cortisone, *1177–1178*

Rhodnius prolixus, as vector of Chagas' disease in South and Central America, 1036–1037

Rhythm
in angina pectoris, 423
atrial bigeminal, *637*
atrial and ventricles independent and synchronization of, 41–43
control of, 745–755
and contractile force in ventricular muscle, *1175*
gallop
apical systolic, 111, 168
in Chagas' disease, 1046
classification and prognosis of, *950*
in congenital mitral atresia, 136
presystolic and hypertension, 108
after pulmonary valvulotomy, 11
idioventricular and heart block, 41–42, *891*
and methoxamine, *644*
nodal
in emetine toxicity, 33
and isorhythmic atrial-ventricular dissociation, 1043
after retrograde aortography, 611
parasympathetic influences on, *152*
and respiratory rate in false alternans, 164
sinus
and false alternans, 165
and mitral commissurotomy, 177
of pulsus alternans, 173
and Vasoxyl, *644*
and ventricular rate in false alternans, 164

Rice diet, *143*

Roentgenkymography, in cardiac mobility study, *997*

Roentgenography
of the abdomen, 627
in anomalous aorta-pulmonary artery communication, 1090–1092
in aortic sinus aneurysms, 115, 118–119
syphilitic, 122
in arterial and bronchial anomalies, 834–838, 842–843
atrial septal defect secundum type, *886*
in Chagas' disease, 1038–1039, 1047
and congenital aortic stenosis, 193, 195
grading of, 215–216
in mitral
commissurotomy, 178, 182
stenosis, 402, *1179–1180*
in splenic agenesis, 530
of syphilitic saccular aneurysm, 120
in systemic lupus erythematosus, 467
in thrombotic occlusion, 767–768

Roentgenology
and heart
size, 807
volume, *1173*
in malignant hypertension, 108, 111
in uncomplicated dextroversion of heart, *886*

Salicylamide, as analgesic and antirheumatic agent, *1177–1178*

Salicylate
hemodynamic effects of, *991*
and rheumatic fever, 1156
and tissue metabolism, *1166*

Salt
restriction after rice diet, *143*
total turnover, 4

Sarcoidosis
and airway resistance, *929*
diffusion capacity in and heart failure, 274

Sarcolemma, rheumatic sera in, *958–959*

SC-2919, and ventricular arrhythmias, *650*

SC-3920, and ventricular arrhythmias, *650*

SC-4289, and coronary atherosclerosis in male, 489–490

SC-6924, and coronary atherosclerosis in male, 489–490

Scarlet fever, and penicillin after rheumatic valvular heart disease, 1146

Schizotrypanum cruzi
and Chagas' disease, 1035–1037, 1040–1041, 1058

Sclerodactylia, and chelation, *1176–1177*

Scleroderma
and airway resistance, *929*
and chelation, *1176–1177*
diffusion capacity in and heart failure, 274

Sclerosis
amyotrophic lateral, 273
electrocardiogram, *638*
coronary
and atherosclerosis, 702, 709, 718, 736–737
and occurrence of coronary anomalies, 805
P wave prolongation in, 1077
and pulsus alternans, 171

Sedimentation rate
and disease activity, 1154–1158
in lupus erythematosus, 126–132
in rheumatic fever, and hormone dosage, 45

Septum
aorticopulmonary and congenital aneurysms, 115
atrial defect
and blood flow, 200–219
closure of, *909*
and exertional dyspnea, 329
heart sounds and thrills recorded simultaneously, 786
and hypertensive vascular disease, 323–340
in infancy, *939–940*
with interventricular communication, *1180*
normal aortograms in, 597
and pulmonary hypertension, 331–332
roentgen aspects of, *886*
and sudden death, 331
and surgery under direct vision, 468
cardiac defects with left-to-right flow, *1003–1004*
and Chagas' disease, 1056
congenital aorticopulmonary window, *923*
defects
interatrial and interventricular, 523
intraventricular, 279, 786–787, 801–803, *998–999*
response to exertion and aortic stenosis, 196
selection for surgical correction of, *916–917*
intact ventricular
and pulmonary atresia, *945–946*
and pulmonary stenosis, 9–15, *884*
interatrial, absent lower portion, 522
interventricular
connecting system, *141*
incomplete, 522
open repair of, *918–919*
rudimentary, 523
and syphilitic aortic sinus aneurysm, 121

Septum (*Cont'd*)
muscular ridge along posterior wall, 521
ventricular
classification of, 350
excitation of, 278
outflow tract, 351
ventricular defect, 209, 349–363
and coarctation of aorta, 362
and congenital aortic stenosis, 194
and hypertensive vascular disease, 323–340
direct vision repair, *1013*
incidence and mortality rates, *939–940*
in infant age group, *1022–1023*
lung biopsy prior to surgery, *905*
and right aortic arch, 362
normal aortograms in, 597
and pulmonary hypertension, 331–332
repair of, under hypothermia, *1181*
selection for surgery for, *929*
versus cardiovascular anomalies, *987*
Serotonin, 161–162
antiserotonins and hypertension, *1018–1019*
metabolism with argentaffin carcinoma, *648–649*
as pressor and vasoconstrictor, 161
in pulmonary embolism, *893*
and reserpine action in brain, *1175*
systemic and pulmonary pressor response to, *145*
Sex (of subject)
and angina pectoris, 425
in anginal syndrome, 228
and aortic sinus aneurysm unperforated, 116
and atherosclerosis, *291*, 485
and blood pressure, *971–972*
bronchial and arterial anomalies, 826–827
and cardiovascular-renal diseases, *1006*
castrates, male, 490
and Chagas' disease, 1037–1039, 1044–1046, 1050–1052, 1056
in coarctation, appraisal after operation, 807
and coronary atherosclerosis, 365–371
and coronary embolism, 1160–1163
and death due to anomalies of coronary arterial distribution, 801–804
and hypertension, 18–23
pulmonary vascular disease, 331
and left axis deviation in pulmonary disease, 241
and lupus erythematosus, 131–132
in myocardial infarction, *137–138*, *634*, *926*
and phlebitis, 472
and potency, after estrogen therapy, 370
and pulmonary valvulotomy, 9
and pure left papillary muscle syndrome, 1134
and rehabilitation, 474
and response to Valsalva maneuver, 72
and syphilitic aneurysms unperforated aortic sinus, 121
and ventricular septal defect, death due to, 357–363
and weight reduction, *645*
Shock
arterial blood pressure in, 4
and bacterial endotoxins, *1024*
cardiogenic, myocardial contractility in, *947*
hemorrhagic
and capillary permeability, *148*
and Dextran, *639–640*
and hypersensitive carotid sinus syndrome, 1104–1112
and metaraminol, *1015*
sedation, and pheochromocytoma, 625
therapy of, *634*
tourniquet, reversibility of, and saline therapy, *633*
"Shoulder arm syndrome"
and angina pectoris, 426, 428
versus anterior chest wall syndrome, *138*
Shunt
arteriovenous "connection" and "drainage," 200–219
bidirectional and ventricular septal defects, 361
calculation of, relative left-to-right, *136*
congenital venoarterial, 272
and death in syphilitic aortic sinus, 121
demonstration of aortography for, 185–187
intracardiac differentiation of, 605
left-to-right
and anomalous pulmonary venous connection, 203
in atrial septal defect, 200–219
and cardiac catheterization, *1173–1174*
and circulatory dynamics, 1090–1092
and common atrioventricular canal, 203
pulmonary arteries from aorta, 608
and pulmonary hemodynamics, *916–917*
and pulmonary pressure, 193
and pulmonary stenosis, *137*, *886*
right-to-left
in pulmonary hypertension, 332
splenorenal, 532
surgical cure, in lobectomy, 1090–1092
venoarterial venous admixture caused by, 280
volume of, in bronchial and arterial anomalies, 828
Sickle-cell anemia, in Negro children, *653*
Side effects
of alseroxylon, 232
of aminometramide, aminophylline and placebo, *907*
of atropine, *146*
of cortisone, 127
of hydralazine, *931*
of hydrocortisone, 127
of norepinephrine, *146*
of peritrate, *139*
of prednisone, 127
of *Rauwolfia serpentina*, 232
of reserpine, *931*
of SU 3088, *144*
Silicone and edema, *148*, *635–636*
Sinus
aortic
anatomy of, 115
rupture of, 122
of Valsalva, 115–116
noncoronary, 115
rate, and Scilla-Perpurat, *151*
right coronary, aneurysm of, 116
syphilitic, of Valsalva aneurysms, and surgical repair of, 123
Sinus rhythm, 770
arrhythmias related to, *148*
conversion to, 569–571
and quinidine, 568
external stimulation and control of heart during, 750
P wave, retrograde conduction, *143*
P wave and QRS complex pattern interpretations, 42
and pulsus alternans, 171
and right bundle-branch block, 42
Sitosterol
action of with cholesterol, 81, 347
in liver, *1172*
and arteriosclerotic heart disease, 77–81
and blood lipid pattern in coronary and peripheral artery diseases, *499*
hypocholesterolemic effect of, *911*
serum and liver lipids responses to, 344
Situs inversus, 520–530
Skin
blood flow and pentolinium tartrate, 590
and cardiologist, 475
lesions, in systemic lupus erythematosus, 127, 132
necrosis, after noradrenalin, *648*
pigmentations of
in adrenal insufficiency versus lupus erythematosus, 128
and estrogen, 366
and thickness of cyanosis, 271
temperatures and pentolinium tartrate, 590
Smoking
and airway resistance, *929*
and circulation, 463, *967*
Sodium
absolute depletion, 1028–1029

in blood and T waves, *143*
changes in cardiac muscle, *153*
concentration, 1027–1031
and body composition, *930*
and fatigue of the cellular mechanism, 1030
in cor pulmonale, 281
diffusion of, 4
dihydrocholate in assessing status of cardiovascular system, *951*
exchangeable content in rheumatic fever after steroid therapy, *905–906*
excretion, 588–590
and congestion of limbs, *296*
and desoxycorticosterone acetate, *296*
after Digoxin therapy, *140–141*
fecal, *141*
and hypophysectomy, *141*
in sweat, *1176*
extracellular and blood pressure, *938*
extrusion and anoxia, *153*
ground substance as cation exchange resin to, 821
in heart failure, 281
and acetylstrophanthidin, *952*
and mercurials, *149*
potassium, 463–464
and pH, 818
renal excretion and Digoxin, *140–141*
restriction of, *140*
salicylate and tissue metabolism, *1166*
serum concentration
in hypertension, *892*
osmolarity, *930*
tolerance in hypertension, *145*
transfer systems and blood pressure, *938*
and water, 1029
retention in the extracellular compartment, 1093–1098
Sodium acetrizoate, and aortography, 596
Sodium amytal
and diastolic blood pressure in malignant hypertension, 111
and work of the heart, 1154
Sodium bicarbonate
distribution of, *644*
respiratory and acid-base changes, *1176*
across walls of blood vessels, 4
hypertonic solutions of for absolute sodium depletion, 1029
urinary excretion of and rice diet, *143*
Sodium gentisate, and aspirin, 1157
Sodium lactate. *See* Lactate
Sodium pentobarbital, negative inotropic effects of, *650–651*
Sodium thiopental, negative inotropic effects of, *650–651*
South African Bantu, β-lipoprotein in, *992*
South America, vectors of *Schizotrypanum cruzi* found in, 1036–1037
Spasm
in heart failure, *140*
vascular, and herpes zoster, 379
Spermatocytogenesis, arrest of, 369
Spina bifida
cervical, and situs inversus of viscera, 521
thoracic, 523
Spine
disease of cervical, and arm pain, 425
vasoregulatory systems and rauwolfia alkaloids, *644*
Splanchnicectomy, survival after, 455
Spleen
congenital absence of, syndrome of, 520–530
in Chagas' disease, 1038–1039, 1050–1052
enlargement of, 417
and systemic lupus erythematosus, 126
Splenic primordia, development of, 530
Splenomegaly
and Chagas' disease, 1037
and lupus erythematosus, 127–133
Standstill
and quinidine therapy, 745–755, 761
See also Cardiac arrest
Staphylococcus
penicillin and streptomycin-resistant, *652*
pericarditis due to, *652*
Stenosis
aortic, *1177–1178*
combined heart catheterization for assessment of, *942*
congenital, 116, 188–198
dilatation after, *147*
heart sounds and thrill recorded simultaneously, 785
left heart catheterization in, *904*
with left ventricular hypertrophy, 52
and pulmonary thrombosis, 774
and pulsus alternans, 171
muscle fatigue after, 196
and response to Valsalva maneuver, 75
sudden death due to, 190
surgical management of, *908*
atresia of pulmonary artery valve, 523
infundibular, 194
congenital, 74
and pressure in right ventricle, 415
of right ventricle, 420
surgery for, 197
lesions, genesis and progression, 483
mitral, 116, 279, 398–406, 762
classification of types, 398–406, *950*, *1004–1005*
after commissurotomy, 180–182
diastolic murmur of, 267, *1170–1171*
and digitoxin, 467
electrocardiographic pattern in, 331, 867, 1132
exercise in, 466
first sound in, *301*, 1169
heart sounds and thrill recorded simultaneously, 785
and hypertensive vascular disease, 323–340
left atrial volume versus pressures, *1004*
left heart catheterization of, *904*
and lung disease, 266
murmur of, versus Austin Flint, *999*
negative U wave, 865
and papillary muscle, 1131–1132
phonocardiography in, *298*
presystolic murmur in, 413
pulmonary arterial oligemia, *1179–1180*
and pulmonary blood volume, *986–987*
and pulmonary congestion, *986*
pulmonary hypertension, 327, 334, 338
and pulmonary thrombosis, 770–773
and pulsus alternans, 171
and quinidine therapy, 758
recurrent, *907–908*
and response to Valsalva maneuver, 75
with sinus rhythm, *894*
and valvuloplasty, 469–470, *931–932*
ventilatory and hemodynamic disturbances, *302*
pulmonary, *308*, 511, 530, 1070
aortography in, 597
and atrioventricular conduction, 121
Blalock-Taussig anastomosis, 512–518
in child, 192
communication with aorta, *886*
with corrected transposition of great vessels, *941*
and exertion, 196
incidence and mortality rates, *939–940*
and intact ventricular septum, *884*
and intravascular pressures, *887*
and left-to-right ventricular shunt, *137*
and multiple congenital anomaly, 530
rheumatic mitral
classification of, 398–402
and hemoptysis, *1176*
subaortic normal aortograms in, 597
tricuspid
congenital, 412–421
diagnostic sign of, 415
valvular pulmonary

Stenosis (*Cont'd*)
infundibular dynamics in, *918*
and intact ventricular septum, 9–16
operative procedure, 198, *924*
pressure pulses in, *940*
thrill and heart sounds, 787–788
Steroid
and corticotropin therapy in nephrotic syndrome, *972*
inflammatory response to, 281
secretion of adrenocortical in congestive heart failure, 1030
therapy
in nonspecific pericarditis, 875
in systemic lupus erythematosus, 127
Stillborn, and ventricular septal defect, 358, 360
Still's disease, 125, 127
Stokes-Adams disease
cardiac arrest in, *647*
external electric pacemaker in, *640–641*
in complete heart block, *891*
external electric stimulation for, *647*
and sodium lactate, 464
Stomach
cancer, 775
duodenum and liver anomalies, 520
gastroenteritis, 776
and situs inversus of viscera, 521
of triatomid bugs, parasite development in, 1037
Strain
left ventricular
and elevation angle between QRS and T vectors, 103
and left axis deviation, 235
ST and T vectors in, 243
transaminase versus electrocardiography in, 796
myocardial, and adenosinephosphatase, *640*
right-heart, *137*
and syndrome of the papillary muscles, 1129
ventricular and intra-atrial block, 1076
Streptococcus
antigen-antibody reaction in tissue, 1142
group A
endotoxin in lysates, *1007*
pharyneal infection with, 457
susceptibility to infection, *995*
hemolytic, *933*
survey of diseases due to, *949*
infection and rheumatic fever, 1138–1143
prophylaxis, 1020–1021
nonhemolytic and erythromycin, *631–632*
viridans, death due to, 801, 804
Streptomycin
monilial endocarditis after antibiotics in, *147*
and staphylococcal endocarditis, *954*
Stress
death due to in aortic stenosis, 194
ergonovine test, *1006–1007*
and wide patent ductus, *135*
Stroke volume
and hypertension, 112
malignant, 110
after mitral valvulotomy, *141*
after pentolinium, 1061–1067
and peripheral pulse pressure, 1120–1127
and pulsus alternans, 167, 169, 171
and serotonin, *145*
Starr's equation for evaluation of, 250–253
Strophanthin, and heart-lung preparation, *646*
Strophanthin-K, versus tryptamine-strophanthidin, *151*
SU 3088, hypotensive effect of, *144*
Sulfadiazine, and streptococcal infections, 1139, 1144–1145
Sulfhydryl, *1166*
Surgeon, cardiac, 4
Surgery
abdominal
aortic aneurysm, 473
for pheochromocytoma, 628
serum transaminase levels after, *293*
anastomosis
for pulmonary stenosis, 516–517
splenorenal arterial, 532–539
aortic and mitral valvular simultaneous pressure measurements in, *909*
for aortic stenosis, 196–197, *908*
in atrial septal defect, 339
under direct vision, 468
in atrioventricular canal defect, *1180*
Beck operation for coronary artery disease, *965–966*
and blood flow direct measurements, *1005–1006*
cardiac
bacterial endocarditis after, *926*
psychotic disturbances with, *985–986*
cardiothoracic ratio after pulmonary valvulotomy, 12–15
in cardiovascular disease, 509
for coarctation of aorta, *884*
appraisal after, 806–814
for congenital aorticopulmonary septal window, *923*
for congenital aortic stenosis, fatigue after, 197
in coronary heart disease, 471
for correction of anomalous pulmonary venous connection, *886–887*
for cyanosis due to tetralogy of Fallot, *308*
and Dicumarol, *883*
direct vision, intracardiac, 468
hemiplegia after, 197, 469
hyponatremia in children after, *950*
hypothermia in, 468–469
interventricular septal defect repair, 918–*919*
intracardiac
cardiac arrest as adjunct in, *964–965*
use of rotating disc reservoir oxygenator in, *924*
and left atrial appendage, *1181*
lung biopsy prior to, for ventricular septal defect, *905*
mitral commissurotomy, follow-up after, 177
with mitral infarction risk, 471
mitral insufficiency, 470
pericardial valve grafts, *908*
mitral valve
fluid and electrolyte disturbances after, *927–928*
hemiplegia following, 469
hyponatremia after, *309*
and myocardial ischemia, *1008*
open cardiac, *1023*
palliation in transposition of great vessels, *1180–1181*
in patent ductus arteriosus, 339
and perforation of aortic sinus aneurysms, 123
pheochromocytoma removal, 622
prolonged exposure of aortic valve, *994*
in pulmonary hypertension, 339
for Raynaud's phenomenon in women, *941–942*
resection for coarctation of aorta, 123
for syphilitic sinus of Valsalva aneurysm repair, 123
thoracic, positive-negative phase respirator during, *980*
for ventricular septal defect, selection for, *929*
Sweating
in pheochromocytoma, 622
potassium and sodium excreted in, *1176*
Sympathectomy
constriction with adrenalin, noradrenalin after, *148*
dorso-lumbar, 409–410
on intercoronary arterial communications, ineffectiveness of, 470
intermittent claudication after, *930–931*
for Raynaud's phenomenon in women, *941–942*
Syncope
episodes of, 189
and hypertension, 109, 111
pulmonary disease, 329–330
and oxygen supply to cerebral tissue, 194
and surgery, for congenital aortic stenosis, 197
vasodepressor, and cardiac output, *933*
Syphilis
and aneurysms of aortic sinuses, 115, 118–122
and Chagas' disease, 1050–1052
and lupus erythematosus, 129, 132
and sex incidence in coronary embolism, 1163
Systole
and diastole, duration of, *153*

phase of pulsus alternans, 164–169
premature ventricular, spread of excitation during, *638*
simulation of at necropsy, 1117–1127
ventricular
in congenital aortic stenosis, 195
retrograde conduction of to atria, *143*

Tachycardia
and absolute sodium depletion, 1029
atrial, reversible changes with quinidine therapy, 577
atrioventricular nodal
electrocardiographic patterns of, 40–41
induction and termination of, 751
in congenital mitral atresia, *136*
and epinephrine
after ephedrine, *152*
after mephentermine, *152*
extrasystolic ventricular in Chagas' disease, 1043
heart disease, *299*
after mitral commissurotomy, 181
paroxysmal, 762
atrial, 295
in Chagas' disease, 1043, 1050–1052
and congenital aortic stenosis, 190
due to ephedrine toxicity, *151*
and levarterenol, *152*
in pheochromocytoma, 622
postural hypotension, and SU 3088, *144*
reaction, after retrograde aortography, 611
reversal of after ouabain, *148*
sinus
and Chagas' disease, 1050–1052
and pulsus alternans, 171
supraventricular, termination of by countershock, 752
and thyrotoxicity, *138*
ventricular
and atherosclerosis prediction, 702, 709, 718, 734
and Chagas' disease, 1050–1052
death due to, 762
with electric currents to, 745–755
electrocardiographic diagnosis, *984*
and levarterenol, *152*
and mitral commissurotomy, *142*
and quinidine, 573
and quinidine therapy, 758, 761
termination of, by countershock, 752

Tachypnea
in congenital mitral atresia, *136*
and ganglionic blocking agents, 110
and lesions of fibrinous pneumonitis, 107

Taussig-Bing complex, and pulmonary hypertension, 338
Teleradiogram, 324–328
Teleroentgenogram, 870
Temperature
and myocardial infarction, *292*
and systemic lupus erythematosus, 125
Tetrachloro - 2 - dimethylaminoethyl-isoindoline dimethochloride, for hypertension, 108
Tetraethylammonium
and pulmonary vascular resistance in mitral stenosis, *302*
tests with
in paroxysmal hypertension, 624
for pheochromocytoma, 624
Tetralogy of Fallot, *973*
and biventricular aorta with pulmonic stenosis, 1114
and Blalock-Taussig anastomoses, 517
and identification of enlargement, 511
incidence, and mortality rates, *939–940*
and pulmonary valvulotomy, 9
surgical correction of, *308*
direct vision intracardiac, 468
Theophylline, for pulmonary disease, 281
Thiamine, and hyperthyroidism, 95
Thiomerin, and congestive heart failure, *1168*
Thiopental
and cardiac output, *301*
concentration of and myocardial function, *1172*
Thoracoplasty, and heart failure, 274
Thoracotomy
and aortic insufficiency, *137*
exchange transfusion, cardiac arrest during, *301*
exploratory, and Blalock - Taussig anastomoses, 517
pulmonary ventilation during, *641*
Thorax
anatomic changes in and electrocardiographic age trends, 101
in congenital aortic stenosis, 195
deformity, *301*
and left axis deviation, 238
and wide patent ductus arteriosus, *135*
Thorazine, cerebral responses to, 380–385
Thrombin, and prothrombin time, *632*
Thromboangiitis obliterans and atherosclerosis, *500*, *966*
and coronary artery disease, 424
Thrombophlebitis
of extremities, and Chagas' disease, 1050–1052
sudden death from in young, 1159–1163
and symmetrical digital gangrene, 1085

Thrombosis
aortic, 532
arterial with pyrexial illness, 1084–1089
of carotid artery after injury of soft palate area, *895*
and Chagas' disease, 1050–1052, 1057
coronary
and atherosclerosis, 702, 709, 718, 736–737
coexistence with cerebrovascular accidents, *139*
death due to, 762
with myocardial infarction, *634*, 874
and quinidine therapy, 758
and vaccination against variola, 138–139
death due to, 256, 516–517, 804
differentiation of primary and secondary, 777
and embolism, 1162
of femoral vein, 770
and hypertensive pulmonary vascular disease, 337
intestinal and infarction, *292*
lateral sinus anomalies of coronary ostia as cause of death, 801
left atrial angiocardiographic diagnosis of, 25–31
massive pulmonary artery, *895*
primary in situ, 766
of pulmonary artery, 266, 769–770
disease associated, 766
and pulmonary tuberculosis, 473
and quinidine therapy, 758
retroperfusion of myocardium due to, *137*
Thrombus
and aneurysms of syphilis, 120
in atria
and antibiotics, 1162
death due to, 762
and quinidine therapy, 758
ball valve versus myxoma, 31
calcified and aortic sinus aneurysm, 118–119
and embolus differentiation, 1159–1160
coronary, 1161
fibrous thickening of and pulmonary hypertension, 265–266
hyaline and luminal change in lupus erythematosus, 129
in left ventricle, 421
mural
as atherosclerotic plaques, *634*
of left atrium, 25–31
mural fibrin disposition of arteriosclerosis, 483
pseudodiverticulum filled, *293*
in right atrium, 417
Thyroid
adenoma, 762
atrial fibrillation after prolonged use of, *638*
function
and estrogen therapy for coronary atherosclerosis, 370–371

Thyroid (*Cont'd*)
and protein rich diet, *143–144*
and reserpine, *648*
hormone
heart response to, 98
and hypophysectomy, *141*
Thyroidectomy, blood pressure after and renotrophine, *144*
Thyrotoxicosis
and angina pectoris, 424, 426, 429
in coronary atherosclerosis, 423
in cardiac disease and life span, *138*
as cause of death due to anomalies of coronary ostia, 801
and Chagas' disease, 1050–1052
and myocardial infarction, *957*
Thyroxine, analog, and dietary cholesterol, 491
Tietze's syndrome, *910*
Tinnitus, and quinidine, 573
Tired cell syndrome, 1030–1031
Tissue
anaerobic metabolism and cardiac output, *956*
arterial mucopolysaccharides of, 480
breast gland, removal of rudimentary in male, 370
chromaffin and pheochromocytoma, 628
conjunctival "hyaline"-like deposits, 393
culture studies in rheumatic fever, *935*
excised, and plasma water and electrolyte exchanges between, *940*
fibrinoid substance in and lupus erythematosus, 130
involvement of in ventricular septal defects, 355, 359
lean mass, and serum sodium content, 1097
leishmaniform organisms in of *Schizotrypanum cruzi*, 1035
lipids high fat and high protein effect on, 488
metabolism, 392
and sodium salicylate, *1166*
necrosis, and occlusion of small peripheral arteries, 1084–1089
oxygenation, *903*
in arteriosclerosis, and lipemia, *964*
potassium studies in, *640*
proliferation of, intimal fiberous, 333
pulmonary, infarction of, 161
response to age and to diabetes, 386–396
septal defects involving, 355–356
thromboplastins in control of anticoagulant therapy, *1011*
tumor of chromaffin, 622
valvular, fibrinoid degeneration of, 420
Tolozoline, and pulmonary hypertension, *991–992*
Tourniquet, venous, and pulsus alternans, 1099
Toxemia
of pregnancy, *299*
hypertension and pyelonephritis simulating, *934*
pressor response to catecholamines as pretest for, *986*
Toxicity
of beta aminopropionitrile hydrochloride, *499–500*
chronic sodium chloride and potassium chloride, *501*
delayed, to hydralazine, 109, 113
of digitalis, 640, *917*, 1131
and intracellular potassium, *640*
and papillary muscle syndrome, 1131
and response to Valsalva maneuver, 74
emetine, 33–37
of gitalin and digitalis leaf, *917*
of hyperpotassemia, cardiac effect of and molar sodium lactate, *909–910*
due to quinidine, 573–581, *1003*
Toxoplasma, intracellular parasites and *Schizotrypanum cruzi*, 1036
Trachea
and anomalous aorta, 523
obstruction of due to pulmonary artery anomalies, *921*
pressure of and cardiac output, *302*
Transaminase
activity, of placenta and pyridoxine, *1172*
and C-reactive protein, *635*
in coronary artery disease, *963*
glutamic oxaloacetic
in coronary artery disease, 790–799
glutamic oxaloacetic released from cardiac muscle, *1173*
and myocardial infarction, *634–635*
transmural, 792
serum, *655*
and myocardial necrosis, *293*
reaction, 882
Transplantation, of anomalous vessel, 831
Transposition
abnormalities of, 530
of aorta, atresia of the pulmonary orifice, 523
aorta and pulmonary artery, 521
correction of the great vessels, *633*, 530
of great vessels, 530, *633*
correction of, *941*
and drainage of right lung into inferior vena cava, 827
incidence and mortality rates, *939–940*
liver, stomach, and pancreas, 523
Trauma
as causation of pericarditis, 881
nonpenetrating injury
to aorta, *980–981*
to heart, *146*
and stretching, 195
Tremor
parkinsonian, *638*
reaction after retrograde aortography, 611
of skeletal muscles electrocardiograms in, *638*
Trendelenburg position, and distention of azygos vein, size of azygos vein, 1082
Triatoma infestans, as vector of Chagas' disease in Central and South America, 1036–1037
Tricuspid valve
septal leaf, 351
ventricular, 359
Triethanolamine trinitrate biphosphate, in angina pectoris, *646–647*
Truncus arteriosus, abnormalities of, 530
Trypanosoma cruzi, and Chagas' disease, 1035
Trypanosomiasis, in Brazil, 1035
Tryptamine-Strophanthidin versus strophanthin K, *151*
Tryptophane and lupus erythematosus, 128
Tuberculosis
of Chagas' disease, 1038–1039, 1050–1052
and coronary embolism, 1161
death due to, 804
diffusion capacity in, and heart failure, 274
hematogenous and heart failure, 274
infiltrative lesion, differential from, 1082
miliary, and heart failure, 274
pulmonary, *308*
death due to, 801
and systemic lupus erythematosus 126
d - tubocurarine, protection against ventricular arrhythmia by, *150*
Tubule
atrophic lipid-filled sertoli cells in, 369
proximal, and diuresis, *149*, *151*
renal, reabsorption and excretion of sodium, 1030
secretory capacity for para-aminohippuric acid, 587
Tumor
and left atrial thrombi differentiation, 31
localization of adrenal and pheochromocytoma, 627
malignant
with metastases, 628
and serotonin, 161
metastatic and coronary artery disease, 423
pheochromocytoma, 622–629
pulmonary or mediastinal, and angina pectoris, 426
Tunica propria
thickening of, after estrogen therapy, 369
Turbidity
positive thymol test and lupus erythematosis, 133
serum
with coronary disease, *499*
and heparin, *493*

tests, and lupus erythematosus, 132
thymol determinations in coronary atherosclerosis, *499*
Typhoid, agglutinins, in rheumatic patients, 1140–1141

Ulcer
duodenal, 801
gastric, death due to, 801
peptic
and angina pectoris, 426, 427
and anticoagulant therapy, 257
and transaminase value, 798
United States
areas where *Schizotrypanum cruzi* found, 1036–1037
hypertension, in American and foreign-born, 17–23
Urea, control of kidney excretion of, *976*, 997
Uremia, 758, 760
and adrenolytic drugs, 615
and blood pressure due to tilt, 409
death due to, 801, 804
and malignant hypertension with renal azotemia, 106–113
and thrombosis of the large pulmonary arteries, 775
Urine
buffer base excretion, 589
chloride in, in geriatrics, *140*
excretion of
and epinephrine, 221
epithelial cells in, 611
and norepinephrine, 221
and pheochromocytoma, 627
flow
and pentolinium tartrate, 589
and piperoxan, 223
5-hydroxyindole acetic acid in, and metastatic carcinoid, 162
17-ketosteroid excretion in, and estrogens, 371
osmotic activity, 589
pH, 589
sodium in, after rice diet, *143*
specific gravity in malignant hypertension with azotemia, 110
Urograms
intravenous and pheochromocytoma, 627
in retrograde brachial aortography, 595
Urokon, and retrograde brachial aortography, 596, 611
Uterus
adenocarcinoma of and quinidine therapy, 758, 762
curettage of, and postcommissurotomy, 182

Vagotomy and arrhythmia, *150*
Vagotomia, due to gastrointestinal changes, 1110
Vagus
reflex stimulation of, external electric pacemaker in, *640–641*
stimulation of
and cardiac arrhythmia, *303*
and intra-atrial block, 1076
supply to sinoatrial, 1111
Valsalva
aortic sinuses of, 115–116
syphilitic aneurysm, 122–123
Valsalva maneuver
as ancillary method for cardiac insufficiency diagnosis, 72–76
and artery occlusion, *913–914*
and distention of azygos vein, size of azygos vein in, 1082
Valve
aortic. *See* Aortic valve
atrioventricular
maldevelopment of, 521–522, 633
and septal defects, 357
single three-cuspid, 523
tensing of, *1167*
calcium in, and mitral commissurotomy, 181
disease of, and thrombosis, 766
fibrotic, and mitral commissurotomy, 181–182
function, *301*
fused mitral and tricuspid, 521
lesion of and conversion of atrial fibrillation, 572
obstruction hemodynamics after, *950*
spring, in treatment for mitral insufficiency, 468
tricuspid
deformed, 522
and thrombosis of large pulmonary arteries, 770
Valvulotomy
left heart catheterization as prerequisite for, *904*
mitral
atrial pressure during, *1181*
low-frequency phonocardiogram, *141*
pulmonary, *308*
cardiothoracic ratio after, 12–15
transarterial, in functioning heart, *942*
and thrombosis of large pulmonary arteries, 770
transventricular pulmonary, 9–15
Valvulitis
aortic and mitral with mitral stenosis, 412–421
rheumatic and leukocytosis, 421
Valvuloplasty, for mitral stenosis, 469, 470, *931–932*
Variola, vaccination against, contraindications for, *138–139*
Vascular bed
biomicroscopic study of bulbar conjunctival, 386–396
capacity, expansion on exercise and gas exchange, 268
capillary, peripheral compression of due to cor pulmonale, *137*
in hypertensive, and blood flow after ganglionic blockade, 1066–1067
pulmonary, pressure in after mitral commissurotomy, 180–182
peripheral, and hypotension, *303*
vasomotor receptors in responses to, *944*
Vascular disease
cerebral, anticoagulants in, *973*
fatty acids and lipid transport in, 484
degenerative and diabetes, hexosamine in, *912*
hypertensive
pulmonary, 323–340
and toxemia of pregnancy, *934*
incidence of malignant, and diabetes, 386
peripheral and atherosclerosis, 737
in retina
and diabetes mellitus, *953–954*
reactivity, *1000–1001*
Vascular system
and ballistocardiographic pattern due to heart beat, *1020*
cerebral diseases, 743–744
cerebral accident and malignant hypertension, 110
coronary circulation time, *943*
failure, and fasting, *890*
peripheral specialty of, 4
pulmonary and wide patent ductus arteriosus, *135*
tone, and hypotension, *303*
and ventricular, resonance phenomenon in, 173
Vasculosis, hyperergic, 337
Vasoconstriction
active, in lesser circulation, *151–152*
and circulating epinephrine, 223
and defibrinated blood, 161
failure of, in leg vessels and postural hypotension, 65
pulmonary and pressor amines, *990*
Vasodilatation
antidromic, in isolated perfused ear, *1175*
and circulating epinephrine, 223
compensatory to blood pressure, 1066–1067
of coronary arteries and nitroglycerin ointment, *139*
pulmonary, *990*
and serotonin, 161
symptoms of and bleeding, 274
Vasopressor agent, and ventricular tachycardia, *142*
Vasoxyl
and cardiac rhythm, *644*
coronary blood flow after and blood pressure, *139*
Vector analysis
and age difference, 100–103
in linear-scale pot, 558–566
cardiac, three geometric quantities as functions of time, 556
from epicardium QRS interval, 238
interpretation of three major in QRS loop, *948–949*
loop correlation, limb and precordial systems, 83–88

Vector analysis (*Cont'd*)
magnitude of surface, *977*
orientation of papillary muscle, 1131
and prolongation of QRS interval, 233
QRS
deformity, 238
and left axis deviation, 239
and T responses to age difference, 100–103
terminal, 233
Q aVf after initial sagittal QRS, *981*
ST and T and left bundle-branch block, 243
U wave, *297*, *298*
variation of, 558
Vectorcardiography, 556–566
in anterolateral peri-infarction, 238
cartesian coordinate graph versus oscilloscopic trace, 558–566
differential, *948*, *953*
direct spatial in incomplete right bundle-branch block, *907*
and electrocardiography, 556
lead system for, *953*
lead-vector concept, 48–54
in right ventricular hypertrophy, *891*
limb and precordial systems, 83–88
QRS changes and coronary occlusion, *953*
and QRS loops
after hexamethonium, *142*
three dimensional, with Frank precordial system, *999*
spatial
linear time scale for, 556–566, *904*
response to localized destruction of myocardium, *955–956*
spatial QRS and T vectors
and age trends, 100–103
and respiration, *1001*
location and number
of electrodes for, 50–54
and results, 556–558
standard spatial conventions of polarity, 437–438
temporal relations displayed in, 559
two systems of, *891*
U wave and T U segment abnormalities 1130
in ventricular hypertrophy, *890*
Wilson tetrahedron and Burger coefficients in, *1023*
Vein
antecubital, blood glucose levels from during exercise, *1016*
central and sublobular fibrosis of, 417
esophageal and azygos, 1080
great, cardiac pressure recording of, *643*
parietal pleural drainage into azygos, 1081
of pelvis and coronary embolism, 1161
peripheral
response to circulating blood volume reduction, *1021*
as source for embolism, 777
portal, and distention of azygos vein, 1082
Vena cava
anomalous drainage of, 521
blockade of inflow, 75
inferior
and anomalous pulmonary veins, 200–219
drainage of right lung into, 826–845
maldevelopment of, 522
obstruction of, and azygos vein, 1080
thoracic, *141*
and ventricular septal defects, 359
left, 520
superior, 522
oxygen content of blood in left-to-right shunt, 216
oxygen saturations in, *136*
right, 520
saturation in and calculation of shunt, *136*
superior
and aortic sinus, 116
distention of in heart failure, 1082
and left-to-right shunt through atrial septal defect, 204, 206
oxygen content, 1070, 1090–1092
Ventilation
and aminophylline, *150*
in emphysema heart, 269
intermittent positive-pressure and cardiac output, *301*
meperidine and/or aminophylline, *150*
rate of, and dyspnea, 268
Ventricle
alternation and heart failure, 1099–1103
aneurysms, *968*
and Chagas' disease, 1050–1052
of posterior wall, *146*
aorta arising from both with pulmonary stenosis or atresia, 1114
asystole and carotid sinus massage, 1105–1112
and atrium
connecting systems, *141*
synchronization and accrochage, 38–43
atrophic flow, tract of right, 419
in Chagas' disease, 1049–1052
changes, due to diabetes, 394
conduction time
during cooling, *148*
during rewarming, *168*
contraction sequence in bundle-branch block, *915*
in diastole
negative pressure of, *994*
suction of, *994*
distensibility, *633*
electric defibrillation, *962*
enlargement of, 767–768
concept of "inflow" and "outflow tract," 510
in congenital aortic stenosis, 195
in malignant hypertension, 112
extrasystoles and Chagas' disease, 1050–1052
failure of left
and congenital aortic stenosis, 194
death due to, 360
failure of right, Valsalva maneuver in diagnosis of, 75
filling of isolated right work load and heart rate effects on, *643*
granulomatous formations and Chagas' disease, 1050–1052
hypertrophy, 265, *1014*
and right bundle-branch block, *914*
strain, and intra-atrial block, 1076
and thrombotic occlusion, 773, 779
time of arrival of activation, *141*
impaired distensibility, *633*
incompletely separated, 522
infarction of, 540–554
involvement, in coronary embolism, 1161
isolated right, filling rate and inotropic drugs, *650–651*
"isometric" contraction of, and unidirectional blood flow, *153*
left
and airway resistance, *929*
anterior wall, definition of terms, 540
left atrium, and aorta simultaneous pressure measurements, *909*
and defect, 356–357
enlarged, 116–120, 122
failure of, 171
hypertrophy of, 122
infarction of the lateral wall, 540–554
and left axis deviation, 233
lateral wall, definition of terms, 540
mechanical pump to replace, *151–152*
outflow tract of, 351
output and sudden death, 194
performance analyzed by electronic computors, *992*
posterior wall, definition of terms, 540
pressures in, and diagnosis of aortic stenosis, 196
pressure-volume study of, *954*
single arterial trunk from, 522
strain pattern, 616
transmural infarction to lateral wall of, 543–546, 549
volume of, *927*
and weight at autopsy, 237
work of, 92, 96–98, 585, 1118, 1120
load, in aorta-pulmonary artery communication, 1090–1092
measurement of, in mitral stenosis, 403–404
multiple extrasystoles and Cha-

gas' disease with *Schizotrypanum cruzi*, 1050
musculature of
overtaxing of, and failure, 265
rhythm and contractile force in, *1175*
negative pressure of, *994*
oxygen content, 1090–1092
papillary muscles, functional derangement, 1129
polytopic, extrasystoles, 1050
posterior wall of, left aneurysm of, *146*
premature contraction in
Chagas' disease, 1043, 1049
and *Rauwolfia serpentina*, *647*
pressure volume diagram, *300*
right
and aortic sinuses of Valsalva, 116
cavity enlarged, 837
in congenital aortic stenosis, 195
enlargement of, 278
filling of isolated, and work, *643*
hypertrophy of myocardium of, *137*
outflow portion, 350
oxygen content and pressure in, 1070
pressure pulses in, in valvular pulmonary stenosis, *940*
pressures in, and pulsus alternans, 170–171
and R waves, 277
size of, after mitral commissurotomy, 178–179
septal defect. *See* Septum, ventricular defect
single cavity, 520, 522
with pulmonary stenosis Blalock-Taussig anastomosis, results from, 512–518
single fibers, electric alternans in, *960*
size of and QRS changes, 234
stroke output of and pulsus alternans, 169
subendocardial and transmural scars, Q waves due to, *996*
and supraventricular stimulation, 749
systemic right pressure and triad of pulmonary hypertension, 273
tachycardia, and atherosclerosis prediction, 702, 709, 718, 734
volumetric changes in mitral valve disease, *944*
Veratridine, and potassium for carotid sinus, *1165*
Veratrine, electrocardiographic alterations induced by, 821
Veratrum alkaloids, *1019*
and cation movements of red cells, *644*
for elderly hypertensive, *146*
for hypertension, *931*
and regitine test for pheochromocytoma, 625
Vibogram, of heart, *305*
Vibography, heart action recorded with, *305*
Virus
common respiratory myocarditis due to, *1001*
encephalitis and myocarditis due to in children, *652*
Viscera
abdominal
blood supply to, 532
situs inversus, 521
congestion of, 412–421
Vitamin
B complex and C, in hyperlipoproteinemia, *982*
K_1
and cation transfer, *644*
and hemorrhage, *295*
Vomiting
following infarction, *138*
in pheochromocytoma, 622
after retrograde aortography, 611

Warfaren sodium, new anticoagulant, *632*
Water
absolute excess of, 1029
balance, and postoperative hyponatremia, *309*
and electrolyte exchanges between excise tissues and plasma, *940*
excretion of and pentolinium tartrate, 589–590
and hypertension
excretion, *955*
metabolism, *892*
intoxication syndrome, 1028–1029
as perfusing fluid, estimate of left ventricular work, 1126
serum and lipids of hyperlipemic serum, *1174*
site of diuresis action, *149*
and stores of osmotically active sodium, 1029
Wolff-Parkinson-White syndrome, serum glutamic-oxalacetic transaminase in, 796

X-ray therapy, for anterior chest wall syndrome, *138*